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Abstract 
Highly sophisticated genetic tools have been deployed in many eukaryotes and bacteria, 
yet those available in the third domain of life: the archaea, remain comparatively limited. 
The constraints this imposes must be overcome if the unique capabilities of this domain are 
to be tapped. One biological pathway found solely within members of the archaea is 
methanogenesis: the conversion of simple molecules into methane. The manipulation of 
methane production through genetic modification of methanogens is highly desirable, since 
in addition to its potential use as a biofuel, methane contributes significantly to the 
greenhouse effect. Among the methanogens, Methanococcus maripaludis (M. maripaludis) 
is one of the best developed as a model, however many of its available genetic tools are 
outdated. The CRISPR/Cas9 system is a relatively recently developed and highly versatile 
genetic technique, and at the outset of this work had not been deployed in any archaeal 
system. The aim of this project was therefore to provide a proof of principle that the 
CRISPR/Cas9 system could be deployed successfully in this organism.  The experimental 
approach selected was a plasmid invader assay, in which the activity of the system could 
be demonstrated by Cas9 mediated plasmid destruction resulting in reduced M. maripaludis 
cell viability. A scheme by which this assay could be conducted using existing genetic tools 
in two different M. maripaludis strains was designed,  and the full series of required 
plasmids was produced. Attempts to use these plasmids to produce the M. maripaludis 
strains required for the invader assay were unsuccessful, and it could therefore not be 
carried out. However, it is anticipated that the assay system designed and plasmids 
produced here should enable the rapid testing of this system were this work continued, 
which should enable the addition of the CRISPR/Cas9 system to the M. maripaludis genetic 
toolbox. 
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Chapter 1: General Introduction 
1.1.1 Genetic Tools in the Archaea 
The repurposing of biological systems to benefit man is reliant on tools which allow 
manipulations at the genetic level. The ease and extent to which this can be achieved is 
limited by the quality and variety of the tools available (1). While significant progress has 
been made in bacterial and eukaryotic models, the development of genetic tools in the 
archaea has lagged behind, limiting the extent to which they can be manipulated (2). 
Archaea are unicellular prokaryotes (3) which were first recognised as a distinct domain of 
life in 1977 (4). They possess a multitude of genes and pathways not found in eukaryotes 
or bacteria (5, 6). The investigation, understanding and ultimately manipulation of these 
unique features is currently reliant upon limited archaeal specific genetic tools: providing 
a clear incentive for further development.  One important pathway found uniquely among 
the archaea is methanogenesis (7). 
1.1.2 Methanogenesis and Methanogens 
Methanogenesis is the process by which simple molecules such as dihydrogen and carbon 
dioxide are converted into methane (6, 8). It is carried out solely by the methanogens: a 
diverse group of species belonging to five different orders of the domain archaea (7). 
Methanogens are obligate anaerobes and occupy a wide variety of environmental niches 
including oceans, wastewater and the gastrointestinal tracts of animals (5, 9).  Methane 
exhibits 21 times the warming potential of carbon dioxide, making it a potent greenhouse 
gas and an environmental concern: particularly in industries such as livestock farming and 
water treatment (9, 10). However, methane can also be used as a biofuel (11). This 
illustrates the potential benefit to manipulating methanogens: both in combatting global 
warming as well as potentially providing a source of energy. Laboratory manipulation of 
methanogens is challenging since they can only be handled anaerobically (6). Despite this, 
genetic tools have been deployed in several species, of which Methanococcus maripaludis 
(M. maripaludis) is one the most well developed as a model (12).  
 
1.1.3 M. maripaludis  
Originally isolated from a salt marsh sediment, M. maripaludis grows optimally at 38°C 
and has a doubling time of just over two hours (13).  Its 1.6 megabase genome has been 
sequenced, which has a low GC content and is predicted to contain approximately 1700 
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protein coding genes (14, 15). M. maripaludis is polyploid, with the number of copies of 
the chromosome fluctuating between approximately 30 and 55 depending on growth phase 
(16). A variety of genetic tools have been developed in this organism, including a PEG-
based transformation protocol (17), a shuttle vector system for expression of exogenous 
genes (18), and a positive/negative selection system for markerless mutagenesis, 
modification of endogenous genes and introduction of heterologous material onto the 
chromosome (19). M. maripaludis is sensitive to the antibiotics puromycin and neomycin, 
and their corresponding resistance genes can be used for selection in this organism (20, 21).   
1.1.4 Existing Genetic Tools in M. maripaludis 
1.1.4.1 Chromosomal modification 
M. maripaludis was found to recombine naturally when exogenous DNA bearing 
homology to a region of the genome was introduced on an integrative (i.e. non-replicative) 
plasmid (22), and the efficiency at which chromosomal modifications could be recovered 
was increased through the development of a PEG-based transformation protocol (17). 
However, these methods were limited since recovery was based on a single integrated 
positive selection marker, which meant that sequential genetic manipulations were not 
possible. This was overcome by the development of a positive/negative selection based 
markerless mutagenesis protocol, in which both markers are removed following 
chromosomal modification, allowing repeated manipulations (19).  
 
This protocol is conducted in the M. maripaludis Mm900 strain, in which the hypoxanthine 
phosphoribosyltransferase (HPT) gene, which confers sensitivity to the base analogue 8-
azahypoxanthine, has been deleted. Material to be introduced onto the chromosome is 
inserted into the backbone of the integrative pCRPrtneo vector, in between approximately 
500 bp of 5’ and 3’ flanking sequence corresponding to each side of the desired 
chromosomal integration site. The pCRPrtneo backbone contains a neomycin resistance 
gene (NeoR) for positive selection, and the HPT gene for negative selection, but no archaeal 
replication origin: so its cargo must be chromosomally integrated to be maintained (19). 
Following transformation (17) of Mm900 with pCRPrtneo, NeoR enables the initial 
selection of cells which have undergone a loop-in recombination event at the target site, 
resulting in the chromosomal integration of the full transformation vector (i.e. insert cargo 
and backbone). Subsequent culturing of transformed cells without selection allows a 
second recombination event between one of the vector flanking regions and the 
corresponding chromosomal flank to take place. This has two possible outcomes, which 
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depend on the flanking regions involved and the relative position of the looped-in region 
to the chromosomal locus. In the first, the vector backbone and intervening region between 
the chromosomal flanks is lost, resulting in the desired product: the vector cargo 
incorporated at the target site on the chromosome. The other equally likely possibility is 
loss of both the vector backbone and insert cargo, resulting in regeneration of the original 
chromosomal target site. Since both possible loop-out events result in the loss of the vector 
backbone, which contains the HPT gene, 8-azahypoxanthine is used to purge non-looped-
out cells, and screening enables recovery of those which have retained the desired insert 
(19). 
 
A second integrative vector, pBLPrt, was also produced. This vector contains flanking 
regions to the M. maripaludis genomic uracil phosphoribosyltransferase (UPT) locus, 
which confers sensitivity to the base analogue 6-azauracil, in addition to all of the 
components present in pCRPrtneo. Material introduced in between these flanking regions 
in pBLPrt can be incorporated into this site on the M. maripaludis chromosome using the 
protocol described above, but without the need for the introduction of flanking regions 
(since they are already present within this vector) (19). 
 
This protocol is used to produce M. maripaludis strains in which all chromosomes bear the 
same desired modification (19). The mechanism by which genetically uniform modified 
chromosomes can be obtained in M. maripaludis, which is highly polyploid, is thought to 
involve rapid propagation of the DNA element conferring a selective advantage to other 
chromosomes via gene conversion, under conditions of strong selective pressure (16). In 
terms of the positive/negative selection protocol, the initial loop-in event presumably takes 
place on a single chromosome, and this intermediate is rapidly propagated to other as yet 
unmodified chromosomes via gene conversion under strong positive selection. Similarly, 
the loop-out event likely initially takes place on one chromosome, and this spreads to the 
others under negative selection. 
 
1.1.4.2 Shuttle vectors 
A cryptic plasmid from M. maripaludis, pURB500 (23),  was used to produce a shuttle 
vector, pDLT44, capable of replication in both M. maripaludis, and E. coli. This vector 
contains a puromycin (PurR) and ampicillin (AmpR) resistance gene for selection in M. 
maripaludis and E. coli, respectively. It had been hypothesised that a region of pDLT44, 
ORF1, coded for a protein responsible for plasmid replication, and that one or both of two 
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regions, ORFLESS1 or ORFLESS2, was the replication origin (18). The M. maripaludis 
S0001 strain was produced by transferring the ORF1 region to the chromosomal UPT site 
in the Mm900 background. S0001 was able to support maintenance of pURB500 derived 
plasmids in which ORF1 had been deleted, demonstrating that this factor functioned in 
trans (12). The smallest plasmid derived from pDLT44 available at the time, pLW40 (12, 
24), was modified by deleting its ORFLESS2 region, creating pAW42. pAW42, was able 
to replicate in S0001, indicating that ORFLESS1 was the replication origin. The S0001 
strain was found to be transformed with pAW42 at a 7000-fold higher frequency than 
Mm900 with pLW40. Additionally, S0001 was transformed with pLW40 more efficiently 
than Mm900. The authors speculated this was because the ORF1 protein, which is 
chromosomally expressed in this strain, would be present immediately after plasmid 
transformation, and therefore permit rapid replication of any pURB500 based plasmid (12).  
 
1.1.4.3 Reporter genes 
While some genetic tools are relatively well developed in M. maripaludis, others are still 
comparatively limited.  Reporter genes are particularly problematic since widely used 
fluorescent proteins such as GFP cannot function in the strict anaerobic environment 
required to support M. maripaludis (25). The beta-galactosidase assay can be used in live 
M. maripaludis cells. However, since the colour formation of the substrate X-gal requires 
oxidised conditions (26), this assay involves the transient removal of plates from the 
anaerobic chamber and spraying with X-gal (27, 28), and is therefore only suitable for 
qualitative analysis of gene expression. Quantitative assays using beta-galactosidase are 
possible (29), but the required oxygen exposure times prohibit the use of living cells and 
must instead be performed on cell extracts (8).  
 
1.1.4.4 Gene expression 
This lack of a simple in vivo quantitative reporter assay is likely partly responsible for the 
relatively limited gene expression systems currently available in M. maripaludis. These 
comprise three constitutive promoters derived from closely related species: the widely used 
Phmv and Pmcr from Methanococcus voltae (M. voltae) (17, 30), and a histone promoter 
from Methanococcus vannielii (M. vannielii) (31). Inducible gene expression is possible 
using the endogenous nif promoter (28, 32). Expression from this promoter is regulated by 
repression based on nitrogen availability, with complete repression in cells grown in the 
presence of ammonium, intermediate repression when grown with alanine, and no 
repression (i.e. full expression) when grown in medium containing dinitrogen as the sole 
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nitrogen source (32). However, M. maripaludis grows somewhat more slowly on alanine, 
but substantially more slowly on dinitrogen compared with ammonium (28), presumably 
due to the high energy demands associated with nitrogen fixation (33). As such, this 
promoter is induced by growth in alanine in studies requiring inducible gene expression 
(34-37). 
 
The situation with the M. maripaludis nif promoter is representative of the majority of other 
inducible gene expression systems currently available for methanogens, which are 
primarily based on endogenous promoters regulated by growth substrates, which in 
addition to making culturing more complicated (38) may also lead to unwanted regulation 
of endogenous genes. These limitations can be avoided by using systems induced by 
substrates that are unlikely to be used by the recipient organism (i.e. from a distantly related 
donor organism). A single example of such a system has been developed in several species 
of the order Methanosarcina. The binding site for the bacterial tetracycline-response 
protein (tetR) was incorporated at different sites within a strong constitutive archaeal 
promoter. Genes under its control could be induced by tetracycline, and the level of 
induction was dependent on the position of the tetR binding site within the promoter. The 
end result was a series of promoters capable of driving different levels of gene expression 
when induced (39). Unfortunately, attempts to transfer this system to Methanococcus have 
been unsuccessful (8). 
 
1.1.5 The CRISPR/Cas System  
1.1.5.1 CRISPR/Cas as a genetic tool 
One tool which has relatively recently been developed is the CRISPR/Cas system. 
Endogenous CRISPR/Cas systems are a type of adaptive immunity in prokaryotes, and are 
found in many bacteria and the majority of archaea (40). They have been classified into a 
number of different types, and CRISPR/Cas9, which is a type II system, is the most widely 
used as a genetic tool (41). CRISPR/Cas9 consists of two components: a customisable 
guide RNA (gRNA) which provides targeting specificity by forming a DNA/RNA 
interaction, and a Cas9 nuclease, which mediates double strand break (DSB) induction. 
When both components are expressed in cells, they associate forming a functional complex 
and cleave DNA complimentary to the 5’ most 20 nucleotides (nt) of the gRNA. The 
targeting specificity of the Cas9 protein can therefore easily be controlled by varying this 
sequence. The only constraint with respect to target site is that it must be immediately 
followed by a 3 bp “protospacer adjacent motif” sequence: “NGG” (42). The CRISPR/Cas9 
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system and its derivatives have been used to perform many useful functions, including (but 
not limited to) genome and epigenome editing, regulation of gene expression, DNA 
imaging and investigating protein-genome interactions (43). CRISPR/Cas9 has been 
deployed in a wide variety of systems including bacteria, plants, animals and fungi (43), 
and it seems likely that the development of this highly versatile tool for use in M. 
maripaludis would be a useful addition to the existing genetic toolbox. 
 
1.1.5.2 CRISPR/Cas in archaea 
At the outset of this study, to our knowledge, no endogenous archaeal CRISPR/Cas9 
system had been reported, and it had not been deployed exogenously in any archaeal 
species. Conversely, type I and III systems, which were known to be endogenous to 
archaea, had been co-opted for the purpose of transcriptional regulation in Haloferax 
volcanii and Sulfolobus solfataricus (44, 45). We envisaged that CRISPR/Cas9 would be a 
superior tool for several reasons. Firstly, unlike type I and III systems, which are reliant on 
large multi-component effector complexes (43), CRISPR/Cas9 requires just two 
components (Cas9 and a gRNA) (46), and is therefore simpler. Secondly, since 
CRISPR/Cas9 is by far the most widely used system it is the best characterised (42). 
Finally, as type II systems were thought to be absent from all known archaea (41) it would 
theoretically have bypassed the potential risk of unwanted effects which may be associated 
with manipulating endogenous systems. During the course of this project, evidence of an 
endogenous archaeal type II system was discovered in two species of nanoarchaea (47). 
Shortly afterwards, Nayak and Metcalf (2017) reported the deployment of the widely used 
bacterial CRISPR/Cas9 system form Streptococcus pyogenes (S. pyogenes) in the archaeon 
Methanosarcina acetivorans (M. acetivorans).  Using this system, the authors were able to 
generate chromosomal modifications in less than half the time that had previously been 
required. The system was also relatively efficient, with chromosomal modifications 
achieved in approximately 20% of successfully transformed cells (48). This demonstration 
further highlights the potential benefits of developing this genetic tool for use in M. 
maripaludis.  
 
1.1.5.3 Deploying the CRISPR/Cas9 system in M. maripaludis 
Before the CRISPR/Cas9 system can be used as a genetic tool in M. maripaludis, it must 
first be to be shown to be functional in this organism. This will therefore be the focus of 
this project. A simple assay to demonstrate functionality of the CRISPR/Cas9 system 
would be to introduce a plasmid encoding Cas9 and a gRNA targeting the M. maripaludis 
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chromosome. Self-targeting of DSBs would be cytotoxic, and expected to result in lethality 
(49). Lower cell counts in test transformations compared with vector controls would 
therefore indicate Cas9 activity.  However, it was anticipated that the polyploid nature of 
M. maripaludis would be problematic for this assay design since all 30–55 copies of the 
genome (16) would theoretically have to be destroyed to give the test output (i.e. cell death).  
 
1.1.6 The Plasmid Invader Assay  
The plasmid invader assay (44) is based on a similar principle and could be adapted for use 
in M. maripaludis to overcome the potential problems associated with its polyploidy. Here, 
DNA encoding both the Cas9 gene and a gRNA targeting the antibiotic resistance gene of 
a plasmid “invader” could be stably introduced into M. maripaludis. This “test” strain 
would then be transformed with the invader plasmid, and colonies would be plated on 
selective medium corresponding to the resistance gene carried on this plasmid. Lower 
colony counts in test transformants (in which the invader plasmid is targeted by Cas9) 
compared with controls (in which it is not) would indicate that Cas9 is active and able to 
destroy the invader plasmid, resulting in reduced survival.  
 
The critical requirement of this assay is that the Cas9/gRNA complex expressed in the test 
strain cells must be able to completely remove the invader plasmid, since cell death 
resulting from plasmid loss is the only way Cas9 functionality would be detected.  In 
theory, the simplest way of increasing the likelihood of this is by designing the system such 
that the ratio of functional Cas9 complexes to invader plasmids is as high as possible: i.e. 
that the Concentration of Cas9 is high relative to the invader. There are two main design 
parameters which could be used to achieve this. Firstly, both components of the 
CRISPR/Cas9 system, the gRNA and Cas9 protein, should be expressed as strongly as 
possible. The simplest approach here would be to place both under the control of the 
strongest promoter possible. In addition, expression of both components from the 
chromosome rather than a shuttle vector would also be expected to result in higher 
expression. This is because the pURB500 plasmid, from which the M. maripaludis shuttle 
vectors are derived (18), was estimated to have a low copy number of approximately three 
per cell (23), whereas the M. maripaludis chromosome has 30-55 (16). Chromosomal 
expression would also theoretically satisfy the second design parameter: that the 
CRISPR/Cas9 components should have been expressed and formed functional complexes 
prior to challenge with the invader plasmid. This would be expected to increase the 
likelihood of complete invader plasmid clearance since the plasmid, which would 
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presumably enter the cell in a single copy following transformation, would theoretically be 
destroyed before it has had a chance to replicate.  
 
This invader assay must be achievable using the genetic tools currently available in M. 
maripaludis. To prove destruction of the invader plasmid is due solely to specific targeting, 
one or both of the CRISPR/Cas9 components would ideally be placed under the control of 
an inducible promoter, and cells induced following transformation with invader plasmid 
shown to exhibit lower survival than un-induced controls. The single inducible promoter 
available in M. maripaludis, nif, is only expressed at intermediate levels when induced by 
growth with alanine (28). Protein expression from nif was found to be lower than from 
Phmv (50), which suggests it is weaker, and therefore does not meet the design constraint 
that the CRISPR/Cas9 components should be expressed as strongly as possible. 
Additionally, low level expression from nif under growth on ammonium (i.e. the un-
induced state) has been reported in several studies (35-37), which could complicate 
interpretation of the invader assay output. The invader assay could equally be conducted 
using constitutive promoters. Two separate M. maripaludis strains could be produced, both 
constitutively expressing Cas9 and a gRNA from the chromosome. Critically, the two 
strains would differ in the targeting specificity of their gRNA: with the test strain 
expressing a gRNA which targets the invader plasmid, and the control strain expressing a 
gRNA which does not. When transformed with the plasmid invader, the test strain gRNA 
would be able to direct Cas9 to the invader, resulting in cleavage, whereas the control strain 
would not, so the plasmid would be retained. Both transformed strains would be plated in 
the presence of the antibiotic corresponding to the resistance gene carried by the invader 
plasmid, and a higher frequency of colonies recovered on control compared with test strain 
transformants would indicate that the CRISPR/Cas9 system was functional (Figure 1.1). 
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If CRISPR/Cas9 mediated plasmid destruction were highly efficient, the most suitable M. 
maripaludis background strain/invader plasmid combination would be S0001/pAW42. 
This is because this combination offers the highest currently available transformation 
efficiency (12), and assuming highly efficient plasmid cleavage in test strain cells, would 
yield the greatest difference in colonies recovered between the test and control strains, since 
more cells in total would be expected to be successfully transformed. If, however, Cas9 
mediated plasmid cleavage is inefficient, this combination could be problematic since test 
strain cells may be unable to clear the plasmid invader effectively before it is able to 
replicate, which is thought to be more rapid in S0001 (12). In this scenario, the Mm900 
Figure 1.1: The plasmid invader assay. 
1: Strains are produced by transforming Cas9 and a gRNA targeting the invader 
plasmid (left) or a control gRNA (right) onto the M. maripaludis chromosome. 2: 
Transformation of the test strain with a puromycin resistant invader plasmid results 
in Cas9 mediated cleavage (left). The control strain cannot target the plasmid, 
which remains intact (right). 3: Plating of the test strain on puromycin results in 
cell death: no colonies are recovered (left). Control plasmid transformants grow on 
puromycin: colonies are recovered (right). 
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strain and the smallest available plasmid it can be used with, pLW40 (12, 24), would be 
more appropriate. The disadvantage of this approach is that the generally lower 
transformation efficiency would be expected to result in overall lower colony recovery, 
which could make detecting differences between the test and control strains more difficult. 
Since the CRISPR/Cas9 system has not to our knowledge been used in M. maripaludis, it 
is not possible to accurately predict how efficient it will be. For this reason, it would be 
appropriate to conduct the invader assay using both background strain/invader plasmid 
combinations.  
 
1.1.7 Project Aims  
The primary aim of this project is to determine whether the CRISPR/Cas9 system is 
functional in M. maripaludis through use of a plasmid invader assay (Figure 1.1). This can 
be divided into a number of sub-aims: 
1. A set of constructs carrying the Cas9 and gRNA components required to produce 
the invader assay M. maripaludis test and control strains will to be designed, and 
an appropriate assembly scheme selected. 
2. The components will be assembled in a cloning vector and then transferred into the 
integrative M. maripaludis transformation vectors, which will be used to transform 
M. maripaludis strains S0001 and Mm900. The established positive/negative 
selection system will then be used to recover the test and control strains carrying 
the CRISPR/Cas9 assemblies on their chromosomes.  
3. The invader assay will be performed by transforming the invader plasmids 
pLW40/pAW40 into these strains, with lower survival in test compared with 
control strains indicating functionality of the CRISPR/Cas9 system. 
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Chapter 2: Materials and Methods 
2.1.1 Molecular Work 
2.1.1.1 Agarose gel electrophoresis 
DNA was separated by size on gels which contained agarose powder (Melford Biolabs) 
dissolved to a final concentration of 1% in TAE buffer (40 mM Tris, 20 mM acetic acid, 1 
mM EDTA). 3.5 µl of SYBR® Safe DNA Gel Stain (Thermo Scientific) was added to each 
120 ml gel, and 5 µl of GeneRuler 1 kb DNA Ladder (Thermo Scientific) was loaded on 
each for size estimation. 6x DNA Loading Dye (Thermo Scientific) was added to samples 
to a final concentration of 1x, with the exception of PCR products which contained 
premixed loading dye. Gels were run at 90 V until the loading dye had migrated 
approximately two thirds of the distance down the gel, then imaged. 
 
2.1.1.2 Resuspending gBlocks 
Lyophilised gBlocks (IDT) were centrifuged at 3000 g for 5 seconds and the pelleted 
material was resuspended in TE buffer (10mM Tris, 0.1mM EDTA, pH 8) to a final 
concentration of 20 ng/µl, then stored at 4°C. 
 
2.1.1.3 Restriction digestion 
All digestions were carried out using New England Biolabs (NEB) restrictions enzymes. 
1-2 µg of plasmid DNA (pDNA) products were digested in standard 50 µl reactions, or 
larger/smaller reaction mixtures scaled appropriately, as per the manufacturer’s 
instructions. 100 ng of digested product was first inspected on a gel to check the size was 
as expected. For plasmid material intended for downstream ligation or dephosphorylation, 
the remainder of the reaction was then either run on a gel and extracted, or used directly in 
the dephosphorylation reaction. For gBlocks, 500 ng of those over 500 bp in size, and 250 
ng of those under, were digested in 50 µl reactions which were otherwise as per the 
manufacturer’s instructions. 20 ng of product was inspected on a gel, and the remainder 
was PCR purified. 
 
2.1.1.4 PCR purification 
Digested or dephosphorylated products were purified using the Wizard® SV Gel and PCR 
Clean-Up System (Promega) as advised by the manufacturer, except the final elution step 
was carried out in 30 µl of Nuclease-Free Water (Promega).  
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2.1.1.5 Gel extraction 
Desired bands were extracted from agarose gels with the Wizard® SV Gel and PCR Clean-
Up System (Promega) as per the manufacturer’s instructions, except that in some cases the 
final elution step was carried out in 30 µl of Nuclease-Free Water (Promega). 
 
2.1.1.6 Plasmid dephosphorylation 
40 µl of pDNA (1.6 µg) which had been digested as described above (see “Restriction 
digestion”) was added directly to 5 µl of 1 U/µl Shrimp Alkaline Phosphatase (Takara Bio) 
and 5 µl of 10X SAP Buffer (Takara Bio). The reaction was mixed by pipetting, and 
incubated at 37°C for 30 minutes, then at 65°C for 15 minutes, then PCR purified. 
 
2.1.1.7 Ligation 
Digested products were ligated using T4 DNA Ligase (M0202S, NEB). 1:1, 3:1 and 6:1 
insert:vector molar ratios were used. Reactions were carried out as advised by the 
manufacturer, except with the heat inactivation step omitted. Most reaction mixtures 
contained the suggested 50 ng of recipient vector in a 20 µl total volume, but in some cases 
25 ng of vector was used. Following incubation at room temperature for 10 minutes, 10 µl 
of ligation reaction was transformed into E. coli (see “Transformation of ligation 
products/plasmids into E.coli”). If this did not yield satisfactory results on plating, the 
remainder of the reaction which had subsequently been incubated at 4oC overnight was also 
transformed. 
 
2.1.1.8 Golden Gate reactions 
For Golden Gate reactions the “Long protocol in ligase buffer” as explained in: 
(synbio.tsl.ac.uk/uploads/a94d80d88a4d03acbe8b53da74fdcf49.pdf) was used. For the 
reaction mixture, the holding vectors containing the fragments to be combined were added 
to 200 ng of destination vector at a 2:1 (holding:destination vector) molar ratio. 0.5 µl of 
400 U/µl T4 DNA Ligase (NEB), 1.5 µl of T4 DNA Ligase Buffer (NEB), 0.5 µl of 10 
U/µl BpiI (Thermo Scientific) and 1.5 µl of 10X BSA (NEB) were then added, made up to 
20 µl with dH₂O, and mixed by pipetting. Reactions were cycled in the Prime Thermal 
Cycler (Techne) as follows: 37oC for 20 minutes, 26 cycles of 37oC for 4 minutes, 16oC for 
4 minutes and 50oC for 5 minutes, then a final step of 80oC for 5 minutes. Reactions were 
held at 16oC and 5 µl of each was transformed into E. coli. 
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2.1.1.9 Transformation of ligation products/plasmids into E. coli 
Material was transformed into chemically competent E. coli strain DH5α (prepared as 
described in “Generating chemically competent cells (E. coli DH5α)”), or dam-/dcm- 
competent E. coli (genotype: ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 galT22 mcrA 
dcm-6 hisG4 rfbD1 R(zgb210::Tn10) TetS endA1 rspL136 (StrR) dam13::Tn9 (CamR) xylA-
5 mtl-1 thi-1 mcrB1 hsdR2) (C2925H, NEB). For DH5α, 5 or 10 µl of material (either 
ligation reaction or 1 ng total of intact plasmid) was added to 100 µl of competent cells 
which had been thawed on ice. The tube was mixed by flicking, incubated on ice for 30 
minutes and heat shocked at 42oC for 1 minute. Cells were incubated on ice for 2 minutes 
and then 1 ml of LB medium (which had been pre-incubated at 37°C) was added. The 
sample was incubated at 37°C under 200 rpm shaking for 45 minutes. A 200 µl aliquot was 
spread on an LB agar plate containing antibiotic, IPTG and X-gal where appropriate (see 
“LB agar plates”). The remainder of the sample was concentrated by pelleting at 6800 g 
for 2 minutes, removing the supernatant leaving approximately 100-200 µl, and 
resuspending the pellet in this. This was spread on an LB agar plate, and plates were 
incubated at 37°C overnight. For dam-/dcm- competent E. coli, 1 ng of intact plasmid 
diluted in a final volume of 5 µl with dH₂O was transformed according to the 
manufacturer’s instructions with the following exceptions. The 37°C incubation step was 
done at 200 rpm shaking. An additional concentrated sample (produced as described above) 
was plated for each transformation. 
 
2.1.1.10 Colony PCR 
Colony PCRs were carried out using DreamTaq Green DNA Polymerase (Thermo 
Scientific). A master mixture was set up according to the manufacturer’s instructions, with 
the exception that template DNA was not added, and then separated into 10 µl aliquots in 
PCR tubes. Under sterile conditions, single E. coli colonies were selected from 
transformation plates using pipette tips and inserted into 10 µl reaction mixtures in separate 
PCR tubes. Tips were left to stand for 2 minutes and then spread onto an LB agar master 
plate in sectors labelled according to the tube of origin. Master plates were incubated 
overnight at 37 °C. PCRs were carried out in the Prime Thermal Cycler (Techne). The 
Thermo Scientific Tm calculator (www.thermofisher.com/uk/en/home/brands/thermo-
scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-
resource-library/thermo-scientific-web-tools/tm-calculator.html) was used to select an 
appropriate annealing temperature according to the primers in each reaction. Reactions 
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were run for 35 cycles, with cycling conditions otherwise as suggested by the manufacturer. 
6 µl of each PCR product was analysed by agarose gel electrophoresis. 
 
2.1.1.11 Plasmid DNA isolation (from E. coli) 
Plasmid DNA was isolated from 5 ml of overnight E. coli culture grown in LB medium 
supplemented with antibiotic where appropriate (see “E. coli culturing”).  Either the 
GeneJET Plasmid Miniprep Kit (Thermo Scientific), or QIAprep® Spin Miniprep Kit 
(Qiagen), was used according to the manufacturer’s instructions, with the exception that 
plasmids which had previously been recovered at very low concentrations were eluted in 
30 µl of the respective manufacturer’s Elution Buffer. 
 
2.1.1.12 Generating chemically competent cells (E. coli DH5α) 
All steps were carried out under sterile conditions. All centrifugations were done for 10 
minutes at 3214 g at 4oC. E. coli DH5a was streaked from a glycerol stock onto an LB agar 
plate and grown overnight at 37oC. A single colony was then used to inoculate 5 ml of LB 
medium, which was incubated overnight at 37oC under 200 rpm shaking. 500 µl of 
overnight culture was used to inoculate 50 ml of LB medium in a 250 ml flask, which was 
incubated at 37oC under 200 rpm shaking for a further two hours. OD₆₅₀ measurements 
were then taken every 15 minutes until the culture reached OD₆₅₀ 0.5-0.6. For the following 
steps the cell suspension was kept on ice as much as possible. The culture was transferred 
to a 50 ml Falcon tube which had been pre-chilled on ice, and incubated on ice for a further 
five minutes. The culture was then centrifuged, the supernatant discarded, and the pellet 
resuspended in 10 ml of pre-chilled 0.1M CaCl₂. The suspension was incubated for 20 
minutes on ice and then spun again. The supernatant was discarded and the pellet 
resuspended in 0.6 ml of 50% glycerol which had been previously added to 1.4 ml of 0.1 
M CaCl₂ and pre-chilled. 100 µl aliquots of the resuspension were snap frozen in liquid 
nitrogen and stored at -80oC. 
 
2.1.1.13 E. coli culturing  
E. coli was grown in LB medium supplemented (where appropriate) with antibiotics to a 
final concentration of 100 µg/ml for ampicillin or 50 µg/ml for kanamycin. Under sterile 
conditions, a single E. coli colony from an LB agar plate, or a piece of frozen material from 
a glycerol stock was picked on a pipette tip and used to inoculate the medium (usually 5 
ml) in a 50 ml Falcon tube. The tube was sealed and incubated at 37oC, 200 rpm shaking 
overnight. 
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2.1.1.14 Long term plasmid storage 
Glycerol stocks were produced for all plasmids which had been confirmed to contain the 
correct insert by sequencing. Stocks were produced by mixing 500 µl of overnight E. coli 
culture containing the sequenced plasmid with 500 µl of 50% glycerol solution under sterile 
conditions in 2 ml Cryo.s™ screw cap tubes (Greiner Bio-One). Tubes were stored at -
80oC. 
 
2.1.1.15 Sequencing reactions 
Plasmid inserts were Sanger sequenced using the Lightrun tube service from GATC 
Biotech. Premixed reactions were produced by adding 400 ng of pDNA to 25 µM of the 
appropriate primer in a final volume of 10 µl, and sent to the company for sequencing.  
 
2.1.2 Aerobic Media and Antibiotics 
2.1.2.1 LB medium  
For 1 L, 10 g of NaCl, 10 g of tryptone and 5 g of yeast extract were added to 1 L dH₂O 
and mixed with a magnetic stirrer for 10 minutes. Medium was autoclaved at 121oC, 15 psi 
for 20 minutes. 
 
2.1.2.2 LB agar plates 
For LB agar, the protocol was as for “LB medium”, except that agar powder was added just 
before autoclaving (15 g per 1 L LB). The medium was cooled to approximately 55oC. 
Under sterile conditions, antibiotics were added (if required) to a final concentration of 100 
µg/ml (ampicillin) or 50 µg/ml (kanamycin) and mixed. The media was then poured onto 
plates (approximately 25 ml per plate), which were left with the lids partially off for 1 hour 
to set. Lids were replaced and plates were stored at 4oC. For blue/white screening, 40 µl of 
100 mM IPTG and 120 µl of 20 mg/ml X-gal were spread over the surface of the plate just 
before bacteria were added.   
 
2.1.2.3 Ampicillin and kanamycin 
For 100 mg/ml ampicillin stock solution, 1 g of ampicillin powder was dissolved in 10 ml 
dH₂O. The solution was filter sterilised into 1 ml aliquots, which were stored at -21oC. 30 
mg/ml kanamycin stock solution was made in the same way except 0.3 g of powder was 
used.  
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2.1.2.4 IPTG 
100 mM stock solutions were prepared and stored as described for antibiotics (see 
“Ampicillin and kanamycin”), except 0.238 g of IPTG powder was used per 10 ml.  
 
2.1.2.5 X-gal 
For 20 mg/ml stock solution, 0.2 g of X-gal was added to 10 ml of dimethylformamide, 
and dissolved by vortexing. 1 ml aliquots were stored in tubes wrapped in aluminium foil 
at -21oC. 
 
2.1.3 M. maripaludis 
2.1.3.1 M. maripaludis culturing 
M. maripaludis cultures were grown in Anaerobic Culture Tubes (Bellco Glass) containing 
5 ml of McCas medium (see below) sealed with 20 mm Blue Butyl Rubber Stoppers (GPE 
Scientific) and crimped with 20 mm Aluminium Crimp Caps (Supelco). To establish 
cultures, a glycerol stock containing the desired strain was transferred to the anaerobic 
chamber on dry ice, along with a fresh McCas tube. The stoppers were removed and a piece 
of frozen culture was transferred from the stock to the McCas tube. The stoppers were 
replaced and the tubes removed from the chamber. 0.1 ml of 2.5% Na₂S was then 
transferred anaerobically to the inoculated McCas tube using a needle and syringe which 
had been pre-gassed with H₂/CO₂. This was then pressurised to 40 psi with H₂/CO₂ (80:20) 
and incubated at 37oC under 110 rpm shaking. Once dense growth was visible (typically 
between 24-48 hours), a subculture was made by transferring 0.2-0.5 ml of culture using a 
needle and pre-gassed syringe into a fresh McCas tube which had had Na₂S added as 
explained above. This was then incubated as explained above. Cultures were maintained 
by subculturing continuously in this manner throughout the project. 
 
2.1.3.2 McCas medium 
All components (Table 2.1) with the exception of DTT were combined in a 1 L round 
bottomed flask (Duran) and mixed with a magnetic stirrer for 10 minutes. DTT was then 
added, and the solution placed under a stream of N₂/CO₂ (30 psi) by inserting a gassing 
cannula into the flask. A bung was placed in the neck of the flask such that a small gap 
where it contacted the cannula was left for displaced air to escape. The solution was made 
anaerobic by heating with a Bunsen burner (blue flame) while swirling continuously. Once 
the colour had changed from blue to colourless, the vessel was sealed by simultaneously 
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applying pressure to the bung while withdrawing the cannula. The flask was taken into the 
anaerobic chamber, and 5 ml aliquots of medium dispensed into Anaerobic Culture Tubes 
(Bellco Glass), which were then sealed with 20 mm Blue Butyl Rubber Stoppers (GPE 
Scientific) (both of which had been placed in the chamber at least 2 hours previously). The 
tubes were removed from the chamber and crimped with 20 mm Aluminium Crimp Caps 
(Supelco). The headspace in the tubes was exchanged 4 times by pressurising to 20 psi with 
H₂/CO₂ (80:20), followed by vacuum withdrawal. Tubes were pressurised to 30 psi with 
H₂/CO₂ (80:20) and autoclaved at 121oC, 15 psi for 20 minutes. 
 
 
 
2.1.3.3 N-free trace minerals (1000x)  
For 100 ml, Na₃Citrate•2H₂O (Table 2.2) was dissolved in 80 ml dH₂O and the pH was 
adjusted to 6.5. The remaining components (Table 2.2) were dissolved in this, and the 
solution was made up to 100 ml with dH₂O.   
 
Table 2.1: McCas medium components. 
See below for recipes of solutions marked 
“*”. 
 
Component Amount
dH₂O 100 ml
NaHCO₃ 1 g
NH₄Cl 0.1 g
NaCl 4.4 g
Na Acetate•3H₂O 0.28 g
Bacto Casamino Acids 0.4 g
Dithiothreitol (DTT) 0.1 g
N-free trace minerals (1000x)* 0.2 ml
Vitamin solution (100x)* 2 ml
N-free general salts solution* 100 ml
FeSO₄ solution* 1 ml
K₂HPO₄ solution* 2 ml
Rasazurin solution* 0.2 ml
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2.1.3.4 Vitamin solution (100x)  
For 1 L, components (Table 2.3) were dissolved in 1 L dH₂O. 
 
 
 
2.1.3.5 N-free general salts solution 
For 1 L, components (Table 2.4) were dissolved in 800 ml dH₂O, then made up to 1 L with 
dH₂O. 
 
Table 2.2: N-free trace minerals 
(1000x) components. 
 Component Amount (g/100 ml)
Na₃Citrate•2H₂O 2.1
MnSO₄•H₂O 0.45
CoCl₂•6H₂O 0.1
ZnSO₄•7H₂O 0.1
CuSO₄•5H₂O 0.01
AlK(SO₄)₂•12H₂O 0.018
H₃BO₃ 0.01
Na₂MoO₄•2H₂O 0.1
NiCl₂•6H₂O 0.025
NaSeO₃•5H₂O 0.3
V(III)Cl 0.01
Na₂WO₄•2H₂O 0.0033
Table 2.3: Vitamin Solution (100x) 
components. 
 
Component Amount (g/L)
Biotin 0.002
Folic acid 0.002
Pyridoxine HCL 0.01
Thiamine HCL 0.005
Riboflavin 0.005
Nicotinic acid 0.005
DL-calcium pentothenate 0.005
Vitamin B₁₂ 0.0001
p-aminobenzoic acid 0.005
Lipoic acid 0.005
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2.1.3.6 FeSO₄ solution 
For 100 ml, 0.19 g of FeSO₄ was dissolved in 100 ml of 10 mM HCL. 
 
2.1.3.7 K₂HPO₄ solution 
For 1L, 14 g of K₂HPO₄ was dissolved in 1 L dH₂O. 
 
2.1.3.8 Resazurin solution 
For 100 ml, 0.1 g Resazurin was dissolved in 100 ml dH₂O.  
 
2.1.3.9 Transformation of plasmids into M. maripaludis 
A slightly modified version of the PEG-based transformation protocol (17) was carried out 
as explained in: (faculty.washington.edu/leighj/protocols/transformation_procedure.pdf). 
All centrifugation steps were carried out at 1070 g, 20oC for 10 minutes. M. maripaludis 
cultures (S0001 strain) to be transformed were grown to an OD₆₀₀ of 0.7-1.0, and then 
pressurised to 30 psi with H₂:CO₂ (80:20). Cells were centrifuged and the supernatant 
removed by inverting the tube, inserting a needle through the stopper and using the pressure 
to pushed it out. 5 ml of transformation buffer was then added using a needle and syringe 
which had been pre-gassed with H₂/CO₂, and the pellet resuspended by tapping the tube. 
The tube was repressurised to 30 psi with H₂/CO₂ (80:20), and centrifuged. The supernatant 
was removed and the pellet resuspended in 0.375 transformation buffer as described above. 
The tube was taken into the anaerobic chamber, the stopper removed, and 5 µg of pDNA 
(which had been placed in the chamber with the cap open at least two hours previously) 
was added and mixed immediately by tapping. The stopper was replaced and the tube 
removed from the chamber.  The tube was flushed with N₂ for 1 minute, and 0.225 µl of 
PEG solution was added using a needle and syringe (pre-gassed as above). Tubes were 
pressurised to 30 psi with N₂ and then incubated at 37oC for 1 hour. A fresh McCas tube 
was prepared by adding 0.1 ml of 2.5% Na₂S with a pre-gassed needle and syringe, and 
Table 2.4: N-free general salts 
solution components. 
  
Component Amount (g/L)
KCL 0.68
MgCL₂•6H₂O 5.5
MgSO₄•7H₂O 6.9
CaCl₂•2H₂O 0.28
NH₄Cl 1
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pressurised to 30 psi with H₂/CO₂ (80:20). The fresh medium was transferred into the 
transformation tube by inserting the long end of a Vacutainer® needle (BD Diagnostics) 
through the stopper of the transformation tube, and just as the pressure was lost pushing 
the short end through the stopper of the inverted McCas tube. The needle was removed and 
the transformation tube was mixed by tapping, repressurised to 30 psi with H₂/CO₂ (80:20), 
and centrifuged. The tube was then inverted carefully so as not to disturb the pellet, the 
long end of a vacutainer needle was inserted through the stopper, and the pressure used to 
expel the supernatant. Once the pressure was released, the short end of the needle was 
pushed through the stopper of a fresh McCas tube (prepared as above), and the two tubes 
were inverted, resulting in the pressurised transfer of the fresh medium into the 
transformation tube. The needle was removed and the pellet resuspended by tapping. The 
tube was flushed with H₂/CO₂ for 1 minute, and then pressurised to 40 psi with H₂/CO₂ 
(80:20). Tubes were incubated at 37oC under 110 rpm shaking overnight, and then 
subcultured into appropriate selection (see below). 
 
2.1.3.10 M. maripaludis outgrowth and selection following transformation 
All incubation steps were done at 37oC under 110 rpm shaking. Following overnight growth 
(see “M. maripaludis transformation” ), 0.2 ml of transformed culture was used to inoculate 
a fresh McCas tube which had had 0.1 ml of 2.5% Na₂S, and neomycin to a final 
concentration of 0.5 mg/ml added using pre-gassed needles. This was then incubated for 2 
days. The following steps were not carried out in this study but are included for reference. 
0.05 ml of the resulting culture is subcultured into McCas containing neomycin, (prepared 
as above), and incubated overnight. 0.05 ml of overnight growth is then subcultured into 
plain McCas tubes (i.e. containing 0.1 ml of Na₂S but no selection), and incubated 
overnight. These cultures are then spread onto McCas agar plates containing 8-
azahypoxanthine to a final concentration of 250 µg/ml, and incubated in a pressure vessel 
at 15 psi, 37oC for 3-4 days. Resulting colonies are then screened for the desired 
modification. 
 
2.1.4 Anaerobic Antibiotics and Solutions 
2.1.4.1 Reducing agent 
100 ml of dH₂O and 100 ml of 1M Tris base were made anaerobic by transferring them in 
250 ml bottles (Duran) to the anaerobic chamber, removing the caps and leaving them for 
24 hours with occasional swirling. For 50 ml of reducing agent, 0.5 g of cysteine•HCL•H₂O 
and 0.39 g of DTT (in tubes that had been opened in the chamber 2 hours previously) were 
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dissolved in 50 ml anaerobic dH₂O. The solution was then filter sterilised through a 0.22 
µm filter unit (Millex®) into a sterile 100 ml anaerobic media bottle which has been placed 
in the chamber the previous day. The pH was adjusted to 7.5 with the anaerobic Tris base. 
For storage, the bottle was stoppered, taken out of the chamber, crimped, pressurised to 12 
psi with N₂, and then placed at 4oC. 
 
2.1.4.2 Transformation buffer 
For 250 ml, all components (Table 2.5) were added to 250 ml dH₂O, mixed with a magnetic 
stirrer for 10 minutes, and the pH was adjusted to 7.5. The solution was taken into the 
anaerobic chamber and made anaerobic as explained previously (see “Reducing agent”). 
50 ml aliquots were then filter sterilised into sterile anaerobic media bottles which had been 
placed in the chamber the previous day, and 1 ml or reducing agent (see above) was added 
to each and mixed. Bottles were left open with occasional agitation until the colour changed 
from blue to colourless, at which point they were prepared for storage as described (see 
“Reducing agent”). 
 
 
 
2.1.4.3 PEG solution 
For 100 ml 40% (wt/vol) PEG solution, 40 g of PEG 8000 (Sigma-Aldrich) was added to 
75 ml of transformation buffer (which had been prepared as explained above up to the point 
where the pH was adjusted to 7.5). The solution was mixed at 60oC with a magnetic stirrer 
for 30 minutes, and then made up to 100 ml with transformation buffer. The solution was 
taken into the anaerobic chamber and prepared from this point as explained for the 
transformation buffer, except that it was not filter sterilised.  
 
Table 2.5: Transformation 
buffer components. 
See above for recipe of solution 
marked “*”. 
 
Component Amount
Tris 1.5 g
Sucrose 30 g
NaCl 5.5 g
MgCl₂•6H₂O 0.05 g
Resazurin Solution* 150 µl 
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2.1.4.4 Na₂S solution 
For 25% Na₂S solution, 12.5 g of sodium sulfide nonahydrate crystals (Sigma-Aldrich) 
were weighed out, taken into the anaerobic chamber and dissolved in 50 ml of anaerobic 
dH₂O in an anaerobic bottle which had been placed in the chamber the previous day. 2.5% 
Na₂S solution was made by diluting the 25% solution in anaerobic water. Solutions were 
stoppered, crimped and stored at room temperature. 
 
2.1.4.5 Neomycin  
For 25 mg/ml stock solutions, 0.25 g of neomycin sulphate powder was weighed out, taken 
into the anaerobic chamber and dissolved in 10 ml anaerobic dH₂O. The solution was filter 
sterilised into an anaerobic media bottle then made anaerobic and stored as explained above 
(see “Reducing agent”).  
 
2.1.5 In Silico Methods 
2.1.5.1 Codon optimisation 
The SpCas9 amino acid sequence was obtained from UniProt (51) (accession number: 
Q99ZW2). For codon optimisation using Jcat (52), the M. maripaludis S2 strain codon 
usage table was selected, with all other settings set to default. As the COOL codon 
optimisation resource (53) does not directly support M. maripaludis, the codon usage 
frequencies for the S2 strain were imported as a custom profile. This data along with the 
total GC and GC3 content values was obtained from the Codon Usage Database (54), which 
sources data from Genbank (55). For the final run used to generate the SpCas9 codon 
optimisation used in this study (Mmp-Cas9) the tool was run using default settings with the 
following exceptions: optimisation criteria: ICU “maximise”, all other options: “ignore”; 
codon auto correction: 0; 5’ folding instability: maximise (to a window of the first 40 
bases); total GC content target percentage: 34.01; GC3 content target percentage: 25.17. 
Output sequences were filtered by ICU score, and of those with the joint highest score one 
was arbitrarily selected. 
 
2.1.5.2 gRNA design 
gRNA target sequences were designed and/or tested using the in-built “Find CRISPR Sites” 
tool in Geneious 10.0.7 (56). To select potential target sites and simultaneously generate 
their predicted on-target scores, the region to be targeted within the appropriate gene was 
selected and the tool was run on “score sites through their on-target activity” with default 
parameters. On-target scores are calculated by Geneious as explained in (57). For off-target 
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analysis, a library was first created containing the M. maripaludis S2 genome sequence, 
the sequences of plasmids pCRPrtneo, pBLPrt, pLW40 and pAW42, and in the case of the 
eGFP gRNA the eGFP gene sequence. Off-target scores for all sites within the candidate 
target regions were then generated by selecting “score sites through off-target analysis” 
using default setting with the following amendments: speed and filter strategy: “slow – 
score all sites”; maximum mismatches allowed against off-target sites: 23; maximum 
mismatches allowed to be indels: 4; score against off-target database: set to the respective 
library for that target region (see above). Off-target scores are calculated by Geneious as 
explained in (58). 
 
2.1.5.3 Random sequence generation 
Random control gRNA targeting sequences were generated using the Random DNA 
Sequence Generator resource (http://www.faculty.ucr.edu/~mmaduro/random.htm). 
 
2.1.5.4 Checking complexity IDT gblocks 
Potential gBlocks were tested using the “Test Complexity” function on the IDT website 
(https://www.idtdna.com/site/Order/gblockentry). 
 
2.1.5.5 Removal of incompatible restriction enzyme sites 
Pre-existing restriction enzyme recognition sites incompatible with the designed cloning 
schemes were removed from gBlocks at the design stage. For sites located within protein 
coding components, the codon usage frequencies corresponding to the organism in which 
that component would be expressed (M. maripaludis S2 and E. coli K12 strains) were 
obtained from the Codon Usage Database (54). For each site, all possible base changes 
which would result in removal of the restriction site while maintaining the identity of the 
amino acid designated by the codon they were located in (i.e. silent) were considered, and 
the change resulting in the use of the next most frequently used codon for that amino acid 
was selected. For restriction sites located outside of coding regions, a single base was 
arbitrarily changed to remove them. 
 
2.1.5.6 Construct design and testing 
Constructs were designed using Geneious 10.0.7 (56). Cloning strategies were checked by 
in silico simulation of all of the digestion/ligation steps in both Geneious (56) and 
Benchling (www.Benchling.com). 
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2.1.5.7 Primer design 
Primers (Table A1, Appendix) were designed using the in-built primer design tool in 
Geneious 10.0.7 (56). 
 
2.1.5.8 Sequence analysis 
Sequence analysis was conducted using Geneious 10.0.7 (56). Reads were trimmed 
manually to remove low quality or ambiguous base calls. These were then aligned to an in 
silico prediction of the appropriate plasmid containing the expected insert. Finally, the 
alignment was inspected manually for mismatches. 
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Chapter 3: In Silico Planning 
3.1 Introduction 
The object of this project is to determine whether the CRISPR/Cas9 system is functional 
in M. maripaludis through use of a plasmid invader assay (Figure 1.1). The production of 
the test and control strains which underpin this assay would require the introduction of the 
two components of the CRISPR/Cas9 system: the Cas9 gene and a gRNA, onto the M. 
maripaludis chromosome. Each would need to be placed into a module containing a 
suitable promoter and terminator (Figure 3.1). The introduction of these expression 
modules onto the chromosome would be achieved using the existing M. maripaludis 
transformation protocol (19), which has three stages. In the first, material to be introduced 
(i.e. the two modules) is assembled within a cloning vector in E. coli. Next, the portion of 
the cloning vector containing both modules is subcloned into an M. maripaludis 
transformation vector. Finally, M. maripaludis is transformed with this vector, resulting in 
chromosomal integration of the expression modules, yielding the test and control strains.  
 
 
 
3.1.1 Chapter Aims 
The first step of implementing the plasmid invader assay, and the aim of this chapter, is to 
design the two expression modules to be assembled within the E. coli cloning vector. This 
can be sub-divided into two parts. In part one, the individual components of each module 
need to be designed. In part two, a system by which they can be physically assembled 
together into a cloning vector must be planned. For the invader assay to confirm that the 
CRISPR/Cas9 system is functional in M. maripaludis, there must be detectably lower 
survival rates in test strain cells compared with the controls (Figure 1.1). The factor 
Figure 3.1: Composition of the Cas9 and gRNA 
modules. 
Two modules will be transformed into M. maripaludis to 
generate the test and control strains: both are composed of 
three separate elements. The Cas9 module (left) contains 
the Cas9 gene and the gRNA module (right) contains 
either the test or control gRNA. Both are under the control 
of a suitable M. maripaludis promoter and terminator. 
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responsible for invader plasmid destruction and ultimately cell death in the test strain (i.e. 
the test output) is the functional Cas9/gRNA complex. It is anticipated that greater amounts 
of this complex will result in higher levels of plasmid destruction, and therefore a more 
pronounced difference in test and control strain cell survival (see Chapter 1). For this reason 
the primary design constraint with regard to the module components and their assembly 
will be ensuring that expression levels of the gRNA and Cas9 protein are as high as 
possible.  
 
3.1.2 Component Design 
3.1.2.1 Promoter and terminator 
Both expression modules (Figure 3.1) must be placed under the control of a strong promoter 
which is functional in M. maripaludis. The gRNA promoter has an additional design 
constraint in that it must have a strict transcriptional start site. This is because the 20 nt 
portion of the gRNA responsible for targeting in the CRISPR/Cas9 system is transcribed 
first (42). Of the promoters available for M. maripaludis, (17, 28, 30, 31), only two: nif 
(59) and a minimal version of Phmv (James Chong, personal communication) have had 
their transcriptional start sites mapped. As discussed previously, nif is not a suitable option 
for the invader assay (see Chapter 1).  The only remaining option, Phmv, is both 
constitutive and strong under normal growth conditions (60), making it an appropriate 
choice. Some promoters exhibit bias, whereby they have a preference for a certain base to 
be transcribed first: for example the U6 promoter which is routinely used to express the 
gRNA component in eukaryotic CRISPR/Cas9 studies requires a G at the +1 position (42). 
It is not known whether Phmv exhibits promoter bias, because the promoter has only been 
used in one conformation. However, in this conformation the first base transcribed is an 
adenine. To account for the possibility of promoter bias in the minimal Phmv it would be 
desirable (if possible) to select gRNA sequences beginning with adenine. 
 
Phmv is known to drive high expression levels (60), which also makes it an attractive option 
for use with the Cas9 module. One potential issue with using the same promoter twice is 
that it could cause undesirable recombination events, either within the cloning vectors or 
on the M. maripaludis chromosome itself. However, using one of the other remaining 
promoters available in M. maripaludis to drive Cas9 expression also presents potential 
risks. The M. vannielii histone promoter has only been used in a single study (31), and is 
therefore a less reliable option than Phmv because it has been validated less extensively. 
The only other remaining option, Pmcr from M. voltae, is used to express the nemocyin 
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and puromycin resistance genes in the M. maripaludis transformation (19) and replicative 
(12, 24) vectors, and would therefore theoretically be subject to the same potential 
recombination difficulties. At just 73 base pairs (bp) in length, the minimal Phmv is 
relatively small, which makes the probability of recombination unlikely. Additionally, 
multiple instances of this promoter have been used to simultaneously drive the expression 
of several genes in M. maripaludis before without issue (James Chong, personal 
communication). Taken together, this suggests that Phmv is also a suitable promoter choice 
for the Cas9 module in the invader assay.  
 
Both modules must also contain a transcriptional termination signal. The only functionally 
characterised terminator sequence in M. maripaludis is the M. voltae MCR terminator 
(Tmcr) (17, 20, 21), making this the only currently available option. 
 
3.1.2.2 Cas9 
Several alternative versions of the Cas9 protein have been used in CRISPR/Cas9 studies in 
various organisms (43). However, by far the most commonly used and therefore widely 
validated comes from S. pyogenes (SpCas9) (42), and will therefore be used in this study. 
When introduced in their native format, exogenous protein coding genes may be expressed 
poorly in new host organisms due to the presence of codons within the sequence which are 
rare in host genes (61). Such a situation would clearly be undesirable in the invader assay, 
since a key determinant of its success is high Cas9 expression. To avoid this, the SpCas9 
sequence should be codon optimised to M. maripaludis. The basic premise of codon 
optimisation is to modify the codons in the exogenous gene such that they correspond as 
closely to the usage bias of the host as possible (62), thereby achieving a better fit to host 
expression parameters, for example by making more economical use of its tRNA repertoire 
(63).  
 
Multiple different methods for optimising codons exist, many of which are supported by 
online tools (64). Systems based on the codon adaptation index (CAI) (65), such as the Jcat 
tool, aim to replace all codons in an exogenous DNA sequence with the most frequently 
used synonymous codon from a subset of highly expressed host genes (52). Jcat comes 
with in-built codon bias data for M. maripaludis, calculated from a set of genes predicted 
to be highly expressed in this organism (52, 66). An alternative but similarly simplistic 
option is to optimise based on host individual codon usage (ICU), which aims to select 
codons based on their proportional usage in a given set of genes (64). ICU based 
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optimisation is supported by the Codon Optimization On-Line (COOL) program, which 
offers additional parameters such as customisable target % GC content (53). However, 
unlike Jcat it does not directly support M. maripaludis. 
 
3.1.3 gRNA 
The invader assay requires the production of two M. maripaludis strains, which differ only 
in that one should be able to target the invader plasmids (test strain) and the other should 
not (control strain). Target site specificity of the CRISPR/Cas9 system is conferred by the 
gRNA. This consists of an invariant structural scaffold sequence, and a variable 20 nt 
targeting sequence. Since this 20 nt sequence is solely responsible for target site specificity 
(67), this stretch of DNA will be the only difference between the test and control strains.  
 
gRNA design must be considered carefully, because different targeting sequences are 
known to exhibit different levels of on- and off-target activity (68). In the invader assay, 
poor on-target activity in the test strain (i.e. selecting a targeting sequence which does not 
deliver the Cas9 component effectively to the target site), could result in no or little invader 
plasmid cleavage. This could mean that even if the CRISPR/Cas9 system was functional in 
M. maripaludis, the level of cell death in the test strain might fall below the level of 
detection, resulting in a false negative outcome. Poor off-targeting (or a propensity for the 
selected gRNA targeting sequence to bind at unintended sites) could be similarly 
problematic. In the worst case, off-target cutting in the cloning or M. maripaludis 
transformation vectors could result in plasmid linearisation and subsequent destruction. 
Leaky activity of Phmv has been reported in E. coli (30), which means such activity could 
prohibit the production of the test strains. Off-targeting to the M. maripaludis chromosome 
could also cause the assay to fail. Cuts resulting in chromosomal destruction could lead to 
reduced survival, although it should be noted that the highly polyploid nature of M. 
maripaludis (16) would theoretically provide some level of buffering against this. Perhaps 
more significantly, ectopic targeting to the chromosome in the test strain would effectively 
sequester a certain proportion of Cas9 away from the intended plasmid invader target, 
which could result in undesirable increases in cell survival.  
 
Algorithms which attempt to assess the quality of candidate gRNA sequences based on 
estimated on- (57) and off- (58) target activities have been developed. However, the extent 
to which these systems can accurately estimate these parameters are limited, particularly in 
the case of off-targeting (69). This means that while such algorithms can serve as useful 
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tools, their outputs should be regarded with caution. The most reliable method for 
determining on-target activity is experimental validation (70). For this reason, it would be 
preferential to use a validated gRNA target sequence in the test strain for the invader assay. 
 
3.1.3.1 Test gRNA 
The test gRNA must be capable of delivering Cas9 to the plasmid invader. The assay will 
be conducted in two different M. maripaludis strains, Mm900 and S0001, each of which 
has its own cognate replicative plasmid (plasmid invader), pLW40 and pAW42, 
respectively (see Chapter 1). The use of a single test gRNA capable of targeting both 
plasmids would be advantageous for two reasons. Firstly, it would reduce the number of 
plasmids which need to be produced, and secondly it would allow more reliable 
comparisons to be drawn between the results obtained in each strain. pAW42 was produced 
through excision of a portion of pLW40 (12), which means any target site on pAW42 would 
be present on both plasmids. The structural backbone of these plasmids can be ruled out as 
containing any pre-validated gRNA target sites since both are unique to M. maripaludis, 
and to our knowledge no study using the CRISPR/Cas9 system has been reported for this 
organism. The protein coding components of these plasmids: an ampicillin and a 
puromycin resistance gene, are good candidates for containing validated gRNA target sites 
since these elements are also present in many other cloning vectors. However, AmpR is 
unsuitable because it is present on the M. maripaludis transformation vectors, leaving just 
the PurR gene. Only a single publication could be found in which a gRNA targeting the 
PurR gene has been validated (71). The authors report their gRNA was able to knock out 
the PurR gene in mouse cells, resulting in a 30% rate of cell death when plated on 
puromycin. This gRNA is particularly suitable for the invader assay because in addition to 
being validated, it has also been successfully used in a similar context (i.e. a cell destruction 
assay). 
 
Another way of obtaining a validated gRNA target site in a feature shared by the invader 
plasmids pLW40 and pAW42 would be to modify both such that a new target site was 
introduced. The advantage of this approach is that it would allow the selection of essentially 
any gRNA, which means that one which has been extensively validated could be selected. 
Highly validated gRNAs can be obtained from online resources such as the Addgene 
validated gRNAs database (www.addgene.org/crispr/reference/grna-sequence), and are 
typically located in genes which are highly targeted in CRISPR/Cas9 studies, such as the 
enhanced green fluorescent protein (eGFP) gene (72-75). 
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3.1.3.2 Control gRNA 
The purpose of the control strain is to demonstrate that any increased level of cell death 
observed in the test strain is due solely to the specific targeting of Cas9 to the invader 
plasmid. As such the key requirement of the control gRNA is that in addition to being 
unable to target any part of the M. maripaludis chromosome or transformation plasmids, 
(as is the case for the test gRNA), it must also not be able to target the invader plasmids. 
An approach which could be used to generate the control gRNA would be to “scramble” 
the targeting sequence of the test gRNA (i.e. generate a random sequence with the same 
GC content). 
 
3.1.4 Construct Design and Assembly 
3.1.4.1 Obtaining parts 
Once the individual components have been designed, they will need to be obtained and 
assembled into the cloning vector. The Cas9 component will have to be obtained as a 
synthesised piece of DNA since it will be codon optimised and thus consist of a novel 
sequence. The remaining components (i.e. Phmv, Tmcr and the gRNAs) could theoretically 
be generated by PCR. However, since they are small relative to the Cas9 gene a simpler 
option would be to have all the components chemically synthesised. DNA synthesis 
services such as gBlocks from IDT are now widely available (76). gBlocks are offered in 
sizes ranging from 500 bp to 3 kb, with cost and production times increasing with size 
(https://www.idtdna.com/pages/products/genes/gblocks-gene-fragments/). It should be 
noted that using this approach will impact on the construct design processes because the 
DNA sequences selected must abide by the synthesis constraints of the manufacturer. In 
addition to size limitations, highly repetitive sequences (particularly at the 5’ and 3’ ends), 
and sequences with very low GC content cannot be ordered as gBlocks 
(https://www.idtdna.com/pages/products/genes/gblocks-gene-fragments/).  
 
3.1.4.2 Combining parts: Golden Gate 
The total size of the unit to be assembled in the cloning vector will be too large to be ordered 
as a single gBlock (the Cas9 gene alone is 4104 bp in length (77)), and will therefore have 
to be split and ordered as separate fragments. This necessitates the use of a strategy for 
combining these into the cloning vector. The Golden Gate system (78) is particularly 
suitable for this application for a number of reasons. Firstly, unlike standard type II 
restriction enzyme cloning it is scarless (79, 80), which means the boundary which must 
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occur somewhere within the Cas9 gene by virtue of its size would be easier to select. 
Secondly, Golden Gate fragments can be easily varied and exchanged (81), which means 
the three different versions of the construct (i.e. harbouring the three alternative gRNAs) 
could be produced simply by modifying the gBlock containing this component. It is worth 
noting that this characteristic also makes the construct more versatile, as further 
modifications could easily be made, for example to incorporate different promoters or 
additional gRNAs. 
 
The Golden Gate system makes use of type IIS restriction enzymes which cleave outside 
of their recognition sequences, leaving short overhangs (78). For example, the widely used 
BpiI enzyme (a BbsI isoschizomer) cleaves 2bp downstream of this site leaving a 4bp 
overhang (82). Complementarity between pre-determined overlaps following digestion 
allows different DNA fragments to be ligated together in a user specified order. This allows 
the assembly of multiple DNA fragments into a destination vector in a one pot, one step 
reaction (83) (Figure 3.2). While double stranded DNA (dsDNA) fragments can in principle 
be assembled directly into a destination vector, they are typically first incorporated into 
intermediate holding vectors to limit assembly errors (80).  
 
Three key design constrains must be followed when designing a Golden Gate strategy. 
First, pre-existing type IIS recognition sites corresponding to the selected enzyme must be 
removed from elsewhere in the fragments/cloning vectors to prevent unwanted cleavage. 
Second, overhangs should be non-palindromic and differ from each other by at least two 
bases to prevent possible unwanted ligation events. Third, the holding and destination 
vectors should have different antibiotic resistances to allow cells transformed with 
undigested holding vector to be purged on plating (79, 83). Provided these parameters are 
met, Golden Gate assembly can in principle be carried out in any vector system. However, 
“MoClo” kits, which contain a series of holding and destination vectors with pre-
determined overhangs can be used to streamline the process (79, 84, 85). These vectors 
often contain useful features, for example inclusion of a LacZ reporter gene in a “dropout” 
region bounded by two type IIS restriction sites allows cells harbouring undigested 
destination vector to be distinguished by blue/white screening (84) (Figure 3.2). 
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Figure 3.2: Golden Gate assembly. 
1:  Parts to be assembled (A-C) are first inserted into holding 
vectors. 2: Each part contains type IIS restriction enzyme 
recognition sites (see below) at each end. The identity of the 
overlaps corresponding to each site are selected such that following 
IIS restriction digestion in a Golden Gate reaction mix containing 
each part and the destination vector, the 5’ overlap of each part 
corresponds to the 3’ overlap of the preceding part. 3: The Golden 
Gate reaction results in the ligation of each part in the correct order 
into the destination vector, replacing the LacZ dropout region. Type 
IIS recognition sites are not retained in this vector, so it cannot be 
cut again in subsequent digestion steps. Following transformation, 
E. coli colonies harbouring the correctly modified destination 
vector are selected by blue/white screening. Numbered white boxes: 
type IIS restriction enzyme recognition sites. Numbers indicate the 
identity of the overlap corresponding to each site.  
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3.2 Results 
3.2.1 Component Design 
The first step in the development of the invader assay was to design a construct carrying 
the elements which when subsequently transformed into M. maripaludis would give rise to 
the test and control strains. These elements comprise two modules (Figure 3.1), which 
should express the two components of the CRISPR/Cas9 system as highly as possible. The 
first part of this process was to select/design the individual parts of each module according 
to the specifications set out previously (See Chapter 3, Introduction). 
 
3.2.1.1 Cas9  
To increase the likelihood of achieving high expression levels, the SpCas9 gene was codon 
optimised for M. maripaludis. Since the optimised Cas9 was to be ordered as a synthetic 
fragment, output sequences also had to meet the IDT gBlocks synthesis requirements. First, 
the Jcat tool was used to generate an optimised sequence (52), however the output 
contained multiple regions which were too repetitive for synthesis, rendering this sequence 
unusable.  
 
Next, an optimisation was generated based on ICU in the COOL program (53). Since 
COOL does not directly support M. maripaludis, codon usage frequencies for this organism 
were first imported as a custom profile. In addition to the ICU parameter, the target total % 
GC and % GC3 (i.e. frequency of a guanine or cytosine at the third codon position) were 
set to correspond to those present in M. maripaludis. The resulting sequence did not contain 
any complexities that would prohibit gene synthesis. However, on visual inspection it 
appeared highly repetitive. Repetitive elements within genes can compromise expression 
levels and/or lead to instability (see Chapter 3, Discussion). To better estimate whether the 
level of repetitiveness in this output was likely to be problematic, it was aligned to other 
codon optimised Cas9 sequences which had been used successfully in other organisms: 
Arabidopsis thaliana (86, 87) and three different Streptomyces species (88). It was reasoned 
that if these sequences were similarly as repetitive, the repetitiveness of the optimisation 
was unlikely to negatively impact functionality. However, in all cases the M. maripaludis 
optimisation appeared to be more repetitive than the validated sequences (Figure A1, 
Appendix). 
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In an attempt to resolve this, additional optimisation runs were conducted in which several 
parameters intended to lower the repetitiveness of the output were tested in COOL. 
However, even on their most stringent settings none of these appeared to make a visually 
detectable impact in terms of repetitiveness. Additionally, some had a negative effect on 
the ICU score (i.e. resulted in optimisations which were more distant from the target M. 
maripaludis codon usage values). For the final run, those parameters which had negatively 
affected ICU were reverted. Those which had not were retained since they had not reduced 
the quality of the optimisation, but may have slightly reduced repetitiveness. The result of 
this final optimisation, hereafter referred to as Mmp-Cas9, was selected as the Cas9 
sequence which would be used in M. maripaludis (Figure A2, Appendix). The codon usage 
frequencies were very close to the average values for native M. maripaludis genes (Figure 
3.3). The GC3 value for the optimised sequence (25.17%) was identical to the average for 
M. maripaludis genes. The total GC content was also very similar: with a value of 34.04% 
in the optimisation compared with an average of 34.01% in M. maripaludis genes.  
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3.2.1.2 gRNA: PurR 
The gRNA component of the test strain must be able to target the Cas9 protein to the 
invader plasmids. To achieve this, the 20 nt gRNA targeting sequence was to be designed 
to target PurR, an element present in both invader plasmids. The sequence of a validated 
gRNA known to be able to successfully target PurR in mouse was already available (71). 
For this validation to be a reliable indicator of functionality in the invader assay, the site it 
targets must also be present in the pLW40/pAW42 plasmids. However, when it was aligned 
to the invader plasmid PurR gene there was a single mismatch (Figure 3.4). Its location was 
particularly unfavourable, since it was within the PAM proximal seed region, which is 
known to be highly important for the gRNA/target interaction. As explained previously, 
Figure 3.3: Comparison of codon usage frequencies between the 
optimised Cas9 gene (Mmp-Cas9) and M. maripaludis. 
Each line radiating from the centre of the circle represents a different 
codon. The relative frequency at which each codon is used is depicted 
by a point on each line. A point touching the line at the edge of the circle 
indicates a frequency of 1 (i.e. always used) and a point touching the 
base of the line in the centre of the circle indicates a frequency of 0 (i.e. 
never used). Points are joined by a coloured line: blue for M. 
maripaludis and red for the codon optimised Cas9. Regions in which no 
red line is visible indicate the usage frequencies between the two are 
identical. 
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the first base in the gRNA should ideally be an adenine due to the potential of promoter 
bias for this base in Phmv, however the first base in the spacer used in mouse was a 
cytosine. Since this gRNA did not start with an adenine, and the alignment had revealed it 
could also not serve as a true validated target due to the presence of a mismatch, it was 
decided to instead design a gRNA to target PurR in silico. 
 
 
 
Indels in the 3’ portion of genes are typically tolerated more than those at more 5’ locations 
since frameshift mutations closer to the end of the gene disrupt fewer amino acids. For the 
test strain to perform as intended, it must be capable of completely abolishing PurR 
function. It was reasoned that since the gRNA used in mouse was able to inactivate PurR, 
targeting Cas9 to the corresponding target site in the invader plasmid PurR gene, or any 
other site closer than this to the start codon should also be sufficient to knock out function. 
As such, the 108 bp 5’ region of PurR (up to and including where the mouse gRNA had 
aligned) was extracted and assessed for potential gRNA target sites using the inbuilt “find 
CRISPR sites” tool in Geneious. 24 potential target sites were identified in this region, with 
estimated on-target activity scores ranging from 0.009 to 0.615 (with one being best 
predicted on-target activity, and zero being worst). Of these potential gRNAs, only one 
began with adenine (hereafter referred to as “gRNA-pur-A”). It binds in the reverse 
orientation between positions 66 and 88 of PurR and has a predicted on-target score of 
0.251 (Table 3.1).  
 
The second critical requirement of the gRNA sequence used for the invader assay is that, 
excluding its intended target site, it should not be able to bind to any other genetic feature 
it could potentially come into contact with: i.e. the M. maripaludis chromosome, the 
Figure 3.4: Mouse gRNA aligned to invader plasmid PurR gene. 
Nucleotide alignment of the validated gRNA from mouse with the 5’ portion of the 
PurR gene from the invader plasmids (pLW40/pAW42). The location of the PAM 
proximal seed region is indicated below the alignment.  Red box = mismatch. Grey box 
= PAM. Labels to the left indicate the identity of each sequence. 
 
Seed Region 
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transformation plasmids pBLPrt and pCRPrtneo, and other parts of the invader plasmids. 
To assess the likelihood of this, the CRISPR site finder tool was used to estimate off-target 
scores. The lowest off-target score for any of the 24 potential gRNAs was 98.86% (with 
values closer to 100% being least likely to form unwanted interactions). The score for 
gRNA-pur-A was 99.86%, and excluding the actual target site on pLW40/pAW42, which 
was identified as a perfect match, the most likely five off-target sites were predicted to be 
in the M. maripaludis plasmids. Despite this, even the “most likely” off-target site, 
identified in pAW42, differed to the gRNA at seven positions (Table 3.1).  This analysis 
suggests that off-targeting is extremely unlikely for any of the 24 potential gRNAs, and 
was as such not a criterion that needed to be considered when deciding between them. 
gRNA-pur-A was therefore selected for use in the invader assay based on the fact that it 
was the only gRNA in the potential target region which began with an adenine. 
 
3.2.1.3 gRNA: eGFP 
Since it had not been possible to select an experimentally validated gRNA for the PurR 
gene, a second gRNA was designed to target pLW40/pAW42 which had been validated. 
There were no more features shared between the invader plasmids which also met the 
requirement of being absent from the pBLPrt/pCRPrtneo transformation vectors. This 
meant the only option would be to introduce a new target by modifying the invader 
plasmids. As explained previously, the eGFP gene has been widely targeted in CRISPR 
studies, so this was selected as the target. Eight eGFP gRNAs were downloaded from the 
addgene “validated gRNA” database and aligned to the 717 bp eGFP gene. The same 
approach was used to identify 119 potential gRNA target sites in eGFP. As expected, this 
included all eight of the validated eGFP sequences.  Similarly to the result for PurR, on-
target activity predictions varied greatly: ranging from 0.002 to 0.858, while off-target 
estimates were all very high (all above 96%). On-target score predictions were disregarded 
as a selection criterion since all eight of the gRNAs obtained from the database had been 
experimentally validated, which is considered to be a more reliable estimate of activity. 
The predicted off-target scores of these eight gRNAs were similar (ranging from 97.54-
99.82%), and none of them began with an adenine. Therefore selection was based solely 
on information reported in the literature. The gRNA selected, hereafter referred to as 
“gRNA-eGFP”, was chosen because unlike the other previously validated candidate 
gRNAs, it had been used successfully in two different organisms (see Chapter 3, 
Discussion). It binds the reverse strand of eGFP gene from positions 152-171, has a 
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predicted on-target score of 0.109, and has nine mismatches to most likely predicted off-
target site (Table 3.1). 
 
3.2.1.4 gRNA: control  
As is the case for the test strains, the control strain should not be able to target Cas9 to any 
part of the M. maripaludis chromosome or the transformation vectors. However, by 
definition it should also not be able to target the invader plasmids. By fortunate 
coincidence, the GC content of both gRNA-pur-A and gRNA-eGFP was 80%, which meant 
that a single scrambled gRNA could serve as a suitable control for both. To produce the 
control gRNA, five random 20 bp sequences each with a GC content of 80% were 
generated. Off-target analyses revealed that all five were predicted to be similarly unlikely 
to bind to any of the genetic features they could potentially come into contact with (all off-
target scores were above 99%). The sequence selected, hereafter referred to as “gRNA-
ctrl” was chosen because it began with an adenine. gRNA-ctrl has an off-target score of 
99.92%, and differs to the sequence of its most likely predicted off-target site at six 
positions (Table 3.1). 
 
 
 
3.2.1.5 Phmv and Tmcr 
Both the Cas9 and gRNA modules will be driven by the minimal Phmv promoter (Figure 
3.5). For Cas9, the full 73 bp promoter sequence was inserted directly upstream of the start 
codon. To satisfy the requirement for a strict transcriptional start site for the gRNA module, 
a shortened version of the promoter was created. This consisted of the 5’ portion of the 
sequence up to and including the base preceding the mapped transcriptional start site 
(Figure 3.5, grey box). This modified Phmv was placed directly upstream of the gRNA, 
Sequence
(5' - 3')
Location
gRNA-pur-A
AGTCGGCGAA
CGCGGCGGCG
0.251 99.86%
TGGCGGCCGCGG
GGGCGGCGAGG
pAW42
gRNA-eGFP
GGGCACGGGC
AGCTTGCCGG
0.109 99.80%
ATTGCAGGGATG
CTTGCCGATGG
M. maripaludis 
chromosome
gRNA-ctrl
ACCGGGCGCA
CCACCGCGTC
N/A 99.92%
ACAGTACGCACC
ACCAGGACGGG
M. maripaludis 
chromosome
Name Sequence
(5' - 3')
Estimated 
Off-Target 
Score 
Most Likely Off-TargetEstimated 
On-Target 
Score
Table 3.1: Targeting predictions for the three selected gRNAs. 
Data was generated using the find CRISPR sites tool in Geneious. PAM sequences are 
underlined. For the most likely off-target site, mismatches between the selected gRNA and 
the binding site are highlighted in red.  
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and should result in transcription beginning precisely with the first base of the gRNA. To 
ensure transcriptional termination, the 26 bp Tmcr was inserted at the 3’ end of both 
modules, immediately downstream of the Cas9 stop codon and gRNA scaffold sequence. 
 
 
 
3.2.2 Construct Design and Assembly 
With the individual components comprising the two modules required for the invader assay 
designed, the next step was to work out a scheme by which they could be assembled 
together into a vector. There were several steps to this process: first the arrangement of the 
two modules in the vector had to be decided. Next, this region needed to be delineated into 
fragments orderable as gBlocks. Finally, the gBlocks would have to be modified so that 
they could be assembled together using the Golden Gate system. 
 
3.2.2.1 Module organisation 
While the spacing of the individual components within each module had already been 
decided (see “Phmv and Tmcr”), the spacing and orientation of the two modules relative to 
each other had to be considered. The simplest option would have been to place one module 
directly in front of the other. However, it was possible that using this orientation might 
cause read through from the 5’ module, which could negatively affect expression of the 3’ 
module. In an attempt to avoid this, the two were orientated facing away from each other 
(Figure 3.6). An unwanted result of this was the creation of a 34 bp region of perfect 
complementarity between the two modules, caused by the shared region between the Phmv 
promoters. To minimise potential difficulties this might have caused in terms of secondary 
structure, a 226 bp “filler” sequence was inserted between the two (Figure 3.6), which was 
obtained from a region of the pUC18 vector backbone. The result was a 4593 bp sequence 
containing all the components necessary for the production of the M. maripaludis invader 
assay strains.  
 
Figure 3.5: Minimal Phmv. 
The minimal Phmv promoter is 73 bp in length. The position of the start 
codon is indicated by the black box. The transcriptional start site has been 
mapped to position 35 (grey box).  
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3.2.2.2 Division into gBlocks 
The 4593 bp unit containing the Cas9 and gRNA modules was too large to be synthesised 
as a single gBlock. This meant that before it could be ordered, it would have to be divided 
into at least two fragments. The production of each of the three different invader assay 
strains would require the production of three different constructs, each differing only by 
the 20 bp gRNA targeting sequence. This meant that three different versions of the first 
fragment carrying the gRNA would have to be ordered. It was decided that this fragment 
should be the smallest (and therefore cheapest) size available, which was 500bp. An 
attempt was made to include the full gRNA module, plus the filler and Phmv controlling 
Cas9, in Fragment 1. This would have made the construct more versatile, since the majority 
of the units could have been easily varied simply by ordering a new 500 bp gBlock. 
However, this fragment could not be synthesised by IDT due to the presence of the 34 bp 
region of complementarity between the two Phmv units. Instead the next best option was 
taken: Fragment 1 was designated as the 387 bp region comprising the full gRNA module 
and the filler sequence (Figure 3.7).  
 
Figure 3.6: Orientation of the Cas9 and gRNA 
modules. 
The gRNA module is orientated in reverse 
relative to the Cas9 module. The two are 
separated by a 226 bp filler sequence. T: Tmcr. 
P: Phmv. F: filler sequence. 
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The remaining region of the construct, comprising the full 4206 bp Cas9 module, needed 
to be separated into two fragments (fragments 2 and 3). The only constraint governing the 
selection of the boundary between these fragments was that once split, both had to abide 
by gBlocks synthesis constraints. Boundaries approximately in the middle of the 4206 
region were arbitrarily selected and the resulting fragments tested for complexity in the 
IDT gBlocks tool. A boundary yielding fragments that could be synthesised was selected, 
which resulted in a 2109 bp Fragment 2, and a 2097 bp Fragment 3 (Figure 3.7). 
 
3.2.2.3 Fragment assembly 
To allow the simple assembly of the three fragments into a construct, a scheme was 
designed such that they could be combined in the correct order using the Golden Gate 
system. There were two stages to this approach. First, each gBlock would be inserted into 
a holding vector through use of restriction cloning (Figure 3.8, Step 2). In the second, a 
Golden Gate reaction would be used to assemble the fragments in the correct order in a 
destination vector (Figure 3.8, Steps 3-4). The Golden Gate vector DVA_BC (84) 
(hereafter pDVA_BC), which contains a dropout region flanked by BpiI sites, was selected 
as the destination vector. For the holding and destination vectors to be Golden Gate 
compatible, both must have different antibiotic resistances. Since pDVA_BC contains an 
ampicillin resistance gene (84), the kanamycin resistant pHSG298 plasmid was selected as 
the holding vector.  
 
As the Golden Gate reaction was to be conducted using BpiI, existing BpiI sites already 
present within the fragments had to first be removed. Four sites were found, all of which 
were located within the codon optimised Cas9 gene. For each site, a single base change 
Figure 3.7: Division of the 4593bp unit into three fragments. 
Schematic overview of the contents of each fragment. Fragment 1 
contains the full gRNA module and the filler sequence. Fragment 
2 contains the first part of the Cas9 module (Phmv and the 5’ 
portion of Cas9). Fragment 3 contains the last part of the Cas9 
module (3’ portion of Cas9 and Tmcr). The size of each module is 
indicated in brackets. T: Tmcr. P: Phmv. F: filler sequence. 
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was introduced at the design stage to remove it, while maintaining the identity of the amino 
acid designated by codon that base was present in (Table 3.2).  
 
 
To make fragments 1-3 compatible with pDVA_BC, BpiI sites which give rise to 4bp 
overlaps corresponding to those flanking the pDVA_BC dropout region were appended to 
the 5’ end of Fragment 1 (Bpi site 1), and the 3’ end of Fragment 3 (Bpi site 4). Next, the 
fragments were made compatible with each other by adding BpiI sites which generate 
matching overlaps to the 3’ end of Fragment 1 and 5’ end of Fragment 2 (Bpi site 2), and 
the 3’ end of Fragment 2 and 5’ end of Fragment 3 (BpiI site 3) (Figure 3.8, Stage 1). The 
overlaps for BpiI sites 2 and 3 were designed arbitrarily, however it was ensured that they 
were not palindromic and differed from all other overlaps in the scheme by at least one 
base.  Next, to allow the initial insertion of each of the fragments into the holding vector 
pHSG298, BamH1 and SacI sites (which are present in the pHSG298 MCS) were appended 
to the ends of each fragment (Figure 3.8, Step 1). Finally, the full scheme as described 
above was simulated in two different software packages (Geneious (56) and Benchling 
(www.Benchling.com)) to check for any inconsistencies. Both programs output pDVA_BC 
containing the three fragments fused together as intended, so the corresponding gBlocks 
were ordered. 
 
Table 3.2: Sites modified in the Cas9 gene to remove pre-existing BpiI 
sites. 
  
Original Modified Original Modified
1 1755 Asp GAC GAT 0.29 0.71
2 1842 Asp GAC GAT 0.29 0.71
3 2256 Gly GGA GGT 0.52 0.26
4 3753 Asp GAC GAT 0.29 0.71
Codon Host Relative Freq.Position Amino 
Acid
Site
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Figure 3.8: Fragment assembly scheme. 
1: Restriction enzyme recognition sites are added to the ends of each of the fragments to 
make them compatible with the assembly scheme. First, BpiI sites (see below) are added 
to enable one step assembly of the fragments into the destination vector pDVA_BC in 
the correct order. External to these, BamHI/SacI sites are added to the 5’ and 3’ end of 
each fragment respectively to enable the initial insertion of each into the holding vector 
pHSG298. 2: Restriction cloning using BamHI/SacI is used to insert each fragment into 
pHSG298. 3: A Golden Gate reaction is conducted using each of the holding vectors 
containing the three different fragments and the destination vector pDVA_BC. 4: 
Complementarity between the BpiI overlaps results in the incorporation of the three 
fragments into pDVA_BC in the correct order. White boxes: restriction sites. B = BamHI. 
S = SacI. Numbered white boxes: BpiI recognition sites. Numbers indicate the sequence 
of the overlap corresponding to each: 1 = TACT, 2 = ATAG, 3 = TCTA, 4 = AATG. T: 
Tmcr. P: Phmv. F: filler  
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3.3 Discussion 
The objective of this chapter was to design the expression modules which when 
transformed into M. maripaludis would give rise to the test and control strains required for 
the invader assay. This was achieved in two stages. In the first the individual components 
of the expression modules were designed, and in the second a system by which they could 
be assembled in the desired order in a cloning vector was planned. However, issues 
encountered during this design process meant that some alterations to the plan as detailed 
in the introduction had to be made. 
 
3.3.1 Codon Optimisation of SpCas9 
The codon optimised Cas9 sequence initially generated with the Jcat tool was too repetitive 
to be synthesised by IDT. This can be explained by the fact that this program is based on 
the CAI method, and simply replaces all codons with their most commonly used alternative 
in a subset of host genes (52, 65). This means that in all cases only one of the possible 
codons for each amino acid was used: a scenario which by definition would result in an 
unavoidably repetitive output (62, 89). Optimisations generated based on ICU in the COOL 
program were comparatively less repetitive, presumably because ICU assigns codons based 
on their relative frequency (53, 64), and can therefore make use of all codons. However, 
while these sequences were orderable as synthetic fragments, they still appeared to be more 
repetitive than other previously validated Cas9 sequences (Figure A1, Appendix). 
 
Repetitive sequences in genes can result in reduced protein expression (90, 91), and in 
severe cases genetic instability which may result in unwanted excision through 
recombination (89), both of which would clearly have been undesirable for this application. 
However, attempts to limit the repetitiveness of the outputs by modifying the optimisation 
parameters in COOL appeared relatively ineffective. This could be explained by the AT 
rich nature of the M. maripaludis genome (14). Optimisations to this organism would be 
expected to favour codons with a high AT content, while making less use of GC rich 
alternatives, resulting in a less diverse and therefore more repetitive sequence. 
Additionally, these efforts also had a negative effect on the quality of the optimisation. 
Since sub-optimal codon content can also hamper expression (92), there was a trade-off 
between the extent of repetitiveness and the fit of the optimisation to the host codon usage 
bias. Ideally it would have been possible to test a rage of optimised Cas9 sequences 
prioritising these conflicting factors to different extents. However this would have required 
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the purchase of additional large gBlocks, and the production of more test strains, and was 
therefore beyond the scope of this study due to both financial and time constraints. For the 
Cas9 codon optimisation selected for the invader assay: Mmp-Cas9 (Figure A2, Appendix), 
the decision was therefore taken to prioritise optimisation quality. 
 
Mmp-Cas9 was produced using codon usage frequencies calculated from protein coding 
gene entries in Genbank (54), which are based primarily on gene predictions (14). It is 
unlikely that this precisely reflects the true codon bias of M. maripaludis since some genes 
may have been predicted incorrectly/not be expressed. Additionally, codon usage 
frequencies averaged across all genes are likely to differ to some extent to those calculated 
using only highly expressed genes (61). A more robust approach may therefore have been 
to optimise Cas9 based on codon usage frequencies calculated solely from experimentally 
validated, highly expressed genes. Despite this, the codon bias data used to generate Mmp-
Cas9 is likely to have been a reasonable approximation for this organism. Perhaps most 
importantly, Mmp-Cas9 does not make excessive use of any codons predicted to be rarely 
used in the host (Figure 3.3), which is thought to be one of the primary factors responsible 
for poor expression of foreign genes in different organisms (61, 62, 91). It should be noted 
that there are many examples of Cas9 genes having been used successfully in 
CRISPR/Cas9 studies in organisms to which they were not initially optimised (93, 94). 
Perhaps most significantly, Nayak and Metcalf (2017) were able to demonstrate Cas9 
functionality in a cell destruction based experiment similar to the invader assay using the 
native S. pyogenes Cas9 in the archaeon M. acetivorans (48). Since Mmp-Cas9 has been 
specifically codon optimised to its host, it should theoretically be expressed at higher levels, 
and therefore perform comparatively better than the Cas9 used in this example. 
 
3.3.2 gRNAs 
3.3.2.1 Off-targeting 
Off-target binding has been described as one of the main weaknesses of the CRISPR/Cas9 
system (95-97), and could compromise the invader assay (see Chapter 3, Introduction). The 
precise rules which dictate CRISPR/Cas9 target site specificity are still not fully 
understood, and a multitude of different techniques, some inherently biased, have been used 
to assess off-target activity in a variety of different systems (98). With this in mind, it is 
perhaps unsurprising that estimates as to the extent to which a gRNA must differ from other 
potential target sites for it to be considered specific vary. In general however, potential 
binding sites with higher numbers of mismatches are thought to be less likely to result in 
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off-target effects (99). Positioning is also important: mismatches in the PAM proximal seed 
region (i.e. the 3’ most 12 bases of the gRNA targeting sequence) generally appear to be 
less well tolerated (100). On these bases, the gRNAs designed for use in this study seem 
unlikely to exhibit off-target effects, since none have fewer than six mismatches to their 
respective most likely predicted off-target site, including in all cases at least two 
mismatches to the PAM proximal seed region (Table 3.1). 
 
Additionally, the software used during the design process gave all three gRNAs highly 
favourable off-target scores (above 99%). In fact, none of the 24 potential target sites for 
PurR and 119 for eGFP were predicted to have an off-target score below 96 %, suggesting 
that (at least according to the software) they were all likely to have been highly specific.  
Since in silico based off-targeting predictions can be unreliable (69), it is possible that these 
values were overly favourable due to incorrect prediction. However, gRNAs targeting these 
genes might in reality be expected to be highly specific. Firstly, the target regions 
considered were within genes of non-host origin, and therefore had comparatively higher 
GC content than the M. maripaludis genome, which comprises the vast majority of the 
sequence to which these gRNAs could potentially bind. Secondly, at just 1.66 Mb in length 
(14), the M. maripaludis genome is relatively small compared with organisms for which 
off-targeting has been widely reported, for example in the 3000 Mb human genome (101). 
Clearly, the odds of a region highly similar to a given target site being present in a genome 
is proportional to its size. In agreement with this, off-targeting is also thought to be less 
likely in bacterial compared with eukaryotic systems for the same reason (102).  
 
3.3.2.2 On-targeting 
The intention had been to use a pre-validated gRNA from mouse (71) to target PurR to the 
invader plasmids. However, due to sequence differences between the two PurR genes 
(Figure 3.4) the decision was taken to instead design this gRNA in silico.  Very low or no 
on-target activity by gRNA-Pur-A could be particularly problematic if M. maripaludis 
possesses some kind of non-homologous end joining (NHEJ) pathway. This is because such 
a repair mechanism could permit re-circularisation of cleaved invader plasmids, allowing 
regeneration of the resistance phenotype even if Cas9 was active. gRNA-Pur-A would be 
critical in this scenario because Cas9 mediated cleavage within the puromycin resistance 
gene itself would be resistant to such regeneration. This is because NHEJ often generates 
indels at the repair site (93), which would lead to inactivating mutations and frame shifts 
within PurR even following re-circularisation.  gRNAs targeted elsewhere on the invader 
60 
 
plasmid backbone would lack this in-built NHEJ resistance, which makes the fact that 
gRNA-Pur-A could not be based on an experimentally validated gRNA undesirable since 
in silico methods alone provide a less reliable estimate of functionality (70). 
 
Fortunately, homologous recombination (HR) appears to be the primary mechanism for 
DSB repair in archaea (103), and while NHEJ has been reported in this domain (104), its 
presence in M. maripaludis seems unlikely based on currently available evidence. No gene 
homologous to Ku, a core component of the NHEJ machinery (104) could be found in the 
sequenced M. maripaludis genome (105). Additionally, the polyploid nature of M. 
maripaludis (16) suggests NHEJ is unlikely to have been required during its evolution, 
since repair templates for the preferred HR repair mechanism would be readily available, 
as is the case in rapidly dividing bacterial species such as E. coli, which are known to lack 
NHEJ (106). With this in mind, and to provide a backup in case gRNA-Pur-A does not 
exhibit sufficient on-target activity, an additional highly validated gRNA which targets the 
eGFP gene was selected.  
 
Of the eight previously validated gRNAs considered (72-75), the one chosen as gRNA-
eGFP was selected because unlike the others it has been previously validated in two 
different organisms: human (referred to as “EGFP Site 1” in (73)) and zebrafish (referred 
to as “egfp gRNA” in (74)). High activity for this gRNA was reported in both organisms: 
> 80% in Zebrafish (74), and ≈70-90% in human cells (73). Clearly, high on-target activity 
of a gRNA in one organism does not necessarily guarantee the same in another.  However, 
it was anticipated that a gRNA which had already been shown to be highly active in two 
different organisms would be more universal and therefore more likely to also have high 
on-target activity in M. maripaludis. The authors also reported that transfecting the plasmid 
harbouring gRNA-eGFP at 20-fold lower concentrations, or in combination with 15-fold 
lower concentrations of the plasmid carrying the Cas9 gene did not result in a substantial 
loss of activity (73). Assuming this gRNA also exhibits this characteristic in M. 
maripaludis, it would be highly desirable for the invader assay as it would provide some 
buffering in the event that the either of these components is not expressed as highly as 
intended. It should be noted however that including this additional gRNA in the study will 
require the production of an extra M. maripaludis test strain, as well as the modification of 
both invader plasmids to include the eGFP target site. This will necessitate more cloning 
steps, which will be more time consuming.  
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3.3.3 Chapter Summary/Next Steps 
In summary, while some concessions have been made, the aims of this chapter have still 
been met: a scheme which should be sufficient to produce the test strains required to carry 
out the invader assay has been produced. The next steps will be to: 
1. Assemble the designed fragments via Golden Gate into pDVA_BC. 
2. Subclone the complete assemblies into the M. maripaludis transformation vectors 
pBLPrt/pCRPrtneo. 
3. Transform M. maripaludis with pBLPrt/pCRPrtneo to produce the test strains. 
4. Modify the invader plasmids pLW40/pAW42 to contain the eGFP target site. 
5. Carry out the invader assay 
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Chapter 4: Molecular Work 
4.1 Introduction 
4.1.1 Chapter Aims 
In the previous chapter a scheme had been designed by which a set of constructs capable 
of producing the test and control strains required to carry out the invader assay could be 
introduced into the E. coli cloning vector pDVA_BC, via the Golden Gate system. The aim 
of this section is to use this design to produce all of the required plasmids and strains such 
that the invader assay can be carried out. This can be split into several sub-aims. First, the 
CRISPR/Cas9 constructs must be assembled into vectors in E. coli. Next, the CRISPR/Cas9 
assemblies need to be transferred into the M. maripaludis transformation vectors. Finally, 
these vectors will be used to transform M. maripaludis, which should result in the 
chromosomal integration of the CRISPR/Cas9 assemblies: producing the invader assay test 
and control strains. An additional gRNA targeting the eGFP gene had also been designed 
in Chapter 3. Since the invader plasmids pLW40/pAW42 do not contain the corresponding 
target site, an additional aim of this chapter will be to introduce this into both of these 
plasmids, making them compatible with the scheme designed. 
 
4.1.2 Delivering CRISPR/Cas9 Assemblies to M. maripaludis Transformation Vectors 
Following the assembly of the CRISPR/Cas9 modules into the E. coli cloning vector, they 
must first be transferred into the M. maripaludis transformation vectors 
pBLPrt/pCRPrtneo, before they can be delivered to the M. maripaludis chromosome. 
Material is introduced into the transformation vectors in between 5’ and 3’ flanking regions 
to the selected chromosomal target site, resulting in the incorporation of this material at the 
corresponding locus in M. maripaludis via HR, following transformation. The current 
method for delivering material ultimately intended for incorporation into the M. 
maripaludis chromosome into these transformation vectors is standard restriction enzyme 
cloning. In the case of pBLPrt this must be done using a single AscI site which is located 
in between 500 bp flanking regions to the UPT locus, such that on transformation material 
introduced into this site is delivered at the UPT locus on the M. maripaludis chromosome. 
pBLPrt is suitable for transformation of M. maripaludis strain Mm900, which has a wild-
type UPT locus (19). However, this vector is not suitable for delivery into S0001, since the 
UPT site in this strain already contains the ORF1 product, which is responsible for the 
increased transformation efficiency phenotype of this strain (12). Integration of the 
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CRISPR/Cas9 modules here using pBLPrt would result in its replacement, which would 
effectively defeat the object of using it. This means the CRISPR/Cas9 assembly must be 
introduced elsewhere on the chromosome in S0001, which can be achieved with the 
pCRPrtneo transformation vector. pCRPrtneo is structurally similar to pBLPrt, except it 
does not contain UPT flanks. This vector can be made compatible with the introduction of 
material at any chromosomal locus in M. maripaludis by transferring said material onto its 
backbone in between approximately 500 bp of 5’ and 3’ flanking sequence corresponding 
to the desired target site (19). This effectively creates a vector functionally identical to 
pBLPrt, except with a different target locus. This target locus must therefore first be 
selected. 
 
4.1.3 Selection of Chromosomal Target Site for M. maripaludis S0001 Strain 
The primary criterion for selecting a target site for the delivery of the CRISPR/Cas9 
assembly into S0001 is that the introduction should not result in any phenotypic effect 
which could be disruptive to the invader assay: as an extreme example, causing lethality. 
Such a scenario could best be avoided by selecting a target site outside of functional 
genomic DNA elements, such as genes. While the locations of many of these elements 
within the M. maripaludis genome have been predicted (14), it is likely that some have 
been missed. Assuming no delays, the M. maripaludis transformation process, including 
the required selection and screening steps, takes several weeks (107). Selection of an 
unsuitable site would therefore be extremely undesirable given the project timeframe. For 
this reason it would be advantageous to select a pre-validated target site (i.e. one that had 
been used successfully before).   
 
One such site is the M. maripaludis MCM-C locus. Replacement of the MCM-C gene with 
a short read-through product resulted in a slight increase in M. maripaludis growth rate, but 
no other phenotypic effect was detected (107). While use of a locus resulting in any 
phenotypic effect (particularly one relating to growth) might initially seem undesirable in 
the case of the invader assay, this could actually be useful. The integration of the three 
alternative CRISPR/Cas9 assemblies at the MCM-C locus, which would give rise to the 
two M. maripaludis test strains targeting the invader plasmids, and the control which does 
not, would happen at the same site. This means that all three (critically including the control 
strain) would be subject to the same increased growth phenotype, allowing comparisons 
between them to remain valid. Assuming the proportion of cells in these test and control 
strains subsequently transformed with the invader plasmids remained the same, an 
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increased growth phenotype would actually be expected to add power to the assay, since a 
greater number of cells would presumably be recovered, which (if the CRISPR/Cas9 
system was functional) would correspond to a greater difference in the number of colonies 
recovered for test vs control strains: i.e. the desired output of the assay.  
 
The plasmid previously used to achieve the integration at the MCM-C locus, pAW10, 
contains a short read-through product in between 500 bp of 5’ and 3’ flanking sequence 
corresponding to the MCM-C locus, cloned into a single NotI site on the pCRPrtneo 
backbone (107). pAW10 could theoretically be repurposed for delivery of the 
CRISPR/Cas9 assemblies into the MCM-C locus in S0001 by replacing the read-through 
product with these assemblies. However, the process of transferring the Golden Gate 
assembled CRISPR/Cas9 modules from the pDVA_BC plasmid into the M. maripaludis 
transformation vectors using standard restriction enzyme cloning is likely to be 
challenging. Firstly, at ≈ 4.6 kb in length, the fully assembled CRISPR/Cas9 product is 
relatively large, and can only be introduced (at least in the case of pBLPrt) using a single 
restriction enzyme, which requires an additional vector dephosphorylation step to prevent 
recircularisation (108). Additionally, neither pBLPrt nor pCRPrtneo support blue/white 
screening, which would make the process of identifying correctly integrated products more 
complicated. For these reasons, it would be desirable to use a more efficient cloning 
technique to produce the required M. maripaludis transformation vectors. 
 
4.1.4 Golden Gate Compatible M. maripaludis Transformation Vectors 
Both pCRPrtneo and pBLPrt contain an ampicillin and kanamycin resistance gene (19), 
and according to the available sequences (James Chong, personal communication) do not 
contain any BpiI recognition sites. This means that both could theoretically be modified to 
act as Golden Gate destination vectors in the place of pDVA_BC, while remaining 
compatible with the assembly scheme designed in Chapter 3, as they can be selected with 
a different antibiotic to the pHSG298 holding vectors, and will not be cleaved ectopically 
by BpiI (81). Achieving the required modifications would involve transplanting the 
pDVA_BC dropout region, which contains a LacZ gene and the BpiI sites (84) to which 
the assembly scheme has been designed, into both. This would allow Fragments 1-3 to be 
assembled directly into both via the Golden Gate system, which would be expected to 
streamline the cloning process for several reasons. Firstly, the pDVA_BC dropout region 
is relatively short, and would only need to be inserted into each of the transformation 
vectors once. The Golden Gate system, which is highly efficient (79), could then be used 
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to assemble the three different versions of the CRISPR/Cas9 modules (each carrying an 
alternative gRNA) into both modified transformation vectors, which due to the introduction 
of the LacZ gene would additionally support blue/white screening. This would effectively 
reduce the number of times standard restriction cloning techniques (without the facility of 
blue/white screening) would need to be used from six to two, and should therefore be 
quicker. Secondly, since the intermediate assembly step in pDVA_BC would be 
eliminated, there would be no requirement for PCR to add appropriate restriction sites to 
the CRISPR/Cas9 assemblies to enable subcloning into the transformation vectors. This 
direct assembly would therefore remove the possibility of PCR induced mutations (83, 85), 
which should simplify screening of the resulting assemblies. To make pBLPrt Golden Gate 
compatible, the pDVA_BC dropout region will have to be inserted at the AscI site in 
between the existing UPT flanks. For pCRPrtneo, this could be achieved by inserting the 
dropout region into pAW10 in between the MCM-C flanks to replace the existing read-
through product. 
 
4.1.5 Modifying pLW40/pAW42 
Since a suitable pre-validated gRNA targeting the puromycin resistance gene in the invader 
plasmids had not been described, a highly validated alternative targeting the eGFP gene 
had also been included in this study (see Chapter 3). The invader plasmids pLW40/pAW42 
do not contain the eGFP gene (12, 24), so the target site will have to first be introduced into 
both to enable them to be targeted by M. maripaludis test strains carrying this gRNA. 
Theoretically, introducing the 20 bp sequence to which gRNA-eGFP is designed to bind, 
plus a PAM sequence into both plasmids should be sufficient to achieve this. To preserve 
plasmid function, it is critical that this target region be introduced into a location in both 
which does not disrupt functional elements, such as PurR. Finally, while not essential, it 
would be desirable to introduce this modification in the same relative location and 
orientation in both plasmids, as this would make results obtained from each more 
comparable, while also simplifying the cloning process. 
  
66 
 
4.2 Results 
4.2.1 Production of Golden Gate Compatible Integrative Vectors pBLPrt/pCRPrtneo 
To streamline the cloning process, the pBLPrt/pCRPrtneo vectors were to be modified such 
that they were compatible with direct assembly of Fragments 1-3 via the Golden Gate 
system. Since the fragments had been designed for assembly into the pDVA_BC vector, 
these modifications would be achieved by incorporating its dropout region (containing 
LacZ and BpiI sites 1 and 4 (Figure 4.2, Panel A)) into both pBLPrt and pCRPrtneo. To 
ensure the resulting assembled Cas9/gRNA constructs would be introduced at the correct 
genomic location following M. maripaludis transformation, the dropout region had to be 
inserted in between the 5’ and 3’ flanking regions corresponding to the genomic target site 
in each integrative vector. In the case of pBLPrt this would involve insertion of the dropout 
region into the AscI site located in between existing flanking regions to the UPT locus 
(Figure 4.2, Panel A). However, for pCRPrtneo (Figure 4.2, Panel A) appropriate flanking 
regions (to the MCM-C locus – see Chapter 4, Introduction) would have to be introduced 
along with the dropout region.  
 
4.2.1.1 Modification via PCR  
The possibility of using a PCR based approach to introduce the modification described 
above was first investigated. This would have involved PCR amplification of the 
pDVA_BC dropout region with primers designed to add restriction sites appropriate for 
insertion into each integrative vector. The products would then have been cloned into the 
AscI site in pBLPrt, and a pair of restriction sites in pAW10 (a derivative of pCRPrtneo 
containing the MCM-C 5’ and 3’ flanks) resulting in replacement of the read through 
product with the dropout region. While this strategy would have been suitable for pBLPrt, 
sequence analysis revealed this would not have been possible in pAW10 because the 
MCM-C 5’ flank was found to already contain two BpiI sites (Figure 4.1), which would 
have impeded correct Golden Gate assembly. While it would theoretically have been 
possible to address this problem using PCR based methods to modify pAW10, it was 
decided that this would be too time consuming, so a different a different approach was 
taken. 
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4.2.1.2 Modification via gBlock 
A gBlock was designed which could be used to concurrently insert the pDVA_BC dropout 
region into pBLPrt, and the dropout region flanked by MCM-C homology arms in 
pCRPrtneo. First, the 550 bp pDVA_BC dropout sequence containing the required features 
(LacZ cassette and BpiI sites 1 and 4) was extracted. AscI sites were appended to each end 
(Figure 4.2, Panel B, Stage 1) such that subsequent restriction cloning using this enzyme 
could be used to transfer the dropout region into pBLPrt between the UPT flanks (Figure 
4.2, Panel B, Stage 3). Next, the 500 bp MCM-C flanking sequences previously used in 
pAW10 were added: with the 5’ flank placed 5’ to the dropout region. NotI sites were then 
added to each end (Figure 4.2, Panel B, Stage 1) to allow the dropout region and MCM-C 
flanks to be transferred together into pCRPrtneo in the same location as had been used in 
pAW10 (Figure 4.2, Panel B, Stage 3). As with Fragments 1-3 designed in Chapter 3, 
BamHI/SacI sites were added to the extreme ends of the gBlock to enable initial insertion 
into an E. coli cloning vector: in this case pUC18 (Figure 4.2, Panel B, Stage 2). Before the 
gBlock was ordered, several pre-existing restriction enzyme recognition sites had to be 
removed to make it compatible with the cloning strategy. A SacI and BamHI site present 
within the LacZ gene of the pDVA_BC dropout region were removed by altering a single 
base or group of bases to use the next most frequently used codon for the amino acid in 
question, in this case using codon usage data from the E. coli K12 strain, which DH5α is 
derived from (109) (Table 4.1). Since the MCM-C 5’ flank is non-coding, a single base 
within each of the two BpiI sites was arbitrarily changed to remove them. The same method 
was used to remove an unwanted NotI site found to be present within a non-coding portion 
of the gBlock.  
Figure 4.1: Structure of the MCM-C homology region in pAW10. 
The location of the pre-existing BpiI sites are indicated in the MCM-C 5’ flanking region. 
Relevant features are labelled. Base numbers are indicated above the figure.  
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Figure 4.2: Producing Golden Gate compatible pBLPrt/pCRPrtneo vectors scheme. 
A) Relevant features of the vectors used in this scheme. pDVA_BC: Golden Gate vector 
containing a dropout region carrying a LacZ gene in between BpiI sites 1 and 4. Golden 
Gate assembly into these sites replaces the Dropout region allowing blue/white screening. 
pBLPrt: M. maripaludis transformation vector containing an AscI site in between 
flanking regions to UPT. Material introduced into the AscI site is incorporated into the 
genomic UPT locus in M. maripaludis via HR on transformation. pCRPrtneo: M. 
maripaludis transformation vector. Material to be introduced can be inserted into the NotI 
site flanked by homology regions to the desired genomic target site. B) Vector 
modification scheme. 1: A gBlock is constructed containing the pDVA_BC dropout 
region and BpiI sites 1+4. AscI sites are added to each end to enable subcloning of the 
enclosed region into pBLPrt. NotI sites external to the MCM-C flanking regions as used 
in pAW10 are then added to the ends of this to allow subcloning into pCRPrtneo. BamHI 
and SacI sites are added to the ends of the gBlock to enable initial insertion into the 
cloning vector pUC18. 2: Restriction cloning with BamHI/SacI is used to insert the 
gBlock into pUC18. 3: The AscI flanked insert in pDropout Mod/pUC18 is subcloned 
into pBLPrt, and the NotI flanked insert into pCRPrtneo. The result is a pair of modified 
Golden Gate compatible M. maripaludis transformation vectors. The presence of the 
Dropout region allows blue/white screening on assembly using BpiI sites 1 and 4. The 
position of these sites in between the UPT and MCM-C flanking regions means 
assembled material can be transferred directly into these loci upon M. maripaludis 
transformation. White boxes: restriction sites. B = BamHI. S = SacI. N = NotI. A = AscI. 
Numbered white boxes: BpiI recognition sites. U = UPT 5’ flank. PT = UPT 3’ flank. 
MC = MCM-C 5’ flank. M-C = MCM-C 3’ flank.  
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4.2.1.3 Subcloning Dropout Mod gBlock into pUC18 
The first step to producing the Golden Gate compatible pBLPrt/pCRPrtneo vectors was to 
subclone the Dropout Mod gBlock into pUC18 (Figure 4.3, Panel A). To generate sticky 
ends compatible with the insert, pUC18 was digested with BamHI/SacI, which yielded a 
band at the expected size (Figure 4.3, Panel B, Lane 4). As the excised fragment was 
estimated to be only 19 bp in length, and therefore too small to be visible on a gel, single 
digestions with each enzyme were carried out to check for complete digestion. Both 
reactions resulted in a single band at the same size as the double digestion (Figure 4.3, 
Panel B, Lanes 2-3), indicating complete digestion with both enzymes. The double digested 
pUC18 product was gel extracted. Next, the gBlock was digested with the same two 
enzymes to allow ligation into the vector, which resulted in a product at the expected size 
(Figure 4.3, Panel C, Lane 3). This was indistinguishable in size from the undigested 
product (Figure 4.3, Panel C, Lane 2), which was as expected since it was predicted to be 
just 32 bp shorter. The remainder of the gBlock double digestion reaction was PCR 
purified, ligated with the gel extracted pUC18 product and transformed into E. coli. A 
control reaction containing digested pUC18 and ligase (+ ligase) was also transformed. 
 
12 colonies were recovered on the test plates (i.e. plates containing E. coli transformed with 
ligated vector and insert) following transformation: all were blue as expected since the 
dropout region of the gBlock contains a LacZ gene. There were a large number of smaller 
white satellite colonies. Only a single blue colony was present on the control plates which 
suggested that the majority of the 12 test plate colonies contained an insert. A colony PCR 
using primers pUC18 CP F1/R1, designed to bind to the pUC18 backbone (Figure 4.3, 
Panel A) and amplify a 2.6 kb product if the correct insert was present was carried out. All 
Original Modified Original Modified
1 48 Glu GAG GAA 0.3 0.7
2 67-69 Ser TCG AGC 0.16 0.33
Site Position Amino 
Acid
Codon Host Relative Freq.
Table 4.1: Sites modified in pDVA_BC LacZ gene to remove pre-existing 
BamHI/SacI sites. 
Site 1 was formerly a BamHI recognition site, and site 2 SacI. Position refers 
to the relative position in the LacZ gene of the nucleotide(s) modified to 
achieve the codon change. “Original” and “modified” refer to the status of the 
codon before and after modification. Host Relative Freq. is the frequency at 
which the specified codon is used proportional to all other codons for that 
amino acid in the E. coli K12 strain. 
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eight tested colonies produced the same banding pattern (Figure 4.3, Panel D, Lane 2), 
which unexpectedly contained multiple bands, none of which were at the expected size. In 
an attempt to identify the origins of these, the PCR was repeated using material from a 
series of control colonies, as well as to the four remaining blue test colonies (Figure 4.3, 
Panel E). The product generated from an unmodified pUC18 containing colony was slightly 
below the expected size of 1 kb (Figure 4.3, Panel E, Lane 5): however the large amount 
of material present likely caused this band to migrate further on the gel, and as such it was 
considered to be at the expected size. The same band was present in the pUC18 colony 
from the + ligase control plate (Figure 4.3, Panel E, Lane 4), which suggested that the 
unexpected bands in the initial colony PCR (Figure 4.3, Panel D, Lane 2) were not caused 
by modification to the vector itself. No product was obtained using satellite colony material 
(Figure 4.3, Panel E, Lane 3), which confirmed that satellite contamination was not the 
cause of the unexpected bands. The four remaining blue colonies all contained a single 
band at 1 kb (Figure 4.3, Panel E, Lane 2), which would be expected if they did not contain 
the insert. However, it seems unlikely that of the 12 colonies tested in total, all eight in the 
first reaction would have a shared but distinct band from those in the second. A more likely 
explanation is that stochastic differences between the two reactions may have affected 
primer binding stringency. Taken together these results suggest that the pUC18 CP F1/R1 
primers were able to bind ectopically to some region of the insert, and were therefore 
unsuitable. 
 
Next a colony PCR using primers pUC18 CP R1 and Dropout Seq F3 (Figure 4.3, Panel 
A) was carried out on colonies representative of each of the two distinct banding patterns 
previously observed for test plate colonies. Since Dropout Seq F3 was designed to bind 
within the MCM-C flanking sequence (which is highly dissimilar to the pUC18 backbone), 
this PCR was expected to be more specific. All five colonies tested produced a band just 
under the expected size of 1.1 kb (Figure 4.3, Panel F, Lane 2), suggesting that all contained 
the correct insert. Unexpectedly, the pUC18 control lane contained a ladder-like banding 
pattern (Figure 4.3, Panel F, Lane 3). Since there was no product in the water control 
(Figure 4.3, Panel F, Lane 4), the most likely explanation was contamination of the pUC18 
product with ladder during gel loading.  
 
Diagnostic digests were carried out on plasmid DNA isolated from two of these colonies 
(colonies 1 and 9), both of which produced the same banding pattern as each other (colony 
1 products are shown). As expected, vector linearization with BamHI resulted in a single 
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band at a size corresponding to the sum of the two components: pUC18 and Dropout Mod 
(Figure 4.3, Panel G, lane 3). Double digestion with BamHI/SacI to liberate the insert from 
the vector backbone resulted in two smaller bands also at the expected sizes, as well as an 
additional band and the same size as the BamHI digested product (Figure 4.3, Panel G, 
Lane 2), indicating incomplete double digestion. Taken together these results revealed that 
the vector contained an insert of the correct size. Finally, the full inserts in colonies 1 and 
9 were sequenced and confirmed to be correct for their full length. Colony 1 and its plasmid 
cargo (hereafter referred to as pDropout Mod/pUC18) was arbitrarily selected for further 
use in this study.  
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4.2.1.4 Generating Golden Gate compatible pCRPrtneo (pCRPrtneo GG) 
To produce the Golden Gate compatible pCRPrtneo transformation vector (pCRPrtneo 
GG), the fragment containing the pDVA_BC dropout region and MCM-C 5’ and 3’ flanks 
was subcloned from the pDropout Mod/pUC18 vector into pCRPrtneo using NotI (Figure 
4.4, Panel A). The cloning strategy was similar to that used to produce pDropout 
Mod/pUC18. However, since pCRPrtneo contains only one NotI site, the NotI digested 
plasmid was first dephosphorylated to prevent recircularisation on ligation, then PCR 
purified. Next, pDropout Mod/pUC18 was digested with NotI and a fragment 
corresponding in size to the MCM-C flanked pDVA_BC dropout region insert was gel 
extracted, ligated to the dephosphorylated recipient vector, and transformed into E. coli. 
 
Since the insert carries a LacZ gene, but the recipient vector does not, colonies resulting 
from the desired ligation event were expected to be easily distinguishable by blue/white 
screening. A majority of blue colonies were recovered on test plates. There were 
approximately half the number of colonies on vector + ligase and vector – ligase control 
plates, but unexpectedly most of these were also blue. Streak plates of the unmodified 
recipient vector containing X-gal had resulted in only white colonies, as would be expected 
for a vector lacking LacZ. This, coupled with the presence of blue colonies from the – 
ligase control indicated the most likely cause was contamination with a second LacZ 
containing plasmid.  
 
Figure 4.3: Subcloning Dropout Mod gBlock into pUC18. 
A) Cloning strategy overview. Double digestion with BamHI/SacI is used to open the 
pUC18 vector (top left) and produce compatible sticky ends on the Dropout Mod 
gBlock insert (top right). The digested vector is gel extracted and the gBlock PCR 
purified before the two are ligated, producing pDropout Mod/pUC18 (middle) 
containing the Dropout Mod insert inside the pUC18 backbone. Approximate expected 
product sizes are shown below each component. White boxes: restriction sites. B = 
BamHI. S = SacI. N = NotI. A = AscI. Numbered white boxes: BpiI recognition sites. 
Green boxes: MCM-C flanks. MC = 5’ flank. M-C = 3’ flank.  Red arrows = primer 
binding sites.  B, C, G) 100 ng aliquots of DNA either undigested (uncut) or digested 
with BamHI and/or SacI on 1% agarose gels. DNA source: B: pUC18; C: Dropout Mod 
gBlock; G: colony 1. Restriction enzymes used are indicated above and lane numbers 
below each lane. Band sizes are in kb to the sides of the figure: ladder to the left, 
products to the right. D, E, F) Reaction products from colony PCRs on 1% agarose 
gels. Primers used: D, E: pUC18 CP F1/R1; F: pUC18 CP F1/Dropout Seq F3. 
Template DNA source is shown above and lane numbers below each lane. Band sizes 
are in kb to the sides of the figure: ladder to the left, products to the right. L = GeneRuler 
1 kb ladder. Red stars are included above bands which are difficult to see. 
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A colony PCR using primers pCRP CP F1/R1 (Figure 4.4, Panel A), which were designed 
to amplify a 2402 bp fragment in the correctly ligated vector, was used to screen the blue 
colonies on the test plates. Several colonies from the control plates were also included in 
an attempt to determine the origins of the ectopic blue colonies. As expected, a white 
colony from the + ligase control plate yielded a product at the size close to that expected 
for unmodified pCRPrtneo (Figure 4.4, Panel B, Lane 3). The product from an ectopic blue 
colony on the – ligase control plate had the same band (Figure 4.4, Panel B, Lane 2). Test 
colonies yielded three distinct banding patterns: colonies 43, 49 and 50 were representative 
of each, but none of these contained a product at the expected size (Figure 4.4, Panel B, 
Lanes 4-6).  
 
To investigate this further, diagnostic digests with BamHI and NotI were conducted on 
pDNA isolated from all five of these colonies. BamHI was expected to cut the pCRPrtneo 
backbone once resulting in a linear product. NotI would liberate the insert from the 
correctly modified vector resulting in two bands, but linearise unmodified vector as with 
BamHI. As expected, banding patterns for the white colony were consistent with 
unmodified pCRPrtneo (Figure 4.4, Panel C, Lanes 2-4). Digestion products for the ectopic 
blue colony (Figure 4.4, Panel C, Lanes 5-7) confirmed the presence of a contaminating 
vector: linearisation with BamHI (Figure 4.4, Panel C, Lane 5) showed that this was 
approximately 2.6 kb in size. Colony 49 also produced this banding pattern, suggesting it 
was derived from the same plasmid, which was unexpected since it had had a distinct 
banding pattern at colony PCR. Colonies 50 and 43 both contained bands very close in size 
to those expected for the correct plasmid product (colony 43 bands are shown: Figure 4.4, 
Panel C, Lanes 8-10). Since only colony 43 had lacked the band expected to correspond to 
unmodified pCRPrtneo at colony PCR (Figure 4.4, Panel B, Lane 4), its insert region was 
sequenced. The results confirmed this colony, hereafter referred to as pCRPrtneo GG, 
contained the full expected product with no mismatches.  
 
It was reasoned that the plasmid contaminant was most likely to have been one used 
elsewhere in this study. Additionally, since the only antibiotic selection used in this section 
was kanamycin, the contaminant must have been KanR. In silico analysis of all KanR 
plasmids used in this work revealed pHSG298 would be expected to give the banding 
patterns in the diagnostic digest (Figure 4.4, Panel C, Lanes 5-7). Since pCRPrtneo is both 
KanR and AmpR, replica plating of colonies screened by PCR in this section onto 
ampicillin plates was expected to result in the death in those containing only pHSG298. 
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However, all 30 colonies tested (including the five analysed above), grew in this condition. 
While it was possible that all colonies from this subset had simultaneously been 
transformed with both plasmids, therefore also gaining ampicillin resistance, it seemed 
unlikely that there was not a single instance of a colony containing only pHSG298, which 
would not have been expected to grow in this condition.   
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Figure 4.4: Generating Golden Gate compatible pCRPrtneo (pCRPrtneo GG). 
A) Cloning strategy overview. Digestion with NotI is used to open the pCRPrtneo vector 
(top left) and liberate the NotI flanked insert from pDropout Mod/pUC18 backbone (top 
right). The digested vector is dephosphorylated then PCR purified and the insert gel 
extracted before the two are ligated, producing pCRPrtneo GG (bottom) containing the 
pDVA_BC dropout region and MCM-C flanks inside the pCRPrtneo backbone. 
Approximate relevant expected product sizes are shown below each component. White 
boxes: restriction sites. B = BamHI. S = SacI. N = NotI. A = AscI. Numbered white boxes: 
BpiI recognition sites. Green boxes: MCM-C flanks. MC = 5’ flank. M-C = 3’ flank.  Red 
arrows = primer binding sites. B) Reaction products from colony PCR on a 1% agarose 
gel. Primers used: pCRP CP F1/R1. Template DNA source is shown above and lane 
numbers below each lane. Band sizes are in kb to the sides of the figure: ladder to the left, 
products to the right. C) 100 ng aliquots of DNA either undigested (uncut) or digested 
with BamHI or NotI on a 1% agarose gel. DNA source: Lanes 2-4: + Lig (white); Lanes 
5-7: -Lig (blue); Lanes 8-10: Colony 43. Restriction enzymes used are indicated above 
and lane numbers below each lane. Band sizes are in kb to the sides of the figure: ladder 
to the left, products to the right. L = GeneRuler 1 kb ladder.  
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4.2.1.5 Generating Golden Gate compatible pBLPrt (pBLPrt GG) 
The Golden Gate compatible pBLPrt vector (pBLPrt GG) was produced by subcloning the 
pDVA_BC dropout region from pDropout Mod/pUC18 into pBLPrt with the same strategy 
as for pCRPrtneo GG, except using AscI (Figure 4.5, Panel A). Unexpectedly, diagnostic 
digestion of the initial pBLPrt recipient vector revealed that its total size was approximately 
9 kb, which was roughly 600 bp larger than expected. Following ligation of the insert and 
this vector, and subsequent transformation, ectopic blue colonies were recovered on 
ligation control plates at similar relative frequencies to test plates as had been the case for 
pCRPrtneo. This suggested that the same plasmid contaminant was also present here. A 
colony PCR with primers designed to bind to the vector backbone and amplify a product 
containing the insert (in this case pBLP CP F1/R1 (Figure 4.5, Panel A)), identified a band 
at the expected size in some test colonies.  
 
Diagnostic digests were carried out on pDNA isolated from two of these: NdeI was 
expected to linearise the plasmid, while AscI would liberate the pDVA_BC dropout region 
insert from the backbone of the correctly ligated product. Both colonies produced the same 
unexpected banding patterns (colony 44 bands are shown: Figure 4.5, Panel B, Lanes 2-4). 
NdeI did not appear to cut the product (Figure 4.5, Panel B, Lane 2), but it had successfully 
linearised the initial pBLPrt plasmid. This may have been due to some change in the 
plasmid backbone, for example a single nucleotide substitution at this site. Since this site 
falls outside of functional plasmid regions, such a substitution would not be expected to 
impede vector function. It is also possible that the failed NdeI digestion was due to a 
procedural error: for example during pipetting of the enzyme. Digestion with AscI resulted 
in a single band at approximately 8 kb (Figure 4.5, Panel B, Lane 3), which presumably 
corresponded to the vector backbone. This product was 400 bp smaller than would have 
been expected based on the available plasmid sequence, and 1 kb smaller than the 
expectation based on the size of the pBLPrt vector used here. There was also no smaller 
band corresponding to the insert, which was unexpected as these colonies had contained a 
band as predicted for the insert at colony PCR. Sequencing of colony 44, hereafter referred 
to as pBLPrt GG, revealed that the full insert had been ligated into the vector backbone at 
the intended site. Since the corresponding insert band had not been recovered at digestion 
this suggested the bands had migrated further on this portion of the gel, which could explain 
the discrepancies in vector backbone size.   
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Digestion of pDNA from two ectopic blue colonies from ligation control plates was also 
carried out with NdeI and AscI. Both produced the same banding pattern: the product was 
not cut with either enzyme (Figure 4.5, Panel B, Lanes 5-7).  These products were 
consistent in appearance to the bands presumed to correspond to uncut contaminating 
plasmid obtained for pCRPrtneo GG (Figure 4.4, Panel C, Lanes 6-7), which strongly 
suggested this contaminant was the same. Neither AscI nor NdeI would be expected to 
cleave pHSG298, which had previously been thought to be the plasmid contaminant. It was 
reasoned that the replica plating test which had suggested the contaminant was ampicillin 
resistant (which would not be expected for pHSG298), may have given this result due to 
degradation of the antibiotic on the plates. To test this, colonies containing the pBLPrt and 
pCRPrtneo plasmids, in addition to the two ectopic blue colonies shown by diagnostic 
digestion to contain the contaminant from both the pBLPrt GG and pCRPrtneo GG 
assembly efforts, were inoculated into LB medium containing ampicillin. Following 
overnight incubation, dense growth was visible for both pBLPrt and pCRPrtneo, as would 
be expected since both vectors carry AmpR. No growth was obtained for the colonies 
carrying the contaminating plasmid, suggesting that it was in fact not resistant to ampicillin 
and therefore could have been pHSG298. To confirm this, pDNA from one of these 
colonies was sequenced with the primers pHSG298 and M13F, which should have bound 
to the pHSG298 backbone. However, both sequencing reads were very short and contained 
only ambiguous, low quality base calls, and were therefore unusable.  
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4.2.2 Assembling CRISPR/Cas9 constructs into pCRPrtneo GG/pBLPrt GG 
With the Golden Gate compatible M. maripaludis transformation vectors (pCRPrtneo GG 
and pBLPrt GG) produced, the next step was to assemble the three fragments designed in 
Figure 4.5: Generating Golden Gate compatible pBLPrt (pBLPrt GG). 
A) Cloning strategy overview. Digestion with AscI is used to open the pBLPrt vector (top 
left) and liberate the AscI flanked insert from pDropout Mod/pUC18 backbone (top 
right). The digested vector is dephosphorylated then PCR purified and the insert gel 
extracted before the two are ligated, producing pBLPrt GG (bottom) containing the 
pDVA_BC dropout region inside the pBLPrt backbone. Approximate relevant expected 
product sizes are shown below each component. White boxes: restriction sites. B = 
BamHI. S = SacI. N = NotI. A = AscI. Numbered white boxes: BpiI recognition sites. 
Green boxes: MCM-C flanks. MC = 5’ flank. M-C = 3’ flank.  Red arrows = primer 
binding sites. B) 100 ng aliquots of DNA either undigested (uncut) or digested with NdeI 
or AscI on a 1% agarose gel. DNA source: Lanes 2-4: colony 44; Lanes 5-7: - Lig (blue). 
Restriction enzymes used are indicated above and lane numbers below each lane. Band 
sizes are in kb to the sides of the figure: ladder to the left, products to the right. L = 
GeneRuler 1 kb ladder.  
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Chapter 3 into them via the Golden Gate system. Three different assemblies in each 
transformation vector were to be produced: each carrying one of the alternative versions of 
Fragment 1 (containing different 20 nt gRNA targeting sequences) along with the invariant 
Fragments 2 and 3. The resulting set of assembled pCRPrtneo GG and pBLPrt GG 
transformation vectors would give rise to the test and control strains (see Chapter 3) when 
transformed into M. maripaludis strains S0001 and Mm900, respectively. The first step in 
this process was to subclone each fragment (Fragments 2 and 3 and the three versions of 
Fragment 1) into the holding vector pHSG298 (Chapter 3, Figure 3.8, Stage 2). Next, the 
fragments would be assembled via Golden Gate into both of the modified M. maripaludis 
transformation vectors. 
 
4.2.2.1 Subcloning Fragment 1 gBlocks into pHSG298 
The three different versions of the Fragment 1 gBlock differed to each other only in their 
20 bp gRNA targeting sequence, which had been designed to target the eGFP and 
puromycin genes (Fragment 1 eGFP and pur) and a non-targeting control (Fragment 1 ctrl). 
The same strategy as had been used to generate pDropout Mod/pUC18 was used to 
subclone all three Fragment 1 gBlocks into separate instances of the kanamycin resistant 
pHSG298 vector (Figure 4.6, Panel A). Following BamHI/SacI digestion of each gBlock 
and the recipient vector, ligation, and transformation, a majority of white colonies were 
recovered on plating, as would be expected since the BamHI/SacI sites in pHSG298 are 
within a LacZ gene. A colony PCR using primers M13 F and PHSG R1 confirmed the 
presence of a product at the expected size in all nine white colonies tested for each of the 
different gBlock ligations. Diagnostic digests were carried out on pDNA isolated from two 
colonies for each of the different versions of Fragment 1 ligated into pHSG298, all of which 
produced the same expected banding pattern. (Fragment 1 eGFP colony 2 bands are shown: 
Figure 4.6, Panel B, Lanes 2-4). All six colonies were sequenced, and the insert in each 
confirmed to be correct. Fragment 1 eGFP colony 2, pur colony 11 and ctrl colony 26 were 
selected for further use, hereafter referred to as pFragment 1 eGFP/pHSG298, 
pur/pHSG298 and ctrl/pHSG298 respectively.  
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Figure 4.6: Subcloning Fragment 1 gBlocks into pHSG298. 
A) Cloning strategy overview. Double digestion with 
BamHI/SacI is used to open the  pHSG298 vector (top left) and 
produce compatible sticky ends on the three Fragment 1 gBlock 
inserts (top right). The gBlocks are PCR purified and each is 
ligated separately into the digested and gel extracted vector, 
producing the three different pFragment 1/pHSG298 vectors 
(bottom), each containing a different version of Fragment 1 
ligated into the pHSG298 backbone. Approximate expected 
product sizes are shown below each component. White boxes: 
restriction sites. B = BamHI. S = SacI. Numbered white boxes: 
BpiI recognition sites. T = Tmcr. P = Phmv. F = filler sequence. 
B) 100 ng aliquots of DNA either undigested (uncut) or digested 
with BamHI and/or SacI on a 1% agarose gel. DNA source: 
Fragment 1 eGFP colony 2. Restriction enzymes used are 
indicated above and lane numbers below each lane. Band sizes 
are in kb to the sides of the figure: ladder to the left, products to 
the right. L = GeneRuler 1 kb ladder.  
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4.2.2.2 Subcloning Fragment 2 gBlock into pHSG298 
The Fragment 2 gBlock was subcloned into the pHSG298 holding vector (Figure 4.7, Panel 
A) as explained for Fragment 1. Following a ligation at a 3:1 insert:vector ratio, just 11 
white colonies were recovered after overnight transformation plate growth. Screening by 
colony PCR using primers M13 F and PHSG R1, which bind to the vector backbone either 
side of the insert, produced several different banding patterns, but no band at the expected 
size was recovered for any colony. The results were similar for a second PCR using the 
internal Frag2 Seq F4 primer (which was designed to bind within the insert), in combination 
with PHSG R1. Unexpectedly, diagnostic digestions on colonies representative of each of 
these distinct banding patterns yielded no products, suggesting they did not contain a 
plasmid. Since the Fragment 2 insert was similar in size to the recipient vector (2149 and 
2675 bp, respectively), it was reasoned that a ligation with a 1:1 insert:vector ratio may be 
more appropriate. Following transformation, a band at the expected size was recovered in 
6 of the 8 white colonies tested by colony PCR with M13 F and PHSG R1. Diagnostic 
digests on pDNA from two of these colonies (colonies 43 and 46) revealed both produced 
the expected banding pattern, with band sizes slightly above those expected (colony 46 
bands are shown: Figure 4.7, Panel B, Lanes 2-4). Sequencing of these colonies confirmed 
they both contained the full Fragment 2 insert, and colony 46 (hereafter referred to as 
pFragment 2/pHSG298) was selected for further use.  
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4.2.2.3 Subcloning Fragment 3 gBlock into pHSG298 
The Fragment 3 gBlock was subcloned into pHSG298 (Figure 4.8, Panel A) as explained 
for Fragments 1 and 2. Colony PCR with primers M13 F/PHSG R1 identified a single white 
colony which produced a band at the expected size for the Fragment 3 insert. In a diagnostic 
digest on pDNA from this colony (colony 1) two bands at the expected sizes were recovered 
for the double digestion (Figure 4.8, Panel B, Lane 2). Similarly to the case for Fragment 
2 colony 46, the linearised product appeared just above the expected size (Figure 4.8, Panel 
B, Lane 3). Sequencing of this colony, hereafter referred to as pFragment 3/pHSG298, 
confirmed it contained the correct insert. 
Figure 4.7: Subcloning Fragment 2 gBlock into pHSG298. 
A) Cloning strategy overview. Double digestion with BamHI/SacI is used to open the  
pHSG298 vector (top left) and produce compatible sticky ends on the Fragment 2 gBlock 
insert (top right). The digested vector is gel extracted and the gBlock PCR purified before 
the two are ligated, producing pFragment 2/pHSG298 (bottom) containing the Fragment 
2 insert inside the pHSG298 backbone. Approximate expected product sizes are shown 
below each component. White boxes: restriction sites. B = BamHI. S = SacI. Numbered 
white boxes: BpiI recognition sites. P = Phmv. Ca = Cas9 5’ end. B) 100 ng aliquots of 
DNA either undigested (uncut) or digested with BamHI and/or SacI on a 1% agarose gel. 
DNA source: Fragment 2 colony 46. Restriction enzymes used are indicated above and 
lane numbers below each lane. Band sizes are in kb to the sides of the figure: ladder to 
the left, products to the right. L = GeneRuler 1 kb ladder.  
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4.2.2.4 Assembling CRISPR/Cas9 constructs into pCRPrtneo GG 
With all the required vectors constructed, a Golden Gate reaction was conducted to 
assemble the three versions of the CRISPR construct (each containing an alternative 
Fragment 1) into pCRPrtneo GG. To achieve this, three separate Golden Gate reactions, 
each containing the pCRPrtneo GG destination vector, the pFragment 2/pHSG298 and 
pFragment 3/pHSG298 holding vectors, and each of the three alternative pFragment 
1/pHSG298 vectors were done in parallel. The anticipated outcome was a set of three 
vectors in which the pDVA_BC dropout region had been replaced with Fragments 1-3 
fused together at their matching BpiI overlaps, enclosed within the MCM-C flanking 
regions in the pCRPrtneo GG backbone (Figure 4.9, Panel A).  
 
Following transformation of the Golden Gate reactions hundreds of colonies were 
recovered, the vast majority of which were white, as was expected since the pCRPrtneo 
GG dropout region contained a LacZ gene, which should have been replaced on correct 
assembly. A colony PCR using primers pCRP CP F1/R1 was conducted on nine white 
Figure 4.8: Subcloning Fragment 3 gBlock into pHSG298. 
A) Cloning strategy overview. Double digestion with BamHI/SacI is used to open the  
pHSG298 vector (top left) and produce compatible sticky ends on the Fragment 3 gBlock 
insert (top right). The digested vector is gel extracted and the gBlock PCR purified before 
the two are ligated, producing pFragment 3/pHSG298 (bottom) containing the Fragment 
3 insert inside the pHSG298 backbone. Approximate expected product sizes are shown 
below each component. White boxes: restriction sites. B = BamHI. S = SacI. Numbered 
white boxes: BpiI recognition sites. S9 = Cas9 3’ end. T = Tmcr. B) 100 ng aliquots of 
DNA either undigested (uncut) or digested with BamHI and/or SacI on a 1% agarose gel. 
DNA source: Fragment 3 colony 1. Restriction enzymes used are indicated above and 
lane numbers below each lane. Band sizes are in kb to the sides of the figure: ladder to 
the left, products to the right. L = GeneRuler 1 kb ladder.  
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colonies for each of the alternative Fragment 1 assemblies. All but one produced a band at 
the size expected for a correctly assembled insert. pDNA from two colonies for each of the 
three Fragment 1 combinations which had given the expected band at colony PCR was 
isolated for diagnostic digestion. BamHI digestion was expected to linearise the correctly 
assembled vector, yielding a 12154 bp product, while NotI would liberate the full Fragment 
1-3 insert and MCM-C flanks from the pCRPrtneo GG backbone, producing 5714 and 6440 
bp products respectively. All six digested plasmids resulted in the same banding patterns 
(pCRPrtneo GG eGFP colony 1 bands are shown: Figure 4.9, Panel B, Lanes 2-4). While 
the linearised product was above the size range of the ladder used, its position, taken 
together with the fact that the bands resulting from the double digestion were at the 
expected sizes, suggested that all colonies contained the correct insert. One plasmid from 
a colony for each of the alternative Fragment 1s (pCRPrtneo GG eGFP colony 1, pur colony 
10 and ctrl colony 19) was sequenced, and all were found to contain the full correctly 
assembled insert with no mismatches to what was expected. These are hereafter referred to 
as pCRPrtneo GG eGFP, pur and ctrl, respectively.    
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4.2.2.5 Assembling CRISPR/Cas9 constructs into pBLPrt GG 
The three versions of the CRISPR/Cas9 constructs were assembled into pBLPrt GG (Figure 
4.10, Panel A) as described for pCRPrtneo GG. Colony PCR with primers pBLP CP F1/R1 
identified a band at the expected size for the insert in all but one of the nine white colonies 
screened for each of the different Fragment 1 assemblies. Diagnostic digests using XmaI 
and AscI were conducted on pDNA isolated from two colonies for each Fragment 1 
combination which had screened positive at colony PCR. XmaI was expected to linearise 
the 13130 bp vector, while AscI was predicted to cut the Fragment 1-3 insert out of the 
vector backbone, giving 4607 and 8523 bp bands respectively. pDNA from five colonies 
gave the same banding pattern (pBLPrt GG eGFP colony 4 bands are shown: Figure 4.10, 
Panel B, Lanes 5-7). For these five colonies, the XmaI product was indistinguishable from 
the uncut control (Figure 4.10, Panel B, Lanes 5 and 6), indicating it had not cut. AscI 
digestion produced a band at the expected size for the liberated insert, but the larger product 
presumed to correspond to the vector backbone (Figure 4.10, Panel B, Lane 7) was 1 kb 
larger than the backbone fragment which had previously been obtained for pBLPrt GG 
(Figure 4.5, Panel B, Lane 3). However, this product did correspond in size to the original 
pBLPrt vector used in this study, which was found to be about 9kb. This suggests that the 
unexpected size which had been obtained for the pBLPrt GG backbone fragment (Figure 
4.5, Panel B, Lane 3) was most likely due to unequal band migration on the gel. 
 
Unexpectedly, pBLPrt GG eGFP colony 3 pDNA was not cut by either enzyme, and all 
lanes contained a band resembling uncut plasmid (Figure 4.10, Panel B, Lanes 2-4) at a 
distinct size to the uncut controls for the other five colonies (Figure 4.10, Panel B, Lane 5). 
Figure 4.9: Assembling CRISPR/Cas9 constructs into pCRPrtneo GG. 
A) Cloning strategy overview. Three separate Golden Gate reactions are conducted using 
the holding vectors containing Fragments 1-3, each using one of the alternative versions 
of Fragment 1 (top) and the destination vector pCRPrtneo GG (middle). The result is a 
set of three vectors each containing the CRISPR/Cas9 construct with an alternative 
gRNA, flanked by the MCM-C homology regions in the pCRPrtneo backbone (bottom). 
Relevant approximate expected product sizes are shown below each component. White 
boxes: restriction sites. B = BamHI. S = SacI. N = NotI. A = AscI. Numbered white boxes: 
BpiI recognition sites. Numbers indicate the identity of the overlap corresponding to each. 
T = Tmcr. P = Phmv. F = filler sequence.  Ca = Cas9 5’ end. S9 = Cas9 3’ end. MC = 
MCM-C 5’ flank. M-C = MCM-C 3’ flank. B) 100 ng aliquots of DNA either undigested 
(uncut) or digested with BamHI or NotI on a 1% agarose gel. DNA source: pCRPrtneo 
GG eGFP colony 1. Restriction enzymes used are indicated above and lane numbers 
below each lane. Band sizes are in kb to the sides of the figure: ladder to the left, products 
to the right. L = GeneRuler 1 kb ladder.  
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The fact that no colonies had been recovered on plates transformed with a control Golden 
Gate reaction using dH₂O instead of component vectors, coupled with the fact that this 
colony has produced a band at the expected size for the desired insert at colony PCR, made 
a contaminating vector explanation seem unlikely. An alternative possibility is that the 
vector in the cell which gave rise to the colony used to generate the digested pDNA had 
undergone a recombination event, resulting in the loss of a fragment containing both AscI 
sites prior to overnight growth on the master plate following colony PCR, but before 
propagation in liquid culture.  
 
Sequencing of one plasmid from a colony for each of the alternative Fragment 1s (pBLPrt 
GG eGFP colony 4, pur colony 13 and ctrl colony 21) revealed that all contained the 
correctly assembled insert. They are hereafter referred to as pBLPrt GG eGFP, pur and ctrl, 
respectively. The XmaI cut site, which is within the insert, was found to be correct in all 
three colonies, suggesting the failed digestion was likely due to enzyme degradation.  
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4.2.3 Modifying pLW40/pAW42 to Contain the eGFP Target Site 
To make the invader plasmids targetable by M. maripaludis test strains carrying the eGFP 
gRNA, they needed to be modified to contain the appropriate target. This would require 
several steps. First, a suitable site for the delivery of the insert needed to be found in both 
vectors. The portion of the eGFP gene to be inserted would then have to be selected, and 
an appropriate cloning strategy for achieving the desired insertion would have to be 
designed. 
 
4.2.3.1 Integration site selection 
To make any results obtained from invader assays using each of the two invader plasmids 
more comparable, while also simplifying the cloning process, an integration site in the same 
relative location in both plasmids was sought. The two vectors were aligned, and the region 
of homology between them inspected for restriction enzyme sites which could be used for 
the integration. All single cutters from the list of 618 “commercially available enzymes” 
available in Geneious (56) were annotated onto the alignment. The critical parameter for 
site selection was that integration at that site should have the lowest possible chance of 
impeding vector function. As such, all sites present within annotated functional 
components such as genes were disregarded. Additionally, sites on the vector backbone 
between linked components: for example a gene and its promoter were also not considered. 
Just three of the annotated recognition sites met these requirements. Due to their relative 
positions, directional cloning using any of the possible pairs was not suitable, meaning 
Figure 4.10: Assembling CRISPR/Cas9 constructs into pBLPrt GG. 
A) Cloning strategy overview. Three separate Golden Gate reactions are conducted using 
the holding vectors containing Fragments 1-3, each using one of the alternative versions 
of Fragment 1 (top) and the destination vector pBLPrt GG (middle). The result is a set 
of three vectors each containing the CRISPR/Cas9 construct with an alternative 
gRNA, flanked by the UPT homology regions in the pBLPrt backbone (bottom). 
Relevant approximate expected product sizes are shown below each component. 
White boxes: restriction sites. B = BamHI. S = SacI. A = AscI. Numbered white boxes: 
BpiI recognition sites. Numbers indicate the identity of the overlap corresponding to each. 
T = Tmcr. P = Phmv. F = filler sequence.  Ca = Cas9 5’ end. S9 = Cas9 3’ end. U = UPT 
5’ flank. PT = UPT 3’ flank. B) 100 ng aliquots of DNA either undigested (uncut) or 
digested with XmaI or AscI on a 1% agarose gel. DNA source: Lanes 2-4: pBLPrt GG 
eGFP colony 3; Lanes 5-7: pBLPrt GG eGFP colony 4. Restriction enzymes used are 
indicated above and lane numbers below each lane. Band sizes are in kb to the sides of 
the figure: ladder to the left, products to the right. L = GeneRuler 1 kb ladder.  
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integration using a single enzyme was the only option, so the ClaI site was selected (Figure 
4.11).  
 
 
4.2.3.2 Modification Strategy 
With the insertion site selected, the portion of the eGFP gene to be placed into it needed to 
be chosen. While the 20 bp target region plus an appropriate PAM sequenced was 
envisaged to be sufficient, a 450 bp portion of the eGFP gene was selected to make it easier 
to handle. The selected region contained the eGFP target site with 141 bp of 5’ and 289 bp 
of 3’ flanking sequence. To facilitate delivery of the selected region of eGFP into the ClaI 
site in pLW40/pAW42, a gBlock compatible with a cloning strategy similar to that used to 
generate the Golden Gate M. maripaludis transformation vectors was designed. The gBlock 
(hereafter referred to as eGFP Mod) contained the selected 450 bp region of the eGFP gene 
flanked by ClaI sites (Figure 4.12, Panel B, Stage 1). BamHI and SacI sites were then 
appended to each end to enable initial insertion into the pUC18 cloning vector (Figure 12, 
Panel B, Stage 2). Subcloning using ClaI would then be used to deliver the eGFP target site 
into the invader plasmids (Figure 4.12, Panel B, Stage 3). The aim had been to generate a 
pair of modified invader plasmids with the eGFP insert not only in the same relative 
location, but also in the same relative orientation. However, since the subcloning step was 
to be conducted using a single enzyme (ClaI), the direction of insertion could not be 
controlled. The full insert was anticipated to be small enough to be covered by a single 
sequencing read, so it was decided that several modified pLW40 and pAW42 plasmids 
would be sequenced to enable the recovery of a pair with the insert in the same relative 
orientation.  
Figure 4.11: Selected insertion site for eGFP target region in pLW40/pAW42. 
The location of the selected ClaI insertion site is indicated at the 5’ end of the region of 
sequence homology between plasmids pLW40 and pAW42. Grey portions of horizontal 
bars indicate shared sequence identity, black portions indicate mismatches, and regions 
without bars show gaps. Functional regions of the sequences and their associated features 
are indicated by coloured arrows. Green = genes: PurR = puromycin resistance gene; 
AmpR = ampicillin resistance gene. Purple = promotors. Red = terminators. Blue = 
replication origins. Labels to the far left indicate the identity of each sequence. Consensus 
positions are indicated by numbers above the alignment. The 3’ portion of the alignment 
containing the non-homologous regions of the two plasmids has been clipped for clarity. 
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4.2.3.3 Subcloning eGFP Mod gBlock into pUC18 
The eGFP Mod gBlock was subcloned into the pUC18 holding vector (Figure 4.13, Panel 
A) using the same approach as had been used for the Dropout Mod gBlock. Following 
ligation of the BamHI/SacI digested gBlock and vector, white colonies, which were 
expected to contain an insert, were screened by colony PCR using the primers M13 F/R. 
Figure 4.12: Producing modified pLW40/pAW42 vectors scheme. 
A) Relevant features of the vectors used in this scheme. pLW40 (left) and 
pAW42 (right) both contain a ClaI site in a location suitable for insertion 
at the same relative position. B) Vector modification scheme. 1: A gBlock 
(eGFP Mod) is constructed containing a portion of the eGFP gene carrying 
the eGFP gRNA target site. ClaI sites are appended to each end to allow 
subcloning into pLW40 and pAW42. BamHI and SacI sites are added to 
the ends of the gBlock to enable initial insertion into the cloning vector 
pUC18. 2: Restriction cloning with BamHI/SacI is used to insert the 
gBlock into pUC18. 3: The ClaI flanked insert in peGFP Mod/pUC18 is 
subcloned into both pLW40 and pAW42 producing a pair of modified 
invader plasmids carrying the eGFP target site, which should be targetable 
by M. maripaludis strains carrying gRNA-eGFP when used as invader 
plasmids. White boxes: restriction sites. B = BamHI. S = SacI. C = ClaI. 
Green box = selected portion of the eGFP gene carrying the gRNA target 
site. 
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The majority of these yielded the band expected for the eGFP insert. Diagnostic digestion 
of one colony (colony 1) revealed that the larger band presumed to correspond to the 
backbone in the double digestion and the linearised plasmid (Figure 4.13, Panel B, Lanes 
2-3) were both larger than expected. Despite this a smaller band close to the expected size 
for the desired insert was recovered (Figure 4.13, Panel B, Lane 2), and sequencing 
revealed this insert was correct for its full length. This colony and its plasmid, hereafter 
referred to as peGFP Mod/pUC18, was selected for further use regardless of the size issues 
with the vector backbone since this region would not be retained in the final plasmid 
products pLW40/pAW42 Mod.  
 
 
4.2.3.4 Generating modified pLW40 (pLW40 Mod) 
To produce the modified pLW40 vector, the ClaI flanked insert containing the eGFP target 
site was subcloned from peGFP Mod/pUC18 into pLW40 using ClaI (Figure 4.14, Panel 
A).  Unexpectedly, initial attempts to cut both pLW40 and peGFP Mod/pUC18 with ClaI 
were unsuccessful. Further investigation revealed this was because the ClaI site in pLW40 
Figure 4.13: Subcloning eGFP Mod gBlock into pUC18. 
A) Cloning strategy overview. Double digestion with BamHI/SacI is used to open the 
pUC18 vector (top left) and produce compatible sticky ends on the eGFP Mod gBlock 
insert (top right). The digested vector is gel extracted and the gBlock PCR purified before 
the two are ligated, producing peGFP Mod/pUC18 (bottom) containing the eGFP Mod 
insert inside the pUC18 backbone. Approximate expected product sizes are shown below 
each component. White boxes: restriction sites. B = BamHI. S = SacI. C = ClaI. Green 
box = selected portion of the eGFP gene carrying the gRNA target site. Red arrows = 
primer binding sites. B) 100 ng aliquots of DNA either undigested (uncut) or digested 
with BamHI and/or SacI on a 1% agarose gel. DNA source: colony 1. Restriction enzymes 
used are indicated above and lane numbers below each lane. Band sizes are in kb to the 
sides of the figure: ladder to the left, products to the right. L = GeneRuler 1 kb ladder. 
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and one of those in peGFP Mod/pUC18 overlapped with Dam sites, which are methylated 
in DH5α: the E. coli strain from which these plasmids had been isolated. To address this, 
both plasmids were transformed into dam-/dcm- competent E. coli cells, which cannot 
methylate these sites. Following purification, both plasmids produced bands at the expected 
sizes when digested with ClaI, indicating that the unexpected backbone sizes previously 
obtained for peGFP Mod/pUC18 (Figure 4.13, Panel B, Lanes 2-3) were likely due to 
abnormal band migration on the gel. The band corresponding to the double digested peGFP 
Mod/pUC18 insert was gel extracted, ligated to digested and dephosphorylated pLW40, 
and the ligation product transformed back into E. coli DH5α.   
 
Since neither the insert nor recipient vector contained a LacZ gene, blue/white screening 
was not possible. PCR of 14 blue colonies using primers pLW40 CP F1/pAW42 CP R1 
revealed that 11 produced a band at the expected size. pDNA from five of these was 
generated for diagnostic digestion and sequencing. BamHI was expected to linearise the 
plasmid. Since these plasmids had been obtained from DH5α, ClaI could not be used for 
the double digestion. Instead, NaeI and SacI, which were expected to cut close to the insert 
borders generating 683 and 10081 bp products were used. The same bands were generated 
from the digested plasmids of all five colonies (colony 1 bands are shown: Figure 4.14, 
Panel B, Lanes 2-4). The double digested band was the same as for the single digestion 
(Figure 4.14, Panel B, Lanes 3+4), indicating either that one of the enzyme target sites had 
mutated/been sequenced incorrectly in the recipient vector, or that one of the enzymes used 
was not functional. It was not possible to accurately estimate the size of the linearised 
products since they were beyond the size range of the ladder. However, since their position 
seemed reasonable given the expected size, and due to time constraints, the inserts in all 
five colonies were sequenced without conducting further digestions. All colonies were 
found to contain a single copy of the correct insert. As expected these were a mixture of 
the two possible orientations.  
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4.2.3.5 Generating modified pAW42 (pAW42 Mod) 
pAW42 Mod was produced using the same approach as for pLW40 Mod (Figure 4.15, 
Panel A). pDNA from five colonies which had been found to contain the expected band at 
colony PCR using the pAW42 CP F1/R1 primers was isolated for diagnostic digestion. 
BamHI was used to linearise the vector, while NaeI and SpeI were used to excise a fragment 
containing the insert from the vector backbone, with expected sizes of 667 and 4743 bp, 
respectively. All pDNA samples produced the same banding pattern. As had been the case 
for pLW40, the double and single digested products were the same (Figure 4.15, Panel B, 
Lanes 3-4). The most likely cause was therefore inactivity of the NaeI enzyme, which had 
been used in both double digests. The linearised product was very close to the expected 
size (Figure 4.15, Panel B, Lane 3), and sequencing revealed that all five plasmids 
contained one copy of the desired insert. As for pLW40, inserts were recovered in both 
directions, which meant that a pair with the insert in the same relative orientation had been 
produced. Due to time constraints further digestions were not carried out.  
Figure 4.14: Generating modified pLW40 (pLW40 Mod). 
A) Cloning strategy overview. Digestion with ClaI is used to open the pLW40 vector (top 
left) and liberate the ClaI flanked insert from the peGFP Mod/pUC18 backbone (top 
right). The digested vector is dephosphorylated then PCR purified and the insert gel 
extracted before the two are ligated, producing pLW40 Mod (bottom) containing the 
eGFP Mod insert inside the pLW40 backbone.  Approximate expected product sizes are 
shown below each component. White boxes: restriction sites. B = BamHI. S = SacI. C = 
ClaI. Green box = selected portion of the eGFP gene carrying the gRNA target site. Red 
arrows = primer binding sites. B) 100 ng aliquots of DNA either undigested (uncut) or 
digested with BamHI or NaeI/SacI on a 1% agarose gel. DNA source: colony 1. 
Restriction enzymes used are indicated above and lane numbers below each lane. Band 
sizes are in kb to the sides of the figure: ladder to the left. L = GeneRuler 1 kb ladder. 
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4.2.4 Producing M. maripaludis test and control strains 
With all the vectors required for the invader assay produced, the next step was to create the 
M. maripaludis test/control strains which, once complete, could be transformed with the 
modified invader plasmids to carry out the invader assay. Producing these strains would 
require transformation of M. maripaludis with the three modified integrative vectors, each 
carrying the assembled CRISPR/Cas9 construct with an alternative version of the gRNA 
flanked by their respective homology arms. Subculturing of the transformed cells in the 
appropriate antibiotics would be used to encourage the desired loop-in/loop-out 
recombination events resulting in replacement of the target M. maripaludis genomic locus 
(UPT for Mm900 and MCM-C for S0001) with the CRISPR/Cas9 constructs. Due to time 
constraints it was only possible to attempt one set of transformations. Strain S0001 was 
selected because it was expected to be transformed at a higher rate.  
 
Figure 4.15: Generating modified pAW42 (pAW42 Mod). 
A) Cloning strategy overview. Digestion with ClaI is used to open the pAW42 vector (top 
left) and liberate the ClaI flanked insert from the peGFP Mod/pUC18 backbone (top 
right). The digested vector is dephosphorylated then PCR purified and the insert gel 
extracted before the two are ligated, producing pAW42 Mod (bottom) containing the 
eGFP Mod insert inside the pAW42 backbone.  Approximate expected product sizes are 
shown below each component. White boxes: restriction sites. B = BamHI. S = SacI. C = 
ClaI. Green box = selected portion of the eGFP gene carrying the gRNA target site. Red 
arrows = primer binding sites. B) 100 ng aliquots of DNA either undigested (uncut) or 
digested with BamHI or NaeI/SpeI on a 1% agarose gel. DNA source: colony 1. 
Restriction enzymes used are indicated above and lane numbers below each lane. Band 
sizes are in kb to the sides of the figure: ladder to the left, products to the right. L = 
GeneRuler 1 kb ladder. 
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The plasmids pCRPrtneo GG eGFP, pur and ctrl, along with an H₂O control, were 
transformed separately into S0001 cells. The cultures used should have been at an OD₆₀₀ 
value of 0.7-1 following overnight growth. However, the S0001 cells used were all growing 
too slowly to allow for this. Overnight cultures, which had been set up 14 hours prior to 
transformation all gave OD₆₀₀ readings below 0.4, and even cultures which had been 
growing for 34 hours gave readings below 0.7. For this reason, the above plasmids/control 
were transformed into a pair of cultures within the correct OD₆₀₀ range which had been 
growing for 58 hours, and the two of the cultures which had been set up 34 hours previously 
that were the most well grown (Table 4.2).  
 
 
 
Following transformation and subsequent overnight growth, the transformed cells were 
each subcultured in duplicate into fresh medium supplemented with neomycin, which 
should have selected for cells which had undergone the desired loop-in recombination 
event, and therefore carried the full plasmid construct including NeoR, integrated at the 
target locus by HR.  For each transformation, a control subculture into medium without 
selection was also carried out. Growth of all cultures was monitored by taking OD₆₀₀ 
measurements every 12 hours, for the full 48 hours required for this selection step (Table 
4.3). 
Hours Grown OD₆₀₀ 
pCRPrtneo GG eGFP 58 0.89
pCRPrtneo GG pur 58 0.78
pCRPrtneo GG ctrl 34 0.57
H₂O 34 0.61
S0001 Culture UsedMaterial Transformed
Table 4.2: S0001 cultures used for transformation. 
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All cultures grew less well when supplemented with neomycin (Table 4.3), as would be 
expected since even cells which had not taken up the NeoR gene were expected to grow in 
this condition. However, at all time points the growth of the H₂O mock transformed control 
cultures was either greater than or approximately the same as each of the cultures 
transformed with plasmid. This was not as expected since theoretically no cells in the 
control should have contained NeoR, and therefore should not have been able to survive 
when supplemented with this antibiotic. In practice some amount of background growth 
had been expected, however since the level of background (i.e. the mock transformed 
control cultures) was the same as that observed for the plasmid transformed cultures, this 
suggested that transformed cultures contained only background cells, and ultimately that 
the transformation had been unsuccessful. Unfortunately there was insufficient time to 
attempt further transformations. 
  
Table 4.3: OD₆₀₀ growth measurements of subcultured transformed cells. 
  
 12 h 24 h 36 h 48 h
pCRPrtneo GG eGFP A + 0.105 0.261 0.302 0.312
pCRPrtneo GG eGFP B + 0.098 0.289 0.359 0.362
pCRPrtneo GG eGFP C - 0.180 0.444 0.656 0.678
pCRPrtneo GG pur A + 0.098 0.185 0.220 0.228
pCRPrtneo GG pur B + 0.104 0.174 0.176 0.181
pCRPrtneo GG pur C - 0.155 0.307 0.422 0.446
pCRPrtneo GG ctrl A + 0.068 0.262 0.266 0.289
pCRPrtneo GG ctrl B + 0.087 0.249 0.265 0.272
pCRPrtneo GG ctrl C - 0.177 0.414 0.558 0.654
H₂O A + 0.110 0.271 0.290 0.293
H₂O B + 0.103 0.284 0.342 0.360
H₂O C - 0.185 0.424 0.606 0.668
OD₆₀₀Material Transformed NeomycinCulture
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4.3 Discussion 
The aim of this section was to produce all the plasmid constructs required for the invader 
assay, and then to use the modified integrative vectors to create the M. maripaludis test and 
control strains which could be used to perform this assay. While all the required plasmids 
were produced, due to time constrains it was not possible to generate the M. maripaludis 
test and control strains. 
 
4.3.1 Construct Assembly Issues 
Due to issues encountered during assembly, the production of many of the constructs 
required for the invader assay was more challenging, and therefore more time consuming 
than expected. Perhaps most notable was the contamination encountered during the 
production of the Golden Gate compatible pBLPrt/pCRPrtneo vectors. The plasmid insert 
used in both cases carried a LacZ gene, while neither recipient vector contained this feature. 
It was therefore anticipated that screening would be simple, since only the desired ligation 
products should have been blue in the presence of X-gal. However, in both cases blue 
colonies were recovered on plates resulting from a control ligation of recipient plasmid 
without ligase, which suggested the presence of a LacZ containing contaminating vector. 
Diagnostic digestion of ectopic blue colonies for both (Figure 4.4, Panel C, Lanes 5-7 and 
Figure 4.5, Panel B, Lanes 5-7) confirmed the presence of a 2.6 kb plasmid contaminant. 
The pHSG298 plasmid matched this digestion profile and was therefore suspected as the 
contaminant. The results of an initial replica plating investigation suggested that this 
plasmid was ampicillin resistant. However, further testing of contaminated colonies in 
liquid medium revealed that it was in fact sensitive to this antibiotic. Since pHSG298 does 
not carry AmpR, this strongly suggested it was the plasmid responsible. However, 
sequencing of pDNA isolated from an ectopic blue colony with primers expected to bind 
to pHSG298 was unsuccessful. The possibility of a procedural error having caused this 
seems unlikely, since all other sequencing reactions set up in parallel were successful. 
Additionally, both primers used had produced high quality sequence when used elsewhere 
in this study, demonstrating their functionality. It is therefore also possible that the 
contaminant was a different plasmid which by chance had the same digestion and resistance 
profile to pHSG298. As this issue had already caused delays, and since the desired modified 
pBLPrt GG and pCRPrtneo GG vectors had been recovered, further investigation of this 
contaminant was not carried out, and its identity remains unknown. 
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Another issue which complicated the construct production process was the generally poor 
performance of colony PCR. In many cases, these reactions resulted in multiple bands at 
unexpected sizes for the corresponding insert, suggesting widespread mispriming. It is 
likely that longer primers with higher melting temperatures would have been more specific, 
and therefore performed better. The approach taken in cases of unexpected colony PCR 
products was to perform diagnostic digestions on pDNA isolated from colonies 
representative of each banding pattern. The rationale behind this was that these likely 
represented colonies containing distinct products, although there was at least one example 
where this does not appear to have been the case: PCR screening of an ectopic blue colony 
and colony 49 when producing pCRPrtneo GG gave distinct banding patterns (Figure 4.4, 
Panel B, Lanes 2+5), but their plasmid digestion profiles were the same (Figure 4.4, Panel 
C, Lanes 5-7). While this approach was ultimately successful, excessive troubleshooting of 
colony PCR reactions, particularly in the early stages of the construct production process, 
contributed to delays.  
 
4.3.2 Constructs Produced 
While the assembly process took longer than expected, the full complement of constructs 
designed for the invader assay were produced. In all cases at least one colony was recovered 
containing a plasmid product with the desired insert. Sequencing of flanking regions 
confirmed that for all of these plasmids, the integration event had occurred at the intended 
site. Ideally it would have been possible to fully sequence all of the vectors intended for 
subsequent use in M. maripaludis. This is because their backbones contain features critical 
to function. For example, the HPT and NeoR genes in the transformation vectors 
pBLPrt/pCRPrtneo are required for the positive and negative selection steps responsible 
for the recovery of colonies carrying their integrated insert cargo following transformation 
(19), and loss or disruption of either would be expected to impede vector function. 
Diagnostic digestions on all M. maripaludis vectors had been conducted before and after 
modification, and with the notable exception of pBLPrt, all had resulted in the expected 
banding patterns. Based on these observations there is no reason to suspect that any of these 
plasmid backbones contain issues which might prohibit function, although diagnostic 
digestion would be unlikely to detect problems such as single nucleotide changes, or small 
insertions/deletions, which at critical locations could equally impede vector function.  
 
The exception here was pBLPrt. The pBLPrt GG backbone fragment (Figure 4.5, Panel B, 
Lane 3) was approximately 1 kb smaller than the initial 9 kb pBLPrt vector which had been 
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used in this study, even though it would have been expected to have been the same size. 
However, the backbone fragment in diagnostic digestions of pDNA from five colonies 
following Golden Gate assembly into pBLPrt GG was again 9 kb (Figure 4.10, Panel B, 
Lane 7). While unlikely, it is possible that this could have been caused by two sequential 
plasmid recombination events: the first resulting in the loss and the second in the gain of 1 
kb. A seemingly more probable explanation, however, is simply that the band for pBLPrt 
GG (Figure 4.5, Panel B, Lane 3) had run further on the gel than would have been expected 
for its size: (i.e. that it was in reality 9 kb). Despite this, the pBLPrt vector used here, and 
therefore the backbone fragment present in the pBLPrt GG colonies, was 600 bp larger than 
what would have been expected based on the plasmid sequence provided (James Chong, 
personal communication). This may have been caused by some form of recombination 
event on the plasmid backbone, after it had been sequenced but prior to use in this study. It 
is also possible that the size observed here reflects the true size of the original plasmid, and 
that the available sequence contains an error.  
 
It was not possible to fully sequence the vectors produced here due to financial constraints, 
and it seems sensible to suggest that backbone sequencing only need be carried out in 
situations where vectors are shown to be dysfunctional. For example, if no colonies were 
recovered in a control transformation of wild type M. maripaludis cells with the invader 
plasmid pLW40 following plating on puromycin, it would be sensible at this point to 
sequence its PurR gene to check whether it contained any inactivating mutation(s), as 
would be expected in this scenario. 
 
4.3.3 Golden Gate Constructs 
Compared with the other cloning steps carried out in this section, particularly those 
involving vector dephosphorylation, Golden Gate assembly was highly efficient, as has 
been reported (83). Given the difficulties encountered during the production of the Golden 
Gate compatible transformation vectors using the single restriction enzyme cloning 
technique required for insertion in between the UPT flanks in pBLPrt (19), and at the NotI 
site in pCRPrtneo as used in pAW10 (107), it seems reasonable to speculate that producing 
all six versions of the assembled CRISPR/Cas9 construct in this manner would have been 
extremely challenging.  While unlikely to have impacted the functionality of the 
CRISPR/Cas9 components, to allow fair comparison between each set of three test and 
control strains it was ensured that all CRISPR/Cas9 constructs were integrated in the same 
relative orientation to their respective homology arms in the transformation vectors. The 
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use of the modified transformation vectors meant that this could be achieved without the 
requirement for additional screening, since all inserts were assembled directionally based 
on the orientation of the dropout region. It is envisaged that the modified transformation 
vectors produced here should enable more efficient construct production and therefore 
more rapid M. maripaludis chromosomal modification at the UPT and MCM-C loci in 
future work. It should however be noted that use of pCRPrtneo GG to integrate material at 
the MCM-C site should be considered carefully, due to the increased growth rate phenotype 
associated with this integration (107), which may be inappropriate for some experiments. 
 
4.3.4 Production of M. maripaludis Test Strains  
An attempt was made to produce one complete set of test and control M. maripaludis strains 
by transforming S0001 cells with the three alternative assembled pCRPrtneo GG vectors. 
However, comparative levels of growth in mock compared with plasmid transformed cells 
subcultured in the presence of neomycin, which should have killed any cells not 
transformed with the pCRPrtneo backbone, suggested that this had been unsuccessful. One 
possible explanation for this is that the transformation itself had failed, resulting in no 
uptake of the desired plasmids, or so little that growth resulting from resistant colonies was 
undetectable compared with that resulting from background. The most likely explanation 
for this is that the cells in the cultures used were not growing rapidly enough to be 
transformed effectively. Transformation of cultures in early stationary phase 
(corresponding to an OD₆₀₀ value of approximately 0.8) was found to give the greatest 
yields of stable transformants in M. maripaludis (17), and the version the protocol used 
here (see Chapter 2) states cultures to be transformed should have reached an OD₆₀₀ of 0.7-
1 following overnight growth. While two of the cultures transformed in this section were 
within the advised OD₆₀₀ range, it had taken 58 hours for them to reach this point, so the 
cells were clearly growing more slowly than advised in the protocol. The same is also true 
for the two other cultures transformed, which even after 34 hours had not reached the 
minimum suggested OD₆₀₀ value. 
 
Another possibility is that some cells were successfully transformed, but the concentration 
of neomycin used was too low to enable efficient selection. The concentration of neomycin 
required to completely inhibit the growth of 10⁷ M. maripaludis cells in a 5 ml culture was 
found to be 1 mg/ml (20).  However, 0.5 mg/ml was used in this study because the higher 
concentration had previously been found to result in poor recovery of transformed cells 
(James Chong, personal communication). Neomycin acts by interfering with ribosome 
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function, causing mistranslation (110). APH3’II, the resistance gene used in pCRPrtneo 
(19, 20, 111, 112) imparts resistance by catalysing the addition of an inactivating phosphate 
group onto the antibiotic molecule (110). The previously observed poor transformation 
efficiency at 1 mg/ml of neomycin was therefore presumably because even cells carrying 
the resistance cassette were unable to effectively inactivate such high levels of antibiotic. 
However, it seems that in this study the lower concentration was not sufficient to result in 
the death of enough untransformed cells to allow growth of successful transformants to be 
detected against the presumably resultant high level of background, suggesting that an 
intermediate concentration would have been more appropriate. It should be noted that these 
two possible explanations need not be mutually exclusive: an inefficient transformation 
resulting in very few genuine neomycin resistant cells would be expected to be 
compounded by subsequent ineffective selection for that small population of desired cells. 
 
While the production of the M. maripaludis test and control strains as attempted here was 
ultimately unsuccessful, if either or both of the possibilities discussed above were 
responsible it is anticipated that they could be overcome with some simple troubleshooting 
steps. While the growth rates of the M. maripaludis cultures maintained throughout this 
study fluctuated considerably, they were growing unusually slowly when this 
transformation was attempted: with more time it would have been possible to coincide a 
transformation with a period of more rapid growth. Additionally, the subculturing steps 
following the transformation could be conducted using a range of concentrations of 
neomycin intermediate between 0.5 and 1 mg/ml, which should permit more effective 
selection.  
 
4.3.5 Chapter Summary 
In summary while it was not possible to produce the test and control strains which would 
have permitted testing of the invader assay due to time constraints, the full suite of vectors 
thought to be sufficient for conducting this assay were produced. This should enable the 
project to easily be continued from the point reached at the end of this chapter. 
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Chapter 5: General Discussion 
The object of this study was to improve the genetic tools available in M. maripaludis by 
adding the CRISPR/Cas9 system to the existing toolbox. The aim was therefore to provide 
an initial demonstration the functionality of CRISPR/Cas9 in this organism, using an 
experimental approach based on a plasmid invader assay (Figure 1.1). Implementing this 
assay had several steps. First, all required constructs and an appropriate assembly scheme 
had to be designed. Second, these constructs had to be assembled. Third, the relevant 
constructs would be used to produce the M. maripaludis test and control strains required to 
carry out the assay. Finally, the assay would be performed by transforming the invader 
plasmids into these strains, with lower survival in test vs control strains indicating 
functionality of the CRISPR/Cas9 system. Unfortunately, the construct design and 
assembly stages proved to be more challenging, and therefore time consuming, than 
initially anticipated. As a result, while an attempt was made, it was not possible to produce 
the M. maripaludis strains required for the invader assay, which could therefore not be 
carried out. Despite this, a full set of vectors thought to be sufficient for conducting the 
assay as designed in this study was produced, which should enable rapid completion were 
it to be continued. 
 
5.1.1 Conducting the Invader Assay 
Completing the project as designed here would require just two successive M. maripaludis 
transformations. The first would produce the M. maripaludis test and control strains 
required for the invader assay. For the S0001 background, this would involve 
transformation with the pCRPrtneo GG eGFP/pur/ctrl integrative plasmids, which carry the 
three alternative versions of the CRISPR/Cas9 assembly. The result would be a set of three 
M. maripaludis strains in this background containing chromosomally integrated 
CRISPR/Cas9 constructs which differ only in their gRNA component: two test strains 
which target the eGFP or puromycin genes of the invader plasmid, and a control strain 
which should not target the invader. The test and control strains in the Mm900 background 
would be produced in the same way, but instead using the vectors pBLPrt GG 
eGFP/pur/ctrl. With the required strains produced, the second transformation is essentially 
the actual invader assay, using the appropriate invader plasmid (pAW42 Mod for the S0001 
background and pLW40 Mod for Mm900). In the first instance, the invader assay would 
be conducted by transforming each set of three M. maripaludis strains (grown to a similar 
OD₆₀₀ value) with the same quantity of the appropriate plasmid invader, and then plating 
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the transformants on puromycin (to which the invader confers resistance). Since only cells 
carrying intact invader plasmid should be able to grow on this selection, control strain 
transformants should be recovered at transformation efficiency. Test strain cells should be 
recovered at transformation efficiency minis the proportion of transformed cells in which 
CRISPR/Cas9 activity resulted in loss of the invader plasmid, and a difference in recovery 
between the two would indicate whether the CRISPR/Cas9 system was functional. 
 
5.1.2 Limitation of the Invader Assay as Designed in this Study 
The invader assay assumes the number of test and control strain cells transformed with 
invader plasmid is equal, and as such any difference in plating efficiency is due solely to 
CRISPR/Cas9 mediated destruction of the invader plasmid in the test strains. The reliability 
of this output therefore depends on ensuring the number of cells transformed between 
cultures is as similar as possible, which is influenced by the amount of invader plasmid 
transformed, the number of cells used, and the transformation protocol itself. Ensuring 
equal amounts of invader plasmid is straightforward since it involves simply adding the 
same amount in each transformation. However, controlling the number of cells used with 
the system described above is more difficult. This is because M. maripaludis strains would 
have to be grown separately prior to transformation. While growth of cultures to a similar 
OD₆₀₀ value should yield similar numbers of cells in each, it would clearly not be possible 
to ensure exactly equal numbers using this approach. For this reason it would be appropriate 
to use a plating method which provides an estimate of the number of viable cells which 
were present in each culture prior to transformation. This could be achieved by splitting 
each of the cultures following transformation and plating serial dilutions with and without 
selection (12). Equivalent numbers of cells at corresponding dilutions for each strain 
without selection would indicate an equivalent number of cells were present prior to 
transformation. However, while this gives an indication it still does not confirm the number 
of viable cells prior to transformation were exactly the same between strains.   
 
In this sense the eGFP gRNA included in this study would be particularly useful. This is 
because M. maripaludis strains carrying this gRNA should not be able to target the 
unmodified invader plasmids pLW40/pAW42, since they do not carry the corresponding 
target site (12, 24). An M. maripaludis culture carrying gRNA-eGFP could be split prior to 
transformation, and half transformed with the appropriate modified invader plasmid (which 
it should target), and the other half transformed with the corresponding unmodified invader 
(which it should not target – effectively serving as the control). This would guarantee that 
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the same amount of M. maripaludis cells were present prior to transformation with the same 
amount of invader plasmid. However what this still does not guarantee is that the same 
amount of cells were actually successfully transformed. While use of the same 
transformation protocol would be expected to result in approximately equal transformation 
rates, the M. maripaludis transformation procedure is relatively complex, and involves 
several steps where samples must be handled separately (17). It is therefore possible that 
stochastic differences between samples could result in slightly different transformation 
rates, which could lead to false conclusion based on the invader assay output. For this 
reason it would be desirable to be able to measure the transformation efficiency of cultures 
transformed with invader plasmids prior to their CRISPR/Cas9 mediated destruction. 
However, this is not possible using this assay design. 
 
The inability to decouple transformation efficiency from Cas9 mediated destruction, i.e. 
the fact that it would not be possible to directly measure what proportion of cells not 
recovered on selection plates following transformation was due to Cas9 mediated invader 
plasmid destruction, compared with cells which were simply not transformed, is probably 
the main weakness of the assay designed here. This issue would be unlikely to be 
problematic in a situation where the CRISPR/Cas9 system was able to destroy the invader 
plasmid highly efficiently. As an extreme example, an output resulting in recovery of lawns 
on control plates compared with no/very few colonies on test plates would clearly be 
indicative of functionality. However, if the CRISPR/Cas9 system were less efficient, small 
differences in transformation rates between cultures could mask its effects. For example, if 
Cas9 activity were only efficient enough to result in invader plasmid destruction in 5% of 
test strain cells, a 5% higher transformation efficiency in control cultures would result in 
equivalent recovery. For the same reason, a 5% reduced recovery in test compared with 
control strain transformations would have to be regarded with extreme caution. It should 
be noted that there is no reason to expect that this should be the case, since the primary 
design constraint followed throughout this project was to produce a system whereby 
CRISPR/Cas9 should have the greatest chance of giving a strong output in the invader 
assay as possible. Namely, the CRISPR/Cas9 components (including a codon optimised 
Cas9) were placed under the control of a strong promoter (60), which would be integrated 
onto the M. maripaludis chromosome at 30-55 copies per cell (16), and should have been 
present as a functional complex prior to challenge with a single instance of the invader 
plasmid on transformation.   
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5.1.3 Improving the Invader Assay: Decoupling  
It is noteworthy that any experimental design which enables transformation of the invader 
plasmid to be decoupled from Cas9 mediated destruction would be expected to be less 
sensitive. This is because by definition the invader plasmid would have to be stably 
transformed into cells prior to targeting by the CRISPR/Cas9 system. It would therefore be 
present at multiple copies (23), which means multiple plasmids would have to be destroyed 
(in close succession) to give the desired output. Indeed, this presumed reduced sensitivity 
is the primary reason why such a version of the assay was not attempted in the first instance. 
However if the assay designed here gave a reasonable output, it could be modified for this 
purpose (i.e. to allow decoupling), which would be expected to provide a more 
scientifically robust demonstration of CRISPR/Cas9 functionality.  
 
5.1.3.1 Inducible promoter 
The simplest way this could be done would be to produce an M. maripaludis strain in which 
the Cas9 and/or gRNA components were placed under the control of an inducible promoter. 
This strain would then be transformed with the invader plasmid, and a pure culture 
generated by selecting for puromycin resistance. The pure culture would then be 
subcultured into medium supplemented with and without the inducer, grown, and then each 
culture split and plated with and without the selection. Since all cells should have initially 
contained the plasmid invader, the difference in relative recovery of colonies plated with 
selection compared to without  between induced and uninduced cultures would give a 
measure of the proportion of cells in which the induction event lead to destruction of all 
the invader plasmids within them. In principle this would be possible using the nif promoter 
(28, 32). This promoter has been used to drive inducible gene expression in M. maripaludis 
by transitioning cells to medium containing NH₄ (in which the promoter is inactive) or to 
medium containing alanine as a sole nitrogen source (in which the promoter is active) (36). 
However, it should be noted that in addition to having to be able to drive high enough 
expression to destroy a greater number of plasmid invaders, protein expression from nif 
was found to be lower than from Phmv (50), suggesting it is weaker, and therefore might 
not be able to drive expression high enough to yield the test output. Leaky expression in 
uninduced conditions, which has been detected for nif (35-37), could also cause problems. 
 
5.1.3.2 Two plasmid system 
Another modified version of the invader assay which would allow transformation to be 
decoupled from Cas9 activity, while also not relying on a (potentially unsuitable) inducible 
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promoter would be a two plasmid system. This would involve the successive 
transformation of two plasmids, the invader and a “killer”, each carrying a different 
selectable marker, into an M. maripaludis test strain which constitutively expresses Cas9. 
The first plasmid transformed into this strain, the invader, would contain a target site for a 
gRNA cassette carried on the second transformed plasmid, the killer. Following 
transformation with the invader plasmid, and establishment of a pure culture, the killer 
plasmid would be transformed. Expression of the gRNA cassette carried on the killer 
plasmid would allow Cas9 mediated destruction of the invader plasmid. Cultures 
transformed with the killer would then be split, with half plated on the selections 
corresponding to both the killer and invader plasmids, and the other half plated only on the 
selection corresponding to the killer. Colonies recovered on plates corresponding to the 
killer plasmid selection would indicate transformation efficiency, while those recovered on 
plates with both plasmid selections would reveal of those cells successfully transformed, 
what proportion underwent CRISPR mediated invader plasmid destruction.     
 
Unfortunately a two plasmid system would not be possible using existing tools available in 
M. maripaludis. Firstly, both plasmids would need to have different replication origins, 
since use of the same would lead to plasmid incompatibility issues (113). However, all 
currently available M. maripaludis replicative plasmids are derived from the same parent 
(18), and therefore presumably possess the same origin. A two plasmid system would also 
require use of two different selections. While both puromycin and neomycin selection is 
possible in M. maripaludis (20, 21), cells grown in neomycin rapidly develop spontaneous 
resistance, and plating on this antibiotic is known to result in growth of satellite colonies 
(20), which would make it inappropriate for this application. For this reason a reliable 
second selection would first be required. The majority of bacterial antimicrobial agents are 
ineffective against archaea due to physiological differences between the two domains. For 
example, archaeal cell walls do not contain peptidoglycan, and its biosynthesis is a common 
target for bacterial antibiotics (114). A better potential source of selective markers might 
be auxotrophic strains. A good candidate in M. maripaludis would be tryptophan. 
Transposon insertions into various regions of its operon was used to generate corresponding 
auxotrophs in M. maripaludis (115), and deletion of the full locus followed by 
complementation on a plasmid vector could potentially serve as a more robust second 
selection strategy.  
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5.1.4 Possible Improvements to Vectors 
The modified M. maripaludis transformation vectors produced in this study, pCRPrtneo 
GG and pBLPrt GG, should be to some extent useful in future work since material can be 
assembled into them using the highly efficient Golden Gate system (83). However, these 
vectors are restricted to two M. maripaludis genomic integration sites. A more versatile M. 
maripaludis transformation vector could be produced by incorporating a Golden Gate 
dropout region, such as that used in this study, into the pCRPrtneo vector backbone. Since 
pCRPrtneo can be repurposed to introduce material into any chromosomal location in M. 
maripaludis by introducing appropriate flanking regions (19), the Golden Gate system 
could be used to incorporate both the material to be delivered and the flanks in this modified 
vector. The primary reason that such a vector was not produced in this study is that 
introducing two additional inserts would have required the modification of two of the 
existing BpiI sites, either on the outer-most insert fragments or within the dropout region 
itself. In principle this would have been relatively straightforward using PCR methods, but 
it would also have been more time consuming. Additionally, it was envisaged that keeping 
the assembly protocol as simple as possible (i.e. with fewer inserts) would be more likely 
to result in successful assembly, since it was not known how well the M. maripaludis 
transformation vectors, which had not to our knowledge previously been used with the 
Golden Gate system, would perform. Based on the performance of the pCRPrtneo GG 
vector produced here, there is no reason to expect that it could not handle additional inserts. 
Producing a more versatile pCRPrtneo could easily be achieved using material produced in 
this study: the pDVA_BC dropout region could be amplified while adding appropriate 
restriction sites from plasmid DNA, and deposited into the pCRPrtneo vector backbone. A 
similar modification could also be made to the pLW40/pAW42 vectors, making them both 
compatible with Golden Gate assembly and blue/white screening, perhaps using the ClaI 
site used in this study.   
 
5.1.5 Removal of CRISPR/Cas9 from M. maripaludis 
Methanogens such as M. maripaludis have multiple potential biotechnological applications 
(116), perhaps most obviously in the production of biofuel (117). Due to perceived risks in 
terms of biosafety, such as the potential transfer of modified DNA to wild-type organisms 
and its possible environmental consequences (118), a system enabling the efficient removal 
of the CRISPR/Cas9 components from M. maripaludis would be desirable, for example to 
meet potential future legislative requirements. The problem with removing a CRISPR/Cas9 
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assembly already integrated into the M. maripaludis chromosome, as intended in the 
invader assay designed here, is that all copies would have to be removed simultaneously, 
which would likely be challenging. One alternative option would be to place the 
CRISPR/Cas9 assembly onto an integrative vector backbone, which is looped-out 
following negative selection. The obvious drawback to this approach is that it would make 
these vectors considerably larger, which may lower transformation efficiency (12). 
Additionally, the CRISPR/Cas9 construct would have to have achieved its desired effect 
during the short time window in which it was present on the chromosome, (i.e. following 
the loop-in but prior to the loop-out event after transformation), and as such would need to 
be highly efficient. Once the CRISPR/Cas9 system is shown to be functional in M. 
maripaludis when expressed from the chromosome, an obvious progression would be to 
demonstrate its functionality when expressed from a replicative plasmid. With this 
achieved, a plasmid curing system in which the replicative plasmid carries a negative 
selection marker could be used to select for cells which had lost this plasmid, similar to that 
described by Nayak and Metcalf (2017) (48). At least two appropriate markers, HPT or 
UPT, are available in M. maripaludis (19). 
 
5.1.6 Possible Applications for the CRISPR/Cas9 system in M. maripaludis 
5.1.6.1 Improvements to M. maripaludis transformation 
DSBs, as induced by the CRISPR/Cas9 system, dramatically increase the rate of HR at the 
target site, provided a suitable repair template is available. Perhaps unsurprisingly, the 
CRISPR/Cas9 system has therefore been broadly implemented to improve chromosomal 
modification rates in organisms in which this had previously been difficult, particularly 
eukaryotes (119). M. maripaludis naturally recombines with introduced material 
homologous to a given genomic target site (22), and development of a PEG-based 
transformation protocol substantially increased the rates at which genomic modifications 
could be recovered (17). Coupled with the established positive/negative selection system, 
strains carrying multiple chromosomal manipulations can be generated (19). However, 
even with these developments, chromosomal modification in M. maripaludis remains 
somewhat cumbersome, and further improvements to the existing protocol would be useful. 
The possibility of achieving modifications via simply inducing a cut at a given target site 
while providing a suitable repair template is not straightforward in M. maripaludis due to 
its polyploidy. Achieving chromosomal gene deletions/replacements, or stably introducing 
material onto the chromosome requires that all chromosomes undergo the desired 
modification. This necessitates the use of a positive selection marker to ensure the complete 
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propagation of the modification onto all copies of the chromosome, which is thought to be 
facilitated by gene conversion (16). For this reason, use of the CRISPR/Cas9 system to 
drive chromosomal modification in the absence of selection would not be expected to be 
appropriate for these applications, since even if highly active it seems extremely unlikely 
that it would be capable of modifying all chromosomes at once. 
 
However, the CRISPR/Cas9 system might be suitable for augmentation of the existing 
positive/negative based modification protocol (19). Induction of a DSB at the intended 
chromosomal target site would be expected to boost the frequency of the HR event required 
for the initial loop-in of the transformation plasmid and its cargo, while concurrently 
increasing the frequency of gene conversion events of the looped-in plasmid to other as yet 
unmodified chromosomes. DSBs at this site would also be expected to increase the 
frequency of loop-out events, and their propagation via gene conversion, once the positive 
selection initially used to select for looped-in plasmids is withdrawn. As such the 
CRISPR/Cas9 system could potentially be used to boost the rates of both recombination 
events required for successful chromosomal manipulation, and therefore improve the 
efficiency of the process in general. It should be noted that because a portion of the genomic 
target locus is replaced with the plasmid cargo using the current positive/negative selection 
procedure (19), as long as the CRISPR/Cas9 target site was selected within this region, its 
loss following the intended modification event would prohibit further Cas9 mediated DSB 
induction.  
 
Such a system could theoretically be achieved by placing both the Cas9 and gRNA 
components on the integrative transformation vector backbone. This approach would have 
the advantage that both components would be removed on successful modification. 
However, this would also increase the size of the plasmid, which as discussed previously 
could have a negative effect on transformation efficiency (12). Also, since both components 
would theoretically only initially be present at a single copy following delivery of the 
plasmid to the cell, expression of both would initially be low. It should be noted, however, 
that any increase in HR at the target site would be expected to increase modification 
efficiency, and following the initial loop in event and subsequent gene conversion the copy 
number of both components would increase, in turn increasing expression, creating a 
positive feedback loop. Another option would be to create an M. maripaludis strain with a 
constitutively chromosomally expressed Cas9. This component would therefore not be 
required on the transformation vector backbone, which would both reduce its size while 
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also providing a large initial amount of Cas9 protein, which means the Cas9 mediated 
augmentation of the initial loop-in event would only be limited by expression of the gRNA 
carried on the plasmid. While use of either of these system would require the integration of 
a different gRNA into the transformation plasmid for each genomic target locus, PCR 
protocols have been developed for other systems which enable the 20 nt targeting sequence 
within the gRNA to be easily exchanged (67). Alternatively, since the full gRNA is only 
100 bp in length (120) it could be ordered relatively cheaply as a synthetic DNA fragment, 
which if coupled with Golden Gate compatible plasmids suggested above, would allow the 
rapid production of transformation vectors carrying alternative gRNA target site 
specificities.       
 
5.1.6.2 Improvements to M. maripaludis promoters 
To our knowledge just four promoters (17, 28, 30, 31) have been used for gene expression 
purposes in M. maripaludis, providing a clear incentive for the development of more 
options. One method which can be used to achieve this is to obtain additional promoters 
from closely related organisms, as illustrated for example by the use of M. voltae promoters 
in M. maripaludis (17, 30). Another option is to modulate the function of existing 
promoters, which could potentially be achieved in M. maripaludis using a variant of the 
CRISPR/Cas9 system known as CRISPR interference (CRISPRi). CRISPRi employs a 
catalytically inactive Cas9 (dCas9) which is able to target but not cleave DNA. In its 
simplest sense, dCas9 can repress target genes when delivered to a promoter through steric 
hindrance of RNA polymerase. In bacteria, dCas9 targeted to different regions of the same 
promoter was found to result in different levels of transcriptional repression (46). A similar 
system could be developed in M. maripaludis: a series of strains carrying constitutively 
expressed dCas9 and gRNAs targeting distinct regions of a known promoter (for example 
Phmv) could be developed. Transforming a gene of interest fused to this promoter into 
these different strains would result in distinct levels of repression, allowing controlled 
expression (Figure 5.1).  
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The obvious limitation of this approach is that the maximal possible level of expression 
would be that of the native promoter, yet higher levels of expression may be desirable for 
some applications. dCas9 can also be used to increase gene expression by fusing it to a 
transcriptional activator, and then using its targeting capabilities to deliver this to a 
promoter in a system termed CRISPR activation (CRISPRa) (121). A transcriptional 
activator has recently been discovered in M. maripaludis (122), which means such a system 
might be possible in this organism (Figure 5.2).  
 
Figure 5.1: Control of gene expression using CRISPRi. 
1: dCas9 and a series of different gRNAs under the control of the constitutive Pmcr are 
stably transformed onto the M. maripaludis chromosome (blue line) producing a set of 
distinct strains. 2: The previously characterised gRNAs each target a different portion 
of Phmv, resulting in distinct but stable levels of repression. A gene of interest (GOI) 
placed under the control of Phmv is transformed into the desired strain depending on 
the required level of expression. Transformation into the strain carrying gRNA1 yields 
90% of the expression level of the standard Phmv promoter, while transformation into 
the strains carrying gRNA2 and 3 give 50% and 10% expression, respectively. 
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5.1.6.3 Unbiased assessment of off-targeting in organisms with small genomes 
Off-targeting by the CRISPR/Cas9 system is thought to be low in organisms such as 
bacteria due to the generally small size of their genomes (49, 102). While this makes logical 
sense, it is possible that the extent to which off-targeting actually takes place in these 
organisms has been underestimated. Self-targeting of the CRISPR/Cas9 system to the 
chromosome has been shown to result in widespread lethality in several bacterial species 
(123-125). It follows that in the case of ectopic targeting, the vast majority of cells in which 
such events had taken place would not be recovered, effectively destroying the evidence. 
This may have led to a general overestimation of CRISPR/Cas9 specificity in organisms 
with small genomes, such as bacteria. Polyploid organisms carry additional copies of the 
chromosome, which act both as a back-up system and a source of repair templates for HR, 
making them more resistant to DNA damage (126) such as the DSBs induced by Cas9. 
Since M. maripaludis is highly polyploid (16) it could present an opportunity for the 
unbiased assessment of CRISPR/Cas9 specificity in an organism with a small genome (14). 
To achieve this, a strain capable of carrying out NHEJ, and therefore producing detectable 
Figure 5.2: Control of gene expression using CRISPRa. 
1: dCas9 fused to a transcriptional activator and a gRNAs under the 
control of the constitutive Pmcr are stably transformed onto the M. 
maripaludis chromosome (blue line) producing an overexpression 
strain. 2: The gRNA targets dCas9 and the attached activator to Phmv, 
resulting in increased levels of expression. A gene of interest (GOI) 
placed under the control of Phmv is transformed into this strain 
resulting in 200% of the expression level of the standard Phmv 
promoter. 
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indels at Cas9 cleavage sites, could first be produced by incorporating the Ku and LigD 
genes onto the chromosome, as was achieved in M. acetivorans (48). Various gRNAs could 
then be tested for their ability to cleave throughout the genome using an unbiased approach 
such as whole genome sequencing (127). It should be noted that while this approach could 
also theoretically be applied in monoploid models such as E. coli, cells which undergo 
perturbations in essential regions of the genome (such as the indels induced by NHEJ) 
would not be expected to be recovered (15), potentially leading to an underestimation of 
off-targeting. This situation would be much less likely in M. maripaludis by virtue of its 
polyploidy (16), since all copies of an essential gene would theoretically have to be 
inactivated to result in cell death. 
 
5.1.7 Summary 
As the only known class of organisms capable of producing methane, methanogens (7) 
such as M. maripaludis have clear potential for biotechnological use (116). While our 
understanding of the genetics and biochemical mechanisms employed by these organisms 
to generate methane has improved (128), our ability to utilise this information is likely to 
be limited by the genetic tools available. While the development of such tools has generally 
lagged behind in the archaea (2), the recent demonstration of the functionality of the 
CRISPR/Cas9 system in M. acetivorans (48) is encouraging. As one of the most well 
developed methanogen models (12), M. maripaludis is an excellent candidate for receipt 
of up-to-date genetic tools. Due to time constraints it was not possible to demonstrate the 
functionality of the CRISPR/Cas9 system in M. maripaludis in this project. However, it is 
hoped that continuation of this work, or work by other groups, should add this highly 
versatile genetic tool to the M. maripaludis toolbox in the near future.     
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Name Sequence (5'-3')
pUC18 CP F1 ACCTCTGACACATGCAG
pUC18 CP R1 GACAGGTATCCGGTAAGC
pCRP CP F1 TCCCCTTCGAGCAAGTAC
pCRP CP R1 GCCTCTTCGCTATTACGC
pCRP CP R2 GCGAGAAAGGAAGGGAAG
pCRP CP R3 CGTCAAAGGGCGAAAAAC
pBLP CP F1 TCCAGAGATTTCCAACGC
pBLP CP R1 TTGGGAGGACTTACAACCG
pBLP CP R2 GAATCAGGAATGGCAGTTGG
M13 F* GTAAAACGACGGCCAGT
M13 R* GGAAACAGCTATGACCATG
PHSG R1 GGAATTGTGAGCGGATAAC
pLW40 CP F1 CCTGCTTGTAAACTTTGCA
pAW42 CP F1 TGCTCTTCTTTCTTTCATGC
pAW42 CP R1 CTTCGATGTGATGGTGATG
Dropout Seq F1 GAATTAATCTCGGGAATGGG
Dropout Seq F2 CTGTTTTCACCTATGGCG
Dropout Seq F3 CGCGCCATAAACTTATTCAC
Frag2 Seq F1 GCGTTGGATGGGCTGT
Frag2 Seq F1 RC ACAGCCCATCCAACGC
Frag2 Seq F2 AGGCGATCTTAATCCTGAC
Frag2 Seq F2 RC GTCAGGATTAAGATCGCCT
Frag2 Seq F3 TGGGGGTGCATCTCAAG
Frag2 Seq F4 CAGCTTTCTTGTCTGGCG
Frag3 Seq F1 CGCAGGTATCAGGACAAG
Frag3 Seq F2 ACTAAAGCAGAACGGGGA
Frag3 Seq F3 GTGCTTTCAATGCCACAG
Frag3 Seq F4 TGTTGAACAGCACAAACATTAT
Table A1: Primers Details. 
All primers excluding those marked * were designed in this 
study. 
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Name Parent Plasmid Insert Details Purpose 
pDropout 
Mod/pUC18 
pUC18 Dropout Mod gBlock 
cloned into pUC18 MCS 
with BamHI/SacI 
Generating pCRPrtneo 
GG and pBLPrt GG 
pCRPrtneo 
GG 
pCRPrtneo NotI flanked region of 
Dropout Mod gBlock 
subcloned into 
pCRPrtneo NotI site 
Generating pCRPrtneo 
GG eGFP/pur/ctrl 
pBLPrt GG pBLPrt AscI flanked region of 
Dropout Mod gBlock 
subcloned into pBLPrt 
AscI site 
Generating pBLPrt GG 
eGFP/pur/ctrl 
pFragment 1 
eGFP/ 
pHSG298 
pHSG298 Fragment 1 eGFP 
gBlock cloned into 
pHSG298 MCS with 
BamHI/SacI 
Generating pCRPrtneo 
GG eGFP and pBLPrt 
GG eGFP 
pFragment 1 
pur/ 
pHSG298 
pHSG298 Fragment 1 pur gBlock 
cloned into pHSG298 
MCS with BamHI/SacI 
Generating pCRPrtneo 
GG pur and pBLPrt GG 
pur 
pFragment 1 
ctrl/ 
pHSG298 
pHSG298 Fragment 1 ctrl gBlock 
cloned into pHSG298 
MCS with BamHI/SacI 
Generating pCRPrtneo 
GG ctrl and pBLPrt GG 
ctrl 
pFragment 
2/pHSG298 
pHSG298 Fragment 2 gBlock 
cloned into pHSG298 
MCS with BamHI/SacI 
Generating pCRPrtneo 
GG eGFP/pur/ctrl and 
pBLPrt GG 
eGFP/pur/ctrl 
Table A2: Plasmids produced in this study. 
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pFragment 
3/pHSG298 
pHSG298 Fragment 3 gBlock 
cloned into pHSG298 
MCS with BamHI/SacI 
Generating pCRPrtneo 
GG eGFP/pur/ctrl and 
pBLPrt GG 
eGFP/pur/ctrl 
pCRPrtneo 
GG eGFP 
pCRPrtneo GG Fragments 1-3 
(Fragment 1 eGFP) 
assembled by Golden 
Gate into pCRPrtneo 
GG BpiI sites 
Introducing eGFP 
targeting CRISPR/Cas 
assembly at M. 
maripaludis MCM-C 
locus 
pCRPrtneo 
GG pur 
pCRPrtneo GG Fragments 1-3 
(Fragment 1 pur) 
assembled by Golden 
Gate into pCRPrtneo 
GG BpiI sites 
Introducing puromycin 
targeting CRISPR/Cas 
assembly at M. 
maripaludis MCM-C 
locus 
pCRPrtneo 
GG ctrl 
pCRPrtneo GG Fragments 1-3 
(Fragment 1 ctrl) 
assembled by Golden 
Gate into pCRPrtneo 
GG BpiI sites 
Introducing control 
CRISPR/Cas assembly 
at M. maripaludis 
MCM-C locus 
pBLPrt GG 
eGFP 
pBLPrt GG Fragments 1-3 
(Fragment 1 eGFP) 
assembled by Golden 
Gate into pBLPrt GG 
BpiI sites 
Introducing eGFP 
targeting CRISPR/Cas 
assembly at M. 
maripaludis UPT locus 
pBLPrt GG 
pur 
pBLPrt GG Fragments 1-3 
(Fragment 1 pur) 
assembled by Golden 
Gate into pBLPrt GG 
BpiI sites 
Introducing puromycin 
targeting CRISPR/Cas 
assembly at M. 
maripaludis UPT locus 
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pBLPrt GG 
ctrl 
pBLPrt GG Fragments 1-3 
(Fragment 1 ctrl) 
assembled by Golden 
Gate into pBLPrt GG 
BpiI sites 
Introducing control 
CRISPR/Cas assembly 
at M. maripaludis UPT 
locus 
peGFP 
Mod/pUC18 
pUC18 eGFP Mod gBlock 
cloned into pUC18 MCS 
with BamHI/SacI 
Generating pLW40 Mod 
and pAW42 Mod 
pLW40 Mod pLW40 ClaI flanked region of 
eGFP Mod gBlock 
subcloned into pLW40 
ClaI site 
Invader plasmid 
targetable by M. 
maripaludis carrying 
eGFP CRISPR/Cas 
assembly 
pAW42 Mod pAW42 ClaI flanked region of 
eGFP Mod gBlock 
subcloned into pAW42 
ClaI site 
Invader plasmid 
targetable by M. 
maripaludis S0001 
strain carrying eGFP 
CRISPR/Cas assembly 
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ATGGACAAAAAATATTCAATAGGATTAGATATAGGGACAAATAGCGTTGGAT
GGGCTGTGATTACTGATGAATACAAAGTACCATCAAAAAAATTTAAAGTACT
TGGTAATACGGATAGACACTCGATAAAAAAAAATTTAATTGGCGCACTTTTA
TTTGATTCAGGAGAAACTGCTGAAGCGACAAGACTTAAAAGGACCGCAAGAA
GAAGATATACTAGAAGAAAAAATAGGATATGTTACTTACAGGAAATCTTTTC
TAATGAAATGGCTAAAGTAGATGATTCATTCTTTCACAGACTCGAAGAATCTT
TTCTGGTAGAAGAAGATAAAAAACATGAAAGGCACCCTATTTTCGGAAATAT
AGTAGATGAAGTTGCCTATCACGAAAAATATCCGACTATTTATCACTTACGAA
AAAAATTAGTTGATTCAACCGACAAAGCAGATTTAAGACTTATATATTTAGC
ATTAGCTCATATGATAAAATTCCGAGGACATTTTTTGATTGAAGGCGATCTTA
ATCCTGACAACAGCGATGTTGACAAACTTTTTATACAGTTAGTACAAACTTAC
AATCAGCTCTTTGAAGAAAACCCAATCAATGCTTCAGGAGTTGATGCAAAAG
CAATTCTTAGCGCAAGATTATCGAAATCTAGGAGGTTAGAGAACCTCATCGC
ACAGCTACCTGGAGAAAAAAAAAACGGTTTATTTGGAAACTTGATTGCATTG
AGTTTAGGGTTAACCCCAAATTTTAAATCAAATTTTGATTTAGCGGAGGATGC
AAAACTCCAGTTGAGCAAAGATACATACGACGACGATTTAGACAACCTTCTT
GCTCAAATAGGAGACCAATACGCAGACCTTTTTCTCGCTGCAAAAAACCTAA
GTGACGCAATTTTACTTTCAGATATACTCCGGGTAAATACTGAAATAACGAA
AGCACCTTTATCCGCATCAATGATCAAAAGATACGACGAACACCATCAGGAC
CTTACTTTATTAAAAGCGTTAGTTAGACAACAACTTCCCGAAAAATACAAAG
AAATATTCTTTGATCAGTCGAAAAACGGATATGCTGGATACATCGATGGGGG
TGCATCTCAAGAAGAATTTTATAAGTTCATTAAACCCATACTTGAAAAAATGG
ATGGAACAGAAGAACTTTTGGTGAAGTTAAATAGGGAAGATTTACTGAGAAA
GCAAAGAACTTTTGATAACGGATCAATACCGCACCAAATTCATCTTGGTGAA
CTCCACGCGATTCTTAGGCGTCAAGAAGATTTTTACCCATTTTTAAAGGATAA
Figure A1: Nucleotide alignment of Cas9 codon optimised to M. maripaludis, A. 
thaliana and Streptomyces. 
Labels on the far left indicate the identity of each sequence. Consensus positions are 
indicated by numbers above the alignment. Examples of regions which appear more 
repetitive in the M. maripaludis codon optimisation are highlighted by boxes. Only the 
first 250 bp of the alignment is shown for clarity. 
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TAGAGAGAAAATCGAAAAAATTTTAACATTTAGAATACCGTACTACGTTGGA
CCATTGGCCAGGGGTAATAGCAGATTTGCTTGGATGACGAGAAAATCTGAAG
AAACAATTACTCCTTGGAATTTTGAAGAAGTTGTCGATAAAGGCGCATCCGC
ACAGTCTTTTATTGAAAGAATGACAAATTTTGATAAAAACTTGCCAAACGAA
AAAGTTTTACCGAAGCATTCCCTATTATATGAATATTTTACTGTTTATAACGA
ATTAACTAAAGTCAAATACGTTACGGAAGGAATGAGAAAACCAGCTTTCTTG
TCTGGCGAACAGAAAAAAGCAATAGTTGATTTATTGTTTAAAACAAATAGAA
AGGTCACTGTTAAACAACTGAAAGAAGATTATTTTAAAAAAATTGAATGCTT
TGATTCAGTGGAAATATCAGGAGTAGAAGACCGATTTAATGCTTCATTGGGT
ACCTATCACGATCTGCTGAAAATTATTAAGGATAAAGATTTCTTAGACAATGA
AGAAAACGAAGACATTTTAGAAGATATTGTATTAACCTTAACGCTTTTTGAAG
ATAGAGAAATGATTGAAGAGAGGTTAAAAACATACGCACATTTATTCGATGA
CAAAGTTATGAAACAGCTAAAACGGCGCAGGTATACAGGATGGGGTCGGCTA
TCTAGAAAACTCATTAATGGAATTCGAGATAAACAATCGGGAAAAACTATTC
TAGACTTTCTAAAATCAGATGGTTTTGCAAATAGAAACTTTATGCAATTAATC
CATGACGATTCTCTTACATTCAAAGAGGACATTCAAAAAGCGCAGGTATCAG
GACAAGGTGATAGCCTACATGAACACATAGCAAATTTGGCAGGCTCACCTGC
AATAAAAAAAGGAATCCTACAGACCGTTAAAGTTGTAGATGAATTAGTAAAG
GTTATGGGAAGACACAAACCAGAAAATATCGTCATTGAAATGGCTAGAGAGA
ACCAAACAACGCAAAAAGGACAGAAAAACTCCAGGGAACGAATGAAAAGGA
TAGAAGAAGGAATAAAAGAACTCGGCTCTCAAATTTTAAAGGAACACCCAGT
TGAGAATACTCAGCTACAAAATGAGAAACTTTATTTATACTACCTACAGAAT
GGTCGAGATATGTATGTTGACCAAGAATTAGATATTAACAGATTAAGTGATT
ACGACGTAGACCACATAGTACCACAGAGTTTTCTGAAAGATGATAGTATTGA
TAATAAGGTTCTAACAAGGTCAGATAAAAACAGAGGAAAGTCAGATAATGTA
CCTAGTGAAGAAGTGGTTAAAAAAATGAAAAATTACTGGCGTCAGCTTTTAA
ATGCGAAATTAATTACTCAAAGAAAATTCGATAATCTTACTAAAGCAGAACG
GGGAGGCCTCTCAGAACTAGACAAAGCAGGATTTATAAAAAGACAGCTAGTT
GAAACGAGACAGATTACGAAACATGTAGCCCAGATCTTGGATTCAAGGATGA
ACACCAAATATGATGAGAATGATAAATTAATAAGGGAAGTAAAAGTTATAAC
CCTCAAATCTAAGCTTGTATCGGATTTCAGAAAGGACTTTCAATTTTACAAAG
TTAGGGAAATTAATAATTACCACCACGCACATGATGCATATCTTAATGCAGTA
GTAGGGACTGCATTAATAAAGAAATATCCCAAACTAGAATCAGAGTTTGTAT
ATGGCGACTACAAAGTATACGATGTTAGAAAAATGATTGCTAAGTCCGAACA
AGAAATCGGGAAAGCAACTGCCAAATATTTTTTTTACAGCAACATTATGAATT
TCTTTAAAACAGAAATTACTCTTGCAAACGGTGAGATCCGGAAAAGACCTCT
TATTGAAACAAATGGGGAAACTGGAGAAATTGTTTGGGATAAGGGACGTGAT
TTTGCAACAGTTCGTAAAGTGCTTTCAATGCCACAGGTAAACATTGTAAAAA
AAACCGAAGTTCAAACAGGTGGCTTTTCAAAAGAATCTATATTACCTAAAAG
AAATAGCGATAAACTGATCGCTAGGAAAAAAGATTGGGACCCAAAAAAATA
TGGTGGGTTTGATAGTCCAACAGTTGCTTACTCTGTTCTTGTCGTTGCAAAAG
TTGAAAAAGGAAAAAGTAAGAAATTAAAATCAGTTAAAGAGCTTCTGGGGAT
TACAATTATGGAACGATCATCTTTTGAGAAAAATCCAATTGATTTCTTGGAAG
CCAAAGGATATAAAGAAGTTAAAAAAGACTTGATTATCAAATTGCCAAAATA
CAGTTTATTTGAACTAGAAAATGGTCGGAAACGCATGTTGGCAAGTGCAGGA
GAACTTCAAAAAGGTAACGAATTAGCATTACCTTCAAAATATGTAAATTTTCT
TTATCTTGCAAGTCATTACGAAAAATTAAAAGGATCACCTGAAGACAATGAA
CAGAAACAGCTATTTGTTGAACAGCACAAACATTATTTAGATGAAATTATTG
AACAGATTTCCGAATTCTCTAAAAGAGTAATCTTAGCAGATGCTAATTTGGAT
AAGGTGCTGAGCGCATACAACAAACACAGAGATAAACCAATTCGAGAACAA
GCAGAAAATATTATCCATTTATTTACATTAACAAATCTTGGTGCACCTGCAGC
TTTTAAATATTTTGATACTACTATCGATAGAAAAAGATATACAAGTACCAAAG
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AAGTTTTGGATGCAACATTAATTCACCAATCAATTACAGGACTTTATGAAACA
AGAATAGATCTAAGTCAGCTTGGTGGAGACTAA 
  
Figure A2: Mmp-Cas9 nucleotide sequence. 
The Cas9 sequence codon optimised to M. maripaludis used in this study.  
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